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This has been planned as a special issue to commemorate “TB Control at the Millennium.”  We
wanted to take the occasion to note what has been accomplished in TB control over the years,
and to look forward to the challenges of the future.  Our focus is mainly on progress made in
this country, since that is our charge and our responsibility, but one cannot talk about TB control
without talking about the important work of researchers and workers in other countries, and
therefore we have included articles about international efforts as well.
In this issue you will find information about the history of the interaction between mankind and
Mycobacterium tuberculosis; the many accomplishments of our partners in TB contol; the past and
present activities of the Division of TB Elimination (DTBE); a timeline of some of the highlights
of TB control over the past century; educational materials available from DTBE; and photos of
historical people, places, events, and memorabilia that we believe you will find interesting.
I also take this opportunity to thank all who answered our invitation to contribute articles to this
very special issue.  I have both learned immensely from and thoroughly enjoyed these various
contributions.
Please feel free to share this with individuals and organizations with an interest in TB control.
We have printed extra copies to be able to accommodate requests for additional copies.
Kenneth G. Castro, MD
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A Glimpse at the Colorful History of TB:
Its Toll and Its Effect on the
U.S. and the World
by Dan Ruggiero
Division of TB Elimination
In their 1969 book Tuberculosis, Lowell et al.
tell us that “Tuberculosis is an ancient disease
with a lineage that can be traced to the earliest
history of mankind . . . In the last millennium
it has been universally distributed among all
branches of the human race.”
Phthisis (from the Greek word to waste away),
scrofula (swellings of the lymph nodes of the
neck), the white plague (the TB epidemic in
Europe during the 18th century), consumption
(progressive wasting away of the body), TB
(the presence or products of the tubercle
bacillus) are all words for tuberculosis marking
a specific point in history. Each has a signifi-
cant connotation and meaning to millions of
people about a disease that has afflicted hu-
mans from the dawn of history and continues
to ravage mankind in large numbers. During
World TB Day 1999 it was reported that an
estimated one billion persons died of the
disease worldwide during the 19th and early
20th centuries alone. This invisible enemy
continues to challenge man’s knowledge and
mock his efforts; the “Captain of the men of
death” continues to march forth leaving
behind a trail of human misery, economic
chaos, and death. What is the origin of this
invisible predator that even today has been
able to adapt and survive by fending off the
many remedies and cures that the best minds
in science have placed before it?
The tubercle bacillus, the organism that causes
TB disease, can be traced as far back as 5000
BC when archeologists found evidence in
human bones of the existence of TB. Evidence
was found in ancient Egyptian mummies
which showed deformities consistent with TB
disease. Paleontologists have concluded that
the disease must have been prevalent in that
part of the civilized world.
Evidence of TB appears in Biblical scripture,
in Chinese literature dating back to around
4000 BC, and in religious books in India
around 2000 BC.  In ancient Greece
Hippocrates mentions TB around 400 BC, as
does Aristotle, who talked about “phthisis and
its cure” (ca. 350 BC).
It was widely believed that European explor-
ers, sailors, and the settlers who followed
Columbus to the new world brought with
them many infectious diseases, among them
TB. However, paleopathologists suspected that
TB existed in the New World before 1492,
based on ancient skeletons and bones that
contained lesions resembling those caused by
TB. Evidence to that effect was found in 1994,
when scientists reported that they had identi-
fied TB bacterium DNA in the mummified
remains of a woman who had died in the
Americas 500 years before Columbus set sail
for the New World.
The TB epidemic in Europe that came to be
called the “Great White Plague” probably
started in the early 1600s and continued for
the next 200 years. The epidemic reached its
peak in western Europe and in the United
States in the late 1700s and early 1800s. In
early 19th century England, TB was so perva-
sive a killer that it dwarfed other dreaded
diseases like cholera and typhus. So common
and so little understood was TB that death
from the disease was accepted as inevitable. TB
in the early 19th century may have accounted
for one third of all deaths.  Death from TB
Evidence of TB in ancient human bone
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was clearly evident in the literature of the time
in the writings of John Keats (1795-1821) in
the Ode to a Nightingale, of John Bunyan
(1628-1688) in The Life and Death of Mr.
Badman, of Charles Dickens (1812-1870) in
Nicholas Nickleby, and of other famous writers
of the time.
In 1720, in his publication, A New Theory of
Consumption, the English physician Benjamin
Marten was the first to conjecture that TB
could be caused by “wonderfully minute living
creatures,” which, once they had gained a
foothold in the body, could generate the
lesions and symptoms of the disease. He
continued that “It may be therefore very likely
that by an habitual lying in the same bed with
a consumptive patient, constantly eating and
drinking with him, or by very frequently
conversing so nearly as to draw in part of the
breath he emits from the Lungs, a consump-
tion may be caught by a sound person . . . I
imagine that slightly conversing with con-
sumptive patients is seldom or never sufficient
to catch the disease.” For a physician living in
such an early era, Dr. Marten showed much
medical insight.
In 1882, at a time when
TB was raging through
Europe and the Ameri-
cas, killing one in seven
people, a German biolo-
gist by the name of
Robert Koch presented
to the scientific commu-
nity his discovery of the
organism that caused
TB.  It was called a
tubercle bacillus because small rounded bodies
(tubercles) occurred in the diseased tissue and
were characteristic of the disease. Through his
many experiments with the organism, Dr.
Koch worked on developing a cure for TB.
Koch was able to isolate a protein from the
tubercle bacillus that he tried as an immuniz-
ing agent and later as a treatment for TB; in
both cases it failed. However, the substance,
now called “old tuberculin,” was to be later
used as the screening tool (tuberculin skin
tests) for identifying  people and animals
infected with tubercle bacilli.
A further significant advance came in 1895
when Wilhelm Konrad von Roentgen discov-
ered the radiation that bears his name. This
allowed the progress and severity of a patient’s
disease to be accurately followed and
reviewed.
Another important development was provided
by the French bacteriologist Calmette. To-
gether with Guerin, he used specific culture
media to lower the virulence of the bovine TB
bacterium, thus creating the basis for the BCG
vaccine still in widespread use today.
TB in America during the colonial period was
accepted as a scourge of humanity that was
common to the poor and rich alike. The first
available mortality figures from Massachusetts
in 1786 indicated 300 deaths per 100,000
population. The peak mortality figure reached
in New England was 1,600 per 100,000 in
1800. With the industrial development, the
epidemic traveled to the Midwest in 1840 and
to the West in 1880. Though the disease
occurred in blacks at a lower rate than in
whites before the Civil War, the increase was
massive among blacks after the war, when
emancipation and urbanization created an
ideal atmosphere for transmission of TB. The
American Indians and Alaskans were the last
American populations to become affected by
the TB epidemic.
At the turn of the century it was estimated
that 10% of all deaths in the United States
were due to TB.  By 1904 the TB death rate
for the United States was 188, by 1920 the rate
was 100 per 100,000, and by 1955 the rate had
decreased to less than 10 per 100,000 people
per year.
The TB sanatorium movement, which was
started in Germany by Dr. Hermann
Robert  Koch
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Brehmeris in the 1850s, did not take hold in
the United States until after 1884.  Edward
Livingston Trudeau, a physician who recov-
ered from TB disease, started a sanatorium in
Saranac Lake, New York, based on the Euro-
pean model of strict supervision in providing
fresh air and sunshine, bed rest, and nutritious
foods.
As infection control measures took hold in
large urban centers of the country, TB patients
who could not be treated in local dispensaries
were removed from the general population
and placed into sanatoriums. Soon a great
movement was underway to build TB sanato-
riums. By 1938 there were more than 700
sanatoriums throughout the United States, yet
the number of patients outnumbered the beds
available.
For those households in which the adults
could not be placed in a sanatorium, children
were removed from infected parents and
placed in preventoriums that were created for
children.
A milestone in the history of TB control in
the United States occurred in the autumn of
1893, when the New York City Board of
Health called on Dr. Hermann Michael Biggs,
the Chief Inspector of the Division of Pathol-
ogy, Bacteriology, and Disinfection, for a
report on TB. In the report, Biggs stated that
TB, which was responsible for more than
6,000 deaths in New York City in 1892, was
both communicable and preventable. Some of
the recommendations made to the Board in his
report were the need to
1) educate the public of the dangers that the
disease posed to the person and his/her con-
tacts,
2) properly dispose of and immediately de-
stroy sputum or the “discharges from the
lungs” of individuals with disease,
3) have all physicians of pulmonary cases
report such cases to the health department,
4) have health inspectors visit the families
where TB exists and deliver proper literature
and take specific measures to disinfect the
areas as may be required,
5) obtain and submit sputum specimens to the
laboratory for analysis, and
6) create a consumptive hospital to care for
indigent patients.
The Board adopted most of the recommenda-
tions made by Biggs, including the creation of
“The Consumptive Hospital.”  These recom-
mendations created a storm of controversy
among the medical community. Many private
doctors objected to the mandatory reporting,
believing that it violated physician-patient
confidentiality. Because of the resistance from
the medical community, reporting practices
were not fully implemented for several years.
In the end, Biggs’ recommendations to the
Board and their implementation in New York
City created the model for TB control pro-
“Little Red,” first cottage for tuberculous patients at
Trudeau Sanatorium.
With no drug therapies, past TB suffers like
these in 1953 were isolated in sanatoriums.
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grams that was emulated by other health
departments across the country and laid the
groundwork for a campaign called the “War
on Consumption.”
During the first part of the 20th century, great
emphasis was placed on improving social
conditions and educating the general public
about good hygiene and health habits. If you
went to public school anytime between 1900
and 1930, you got the TB message, which said
essentially that spit is death.  In hospitals it
was common to see signs that read “Spit Is
Poison.” Notices were plainly printed in
public places and government buildings that
stated “Do Not Spit on the Floor; To Do So
May Spread Disease.”
In the 1920s, when fresh





collapsed one of the
lungs (pneumothorax).
During this time there
were many other “sure-
cure” remedies being advertised by many firms
and physicians.
In 1902 at the first International Conference
on Tuberculosis held in Paris, Dr. Gilbert
Sersiron suggested the adoption of the Cross
of Lorraine, used by the Knights of the First
Crusade, as the symbol of a new movement, a
crusade for good health against sickness and
death, and against TB. The double-barred cross
was adopted as the international symbol for
the fight against TB. This symbol was later
adopted in 1904 in the United States by the
forerunner of the American Lung Association.
It was not until the turn of the century that
private voluntary groups in the United States
joined the fight against TB. In April 1892, Dr.
Lawrence F. Flick organized the first Ameri-
can voluntary anti-TB organization, the
Pennsylvania Society for Prevention of Tuber-
culosis. The organization was instrumental in
helping organize free hospitals for poor con-
sumptive patients in Philadelphia. In 1902,
Dr. S. Adolphus Knopf of New York was one
of the men responsible for the movement that
launched the Committee on the Prevention of
Tuberculosis of the Charity Organization
Society of New York City.  The aim of the
committee was to disseminate information
that TB was a communicable, preventable, and
curable disease.  The Committee advanced the
movement for hospitals, sanatoriums, and
dispensaries for consumptive adults and chil-
dren. As a result of his focus on the need for a
national TB association, in 1904 a voluntary
health agency was organized under the Na-
tional Association for the Study and Preven-
tion of Tuberculosis, later renamed the Na-
tional Tuberculosis Association (NTA) and
now known as the American Lung Associa-
tion.
To fund the activities of the many local affili-
ates, the Association adopted a method that
was originated in Denmark in 1904 by Einor
Holboll, a Danish postal clerk, who sold
Christmas Seals. In 1907, many TB sanatori-
ums had sprung up all
around the country; most
were small and make-
shift. One in Delaware
was in such urgent need
of funds that it was going
to have to close unless
$300 could be raised.
Dr. Joseph Wales, one of
the doctors working at
that sanatorium, con-
tacted his cousin, Emily
Bissell, to help raise the
money.  Emily was a welfare worker in
Wilmington, Delaware; she was also active in
the American Red Cross and had fund-raising
experience. After reading an article about the
Christmas seals in Denmark, she created a
design, borrowed money from friends, and
had 50,000 Christmas seals printed. The seals
Emily Bissell
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were sold for a penny each at the post office.
She worked hard to make the campaign a
success, personally presenting the idea to all
sorts of groups and officials, including the
Philadelphia North American newspaper,
emphasizing how buying Christmas seals
would help children and adults with TB. The
idea took hold, and by the end of the holiday
season, $3,000 had been raised — 10 times the
amount she had set out to raise. By 1946 at
least 10 million people were purchasing seals
or giving to the Christmas seal fund. The
Christmas seal campaign was so widely adver-
tised on buttons, milk caps, postcards, school
booklets, billboards, book marks, rail and bus
passes, etc., that it permeated many aspects of
social life.  The National TB Association said
at that time that “No
nationwide program
has rested for so many
years on so broad a
base made up of mil-
lions of small gifts.”
Then, in the middle of
World War II, came
the final breakthrough,
the greatest challenge
to the bacterium that
had threatened human-
ity for thousands of years: chemotherapy.
In fact, the chemotherapy of infectious dis-
eases, using sulfonamide and penicillins, had
been underway for several years, but these
compounds were ineffective against Mycobac-
terium tuberculosis. Since 1914, Selman A.
Waksman had been systematically screening
soil bacteria and fungi, and at the University
of California in 1939 had discovered the
marked inhibitory effect of certain fungi,
especially actinomycetes, on bacterial growth.
In 1940, he and his team were able to isolate
an effective anti-TB antibiotic, actinomycin;
however, this proved to be too toxic for use in
humans or animals.
Success came in 1943. In test animals, strepto-
mycin, purified from Streptomyces griseus,
combined maximal inhibition of M. tuberculo-
sis with relatively low toxicity. On November
20, 1944, the antibiotic was administered for
the first time to a critically ill TB patient. The
effect was almost immediate and impressive.
His advanced disease was visibly arrested, the
bacteria disappeared from his sputum, and he
made a rapid recovery. The new drug had side
effects — especially on the inner ear — but the
fact remained, M. tuberculosis was no longer a
bacteriological exception; it could be assailed
and beaten into retreat within the human
body.
A rapid succession of anti-TB drugs appeared
in the following years. These were important
because with streptomycin monotherapy,
resistant mutants began to appear within a few
months, endangering the success of antibiotic
therapy. However, it was soon demonstrated
that this problem could be overcome with the
combination of two or three drugs.
Although there were some attempts at provid-
ing guidance on TB control measures through
publication and conferences, the federal con-
trol of TB did not occur until the mid-1940s,
when the 1944 Public Health Service Act
(Public Law 78-410) authorized the establish-
ment of a TB control program. On July 6,
1944, the Surgeon General established a Tuber-
culosis Control Division in the Bureau of State
Services of the Public Health Service (PHS).
Doctor Herman E. Hilleboe was appointed
medical director of the new division. The
Public Health Service provided supplemental
fiscal support to state and local health depart-
ments for TB control activities through for-
mula grants and special grants-in-aid. These
grants were to assist states in establishing and
maintaining adequate measures for prevention,
treatment, and control of TB and focused
greater attention on the need for case finding.
TB Control at the Millennium
6
In 1947, the PHS organized and supported
mass x-ray screening in communities with
populations greater than 100,000. Over a
period of 6 years more than 20 million people
were examined; the program ended in 1953.
The mobile x-ray
vans continued to be
used in the commu-
nities into the mid-
1960s. It was com-
mon use to show
well-known figures






A new era was advancing with the introduc-
tion of TB drugs, resulting in a declining
morbidity. The mainstreaming of TB treat-
ment to general hospitals and local community
clinics reduced the need for and dependency
on sanatoriums. In 1959 at the Arden House
Conference, sponsored by the National Tuber-
culosis Association and the U.S. Public Health
Service, recommendations were made for
mobilizing community resources and applying
the widespread use of chemotherapy as a
public health measure along with other case-
finding activities under the control of public
health authorities.  With the natural decline in
disease and the introduction of chemotherapy
in the 1940s and 1950s, TB disease started to
take on a dramatic decline in the United
States. Morbidity declined at a rate of about
5% per year until 1985, when 22,201 cases
were reported in the U.S. for a case rate of 9.3
per 100,000 population.  By 1970, only a
handful of sanatoriums still remained in the
United States and by 1992 there were only
four TB hospitals with 420 beds providing
care.
Between 1953 and 1979, along with the declin-
ing morbidity came declining funding from
state, local, and federal agencies responsible for
TB control. The cutback in TB control pro-
grams across the country left a dismantled and
frail public health infrastructure, too weak to
ward off the emergence of a new epidemic
wave that was brewing. Little did the experts
know that a new illness that was first observed
among gay men in New York City and San
Francisco (HIV/AIDS) would have a dramatic
impact on TB morbidity.
The mid-1980s and early 1990s saw an increase
in TB morbidity.  It was not long before the
country started to see TB and HIV
coinfections as well as cases with multidrug
resistance. Facilities with poor or no infection
control measures experienced numerous
nosocomial outbreaks, and there were high
death rates in hospital wards and correctional
facilities throughout the country.
The unprecedented
media coverage of TB,
a disease barely no-
ticed for more than 20
years, gave rise to
increased funding by
state, local, and fed-
eral agencies for TB
control activities.
With the infusion of
funds came the task of
rebuilding a national
infrastructure to control TB and the introduc-
tion to TB control programs of a concept that
was old, yet new: that of directly observed
therapy (DOT), in which the TB patients
ingest or take their therapy in the presence of
a health care worker.
As the numbers of TB cases continue to
decline in the United States, nearly half of the
new cases reported are occurring in people
who have immigrated to the United States. In
1998, of the 18,361 cases reported in the
United States, 7,591 or 41.3% occurred in
foreign-born persons. Most of these persons
came to the United States from countries
where TB is still endemic (e.g., Mexico, the
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Philippines, Viet Nam, China, and India).
While the United States continues to bring its
TB problem under control, it must be realized
that the United States is not an island unto
itself, isolated from the rest of the global
community.
In 1993, the World Health Organization
declared TB a global emergency. Approxi-
mately 8 million new cases and 2-3 million
deaths occur each year around the world from
TB. In an effort to reduce TB morbidity and
mortality worldwide, we must share our
expertise, successes, and failures, if we are to
move toward national and global TB elimina-
tion.
We have the power to relegate this ancient
enemy to the confinement of laboratory vials
and store it in a deep freeze. As we journey
into a new century and a new millennium, we
will face new opportunities and challenges and
write new chapters in the history of TB.  Will
we learn from the past?  Will we develop and
use new technology to the utmost efficiency?
Will we utilize our resources prudently, and
share information with our neighbors? Will
we devote our energies and talents to the
elimination of our common enemy?  How
long will it take us to accomplish our goals?
How many more lives will be sacrificed to
TB? The answer to those questions rests in
each of us who works in TB control.
In 1956, the Minnesota Tuberculosis and
Health Association encouraged school chil-
dren to be Knights of the Double-Barred Cross
and to pledge “. . . to do everything . . . to
overthrow the enemy, TB.” Are we willing to
take the same pledge today?
Where We’ve Been and Where We’re
Going:  Perspectives from CDC’s
Partners in TB Control
Changes I’ve Seen in TB,
1949 - 1999
 by William W. Stead, MD, MACP
Former Director, TB Program
Arkansas Department of Health
Professor of Medicine Emeritus, UAMS
When I took a junior staff position with the
TB Service at the Minneapolis Veterans Hospi-
tal in July 1949, under Drs. J.A. Myers and
W.B. Tucker, I had no interest in TB.  In my
spare time I worked with Drs. Richard Ebert
and Don Fry in the physiology of emphysema.
The TB dogma at the time was that primary
TB occurred in childhood and almost never
became serious except in infants.  TB in adults
was the challenge and was said to be caused by
catching a new infection on “previously
sensitized tissues.”
I lived with this paradigm until 1953 when I
was recalled by the army as the Assistant
Chief of the TB Service at the Fitzsimons
Army Hospital in Denver.  We had an 80-bed
ward full of young men returning from Korea
with what was then called “idiopathic pleural
effusion.”  Because of the occasional need to
explore one of these, we learned that such
effusions were due to soiling of the pleura by a
small subpleural lesion of primary TB in the
lower half of one lung (Am Rev  Tuberc Pulm
Dis, 1955).
My real immersion in TB came in 1960 at
Marquette University as Chief of the Pulmo-
nary Disease Section of the Milwaukee
County Hospital/Muirdale TB Sanatorium.
This was 3 years after the death of my 83-year-
old father, whose autopsy showed cavitary TB
in the right upper lobe and active renal in-
volvement.  I felt pretty sure he had not been
reinfected, because there were old scars on the
screening chest x-ray (CXR) done on admis-
sion to the extended care facility 3 years earlier
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and all patients were x-rayed annually to
screen for TB.  It seemed pretty evident that
his TB was due to reactivation of some of
those old scars.
So, I sought the help of my four older siblings
(including Eugene, who is 10 years my senior
and at the time was Chairman of Medicine at
Duke).  We were able to piece together a likely
scenario. Dad’s father had died of “consump-
tion” in 1890 when Dad was a healthy 15-year-
old.  In 1902 he had some illness of which we
had no details except that a doctor had sug-
gested that Dad sleep out-of-doors as much as
possible.  Later, as a traveling salesman over
four southern states, he would sleep in a tent
at the edge of whatever town he happened to
be in at dusk.  Eugene traveled with him some
summers and attests to this story.
I can recall that Dad commonly “hawked and
spit” a greenish-yellow sputum. Gene recalled
that he required frequent massage of a “boggy”
prostate gland and that he had a number of
episodes of painless hematuria, all of which
suggested chronic renal TB.  Finally, in 1941 a
sister returned home with a pre-school son
who at age 6 developed an illness with a
cough, positive tuberculin skin test (TST), and
abnormal CXR.  He was confined to bed for 6
months.  At the time Dad was not suspected as
the source.  Two of my siblings and I had
positive tuberculin tests.  Mother remained
well but I have no information on her TST.
With this scenario suggesting a long and
largely healthy life with TB, I began to ques-
tion the dogma of adult TB being due to an
exogenous reinfection.  Fortunately, the
Sanatorium had vast numbers of old CXRs,
some back to glass plates.  With these I was
able to find old scars in a fairly large percent-
age of our active cases of TB and published
two papers on the natural history of TB in
man (Am Rev Respir Dis, 1967, and New Engl J
Med, 1967).
At about the same time we showed that
primary TB in adults can produce the full
spectrum of pulmonary lesions seen in cases of
reactivated TB (Ann Intern Med, 1968).
It was not until the 1970s as TB Controller for
Arkansas that I really began to understand TB.
In 1976 we encountered an outbreak of TB in
our state prison with evidence that it had been
going on for at least 5 years.  Ten active cases
among 1,500 inmates gave an incidence of 667/
100,000 vs 21 in the state at large that year.
We found about 100 TST converters, evenly
split between black inmates and white inmates
(JAMA, 1978).  At the time I did not realize
that there were about 1,000 white and only
500 black inmates. So, I missed the difference
in their infectibility.  I held a monthly Chest
Clinic at the prison for 8 years to screen new
inmates for TB and to see that TST reactors
got INH therapy.
My next shock came in 1978 when we found
an outbreak at a nursing home.  I was not
surprised at finding a case of TB in a nursing
home, because most of the population would
be TST positive from living through the 1920s
and 1930s when TB was so common.
Hermione Swindol, PHN, argued that it
would spread and she proved to be right.
What I did not know then was that healthy
elderly people often outlive their TB germs
and the TST reverts to negative. Only 15%-
20% of new admissions were TST positive,
leaving 80%-85% susceptible to a new infec-
tion.  We found 60 converters, 10 of whom
had active TB (Ann Intern Med, 1981).
Because of these findings we got the 225
nursing homes in Arkansas to do two-step
TSTs on all new admissions not known al-
ready to be positive.  Twice a year they report
TSTs of their new admissions and update the
data on other residents.  At first I kept the
records in a Radio Shack TRS80 Model 1
computer. I now have demographic, skin test,
and TB data on 115,000 nursing home resi-
dents from 1984 through 1998 (Int J Tuberc
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Lung Dis, 1998).  Only 5%-10% of admissions
to our nursing homes are TST positive now.
Perhaps the principal discovery that has come
from these data is that there is a significant
difference in innate resistance to TB infection
between whites and blacks.  In addition, study
of our TB case data base from 1976-1997
shows that blacks with active TB are 50%
more likely than whites to be sputum-smear
positive and thus highly infectious.
I am now preparing a paper to show the
important public health implications of such a
difference in TB risk.  While health depart-
ments routinely try to identify all close con-
tacts with infectious cases of TB, a particularly
great effort should be made among the African
American and Native American contacts
because of their greater risk both of infection
and of becoming infectious.  It is important
for such reactors to take the full course of
chemoprophylaxis to prevent development of
TB and further spread.  This applies especially
to exposures in close living quarters, i.e.,
dormitories, nursing homes, shelters, and
prisons.
It has been an interesting half century.  The
best part was the quarter century in public
health in Arkansas from 1973-1998.
TB Control in New York City:
A Recent History
by Paula I. Fujiwara, MD, and
Thomas R. Frieden, MD, MPH
Current and former Directors of the
NYC TB Control Program
Many of the tenets of modern TB control
were developed more than a century ago in
New York City by Dr. Hermann Biggs, a
physician working for the Department of
Health. These included the policies of free,
high-quality sputum examination, the manda-
tory reporting of cases, health department
supervision of isolation and treatment, educa-
tion of the public regarding TB, and the
fostering of a social movement for control of
the disease. The City’s TB control program
waxed and waned over the next 100 years,
with the lowest number of reported TB cases
in the city occurring in 1978.
During the 1980s, the rapid rise in TB was
fueled by the human immunodeficiency virus
(HIV) epidemic; growing poverty,
homelessness, and incarceration rates; and
immigration from countries with high TB
prevalence.  In this context, the infrastructure
of TB control had been dismantled, the victim
of a one-two knockout punch of a fiscal crisis
in the City and a change to a system of block
grants for federal funding.  One long-time
employee, when asked how it felt to see the
increase in cases year after year, said, “We
thought that’s just the way it was.” Staff were
trapped in a cycle of reporting cases, starting
treatment on those they could locate, but
losing many of them. Staff knew they should
be searching for the lost patients but were
distracted by the overwhelming number of
new infectious cases. Citywide, less than half
of the patients completed treatment. Repeated
warnings from experts and panels did not lead
to increased concern or funding.
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It was not until 1991 that TB got the attention
it warranted.  The first alarm was a series of
nosocomial outbreaks of multidrug-resistant
TB (MDR TB) in various hospitals in New
York City. The second alarm was the an-
nouncement of the results of a month-long
citywide drug resistance survey, which re-
vealed that 19% of all M. tuberculosis cultures
in New York City were resistant to isoniazid
and rifampin. Remarkably, half of all patients
with positive cultures had been treated before,
many of them for months.  These patients
represented a failure of the system to ensure
that patients were reliably treated, and fully
one third of these patients had MDR TB. By
comparison, a nationwide survey during the
first quarter of 1991 showed that only 3% of
all cultures were multidrug-resistant (with
New York City accounting for two thirds of
the cases), a proportion similar to that in New
York City just 7 years earlier, in a 1984
survey.
Phase I:  the battle
Dr. Karen Brudney, an astute clinician with
international experience in TB control who
had worked with Dr. Karel Styblo in Nicara-
gua, called the City Health Department to
report that she suspected that drug resistance
was increasing. Dr. Brudney had written
highly publicized (and accurate) articles high-
lighting the dismantling of the TB control
infrastructure in New York City and docu-
menting that in Central Harlem, only 11% of
patients started on treatment completed the
treatment.  In 1991, one of the authors (TF),
then working at the New York City Depart-
ment of Health as an Epidemic Intelligence
Service Officer, conducted the citywide survey
of drug resistance mentioned above in re-
sponse to Dr. Brudney’s concern. Working in
one of the Department’s chest clinics since
1990, he had seen the TB problem first-hand.
Margaret A. Hamburg, who was the Commis-
sioner of Health at that time, appointed Dr.
Frieden the Director of the Bureau of TB
Control (changed in September 1999 to the
NYC TB Control Program). At the height of
the epidemic in early 1992, in a meeting with
the entire staff of the Program, Dr. Frieden
surprised staff by stating that he was “proud to
be part of the organization that would control
TB in New York City.” The basic tenets of
the program were developed: the patient is the
VIP, directly observed therapy (DOT) is the
standard of care for TB treatment, laboratories
need to be supported and monitored, comple-
tion of treatment is the report card of how
well the program is performing, and every
staff member is accountable for his or her
performance. Against considerable barriers,
doctors, nurses, outreach workers, and other
staff were hired, chest clinics were opened on
Saturdays and evenings, and the TB Program
became a significant source of income for the
Department of Health through improved
billing practices.  TB control doctors and
nurses even performed new employee physi-
cals so staff could be hired without the typical
months-long delays.  The TB program had the
crucial and unwavering support of Commis-
sioner Hamburg.
At every opportunity, it was emphasized that
outreach workers were “modern public health
heroes.” The TB Program worked on multiple
fronts, simultaneously striving to improve the
medical care of TB patients, promote standard-
ized treatment guidelines, expand surveillance,
improve laboratories, expand social services
for TB patients, control outbreaks in hospitals
and correctional facilities, encourage and
conduct epidemiologic studies, educate and
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train doctors and other staff, and delineate the
proper use of increasingly restrictive measures
against TB patients, including detention.
After a visit by Dr. Karel Styblo to New York
City, the TB Program implemented a cohort
review process, in which the Director person-
ally reviewed every one of the thousands of
cases for treatment details and completion.
The outcome was a steep increase in comple-
tion rates and, beginning in 1993, a steep
decline in the number of reported TB cases.
More impressive was the even sharper decline
in the number of reported cases of MDR TB,
from 441 cases in 1992 to just 38 cases in 1998.
Cases of TB in US-born persons decreased
from 2,939 in 1992 to 700 in 1998.
Phase II:  new frontiers
After completion rates increased, cohort
review meetings began to include information
on contact evaluation and preventive treat-
ment. The efficacy of this process was recog-
nized when, in 1998, the NYC TB Control
Program was honored as one of 25 finalists,
out of a field of more than 1,300 nominees, for
the prestigious Innovations in American
Government Award, given by the Ford Foun-
dation and the Harvard School of Govern-
ment.
After TB case completion rates improved,
program staff began to concentrate on treat-
ment of patients with latent TB infection
(LTBI), especially those at high risk of devel-
oping TB disease, such as the HIV-infected,
close contacts, recent immigrants from TB-
endemic countries, and persons with evidence
of “old” TB. A unit to monitor treatment of
immigrants and refugees was created, and an
expanded contact investigation unit evaluated
cases of TB in workplace as well as congregate
and school settings. Treating those who “only”
have TB infection rather than disease has been
in many ways even more difficult than treat-
ing those with TB disease. It has been difficult
to convince people to take medications when
they do not feel sick. The City’s health code
does not allow (nor should it) the TB program
the same powers to use increasingly restrictive
measures against the patients who do not take
treatment for LTBI.  Some physicians in New
York City, including many trained outside of
the country, do not believe that treatment for
LTBI is important, and pass this belief on to
their patients.
Facing the next century, one of the program’s
biggest challenges is to improve completion of
treatment for LTBI while at the same time
effectively treating the more than 100 new
cases of TB that arise every month.
Phase III:  New York City in the context of
global TB control
During the late 1980s and early 1990s, HIV
fueled New York City’s TB epidemic.  This
masked the slower rise in the number of cases
in persons born outside of the United States.
In 1997, the percentage of cases in foreign-born
persons in New York City exceeded the
number of cases in United States-born persons
for the first time in recent history. The rise in
cases in the foreign-born has created new
challenges. Bicultural and bilingual staff have
been hired. People’s fears that the TB control
program is connected to the Immigration and
Naturalization Service must be quelled. People
from Ecuador, the Dominican Republic,
Puerto Rico, and Mexico may share a common
language, but have disparate beliefs about TB
transmission and risk. It is not possible to have
a one-size-fits-all approach to identifying
patients, encouraging them to present for
evaluation and treatment of TB disease or
infection, and helping them adhere to treat-
ment. TB control activities must be specifi-
cally tailored not only to the patients, but also
to those who provide their care. When pa-
tients move back to their country of origin,
New York City’s program staff communicate
with patients’ health care providers to ensure
that adequate treatment continues. It is not
unusual for staff to call Costa Rica, Pakistan,
Mexico, or the Ivory Coast to glean informa-
tion on treatment completion in order to
“close the loop” for cohort reporting!
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What is the role of New York City in the
global fight against TB?  Many people migrate
to places such as New York City to better
their economic lot, and many of these people
come from areas of the world where TB is
endemic. New York City’s TB cases represent
a microcosm of TB around the world; in 1998,
these cases came from 91 countries, led by
China, the Dominican Republic, Haiti, Ecua-
dor, India, and Mexico. In some instances,
people (including those with MDR TB) come
to New York City specifically to be treated,
having heard of the program’s success.
One of New York City’s contributions to the
global battle against TB is to support interna-
tional colleagues’ TB control efforts, to advo-
cate for more funding for these programs, and
to be gracious hosts and teachers when offi-
cials from different countries visit to learn
about New York City’s success.  In 1900, the
TB control program of the New York City
Department of Health, under the leadership of
Herman Biggs, was an international model.
Today, New York City’s experience provides
global hope and evidence that even in the
context of an HIV epidemic and a high rate of
multidrug resistance, the battle against TB can
be won and the disease can be controlled.
Not by DOT Alone
by J. Michael Holcombe, MPPA, CPM
Mississippi TB Controller
Mississippi proved directly observed therapy
(DOT) to be a great tool toward TB elimina-
tion. However, DOT is not a programmatic
cure-all, a stand-alone solution, or the prover-
bial yellow-brick road. Not what you expected
to hear from Mississippi, is it?
We know that DOT is the best way to treat
TB. It might not always be the most conve-
nient or the easiest, but with the correct drugs,
dosing, monitoring, and delivery, it is unsur-
passed at present.  When it comes to DOT and
its impact, we must remember the Chinese
proverb, “Hear and forget; see and remember;
do and understand.”
With full implementation of universal DOT
on a statewide basis in the mid-1980s, TB
program performance indicators began to
improve. Patients’ sputum converted faster,
reducing the potential period of infectiousness;
a greater percentage of patients completed
therapy; a greater percentage completed
therapy in a timely manner; the number of
patients acquiring drug resistance decreased
rapidly; the number of program admissions
for inpatient care dropped dramatically; the
average length of an inpatient stay dropped;
and the number of new TB cases began to fall.
The reduction in morbidity allowed more
time for contact follow-up, the expansion of
targeted testing, and the implementation of
directly observed preventive therapy in select
high-risk populations. This increased the
number of patients on preventive therapy and
the percentage of patients completing preven-
tive therapy.
To further support the strengthened efforts,
laws were modified to improve our ability to
protect the public from patients who fail to
cooperate with treatment or isolation, and
rules were changed to improve reporting. We
placed emphasis on outpatient care and priva-
tized elements of the program best and most
efficiently provided by private providers —
radiology services, for example — to expand
availability, improve quality, and ameliorate
cost.
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Many told us universal DOT could not be
done; a few said it should not be done. But we
continue to truly believe DOT is the best
service we can offer our patients and the
public. We believe DOT offers the surest and
best chance for a timely cure. Why should we
treat anyone with less than what we believe is
the best we can offer? Their future is our
future.
True, Mississippi has made great strides in TB
control. But we’ve made those strides not by
DOT alone.
Each and every one of those great strides was
made by everyday people: nurses, aides, clerks,
outreach workers, doctors, disease interven-
tion specialists, and volunteers — hard work-
ing, dedicated, and passionately devoted
individuals who were, and are, determined to
make a difference one patient, one facility, one
community at a time.
From the establishment of our sanatorium
early in the century through its demise and the
rise and continuing refinement of our outpa-
tient treatment delivery system, public health
nurses have made most of those great strides
possible.  Usually, the nurse comforts, edu-
cates, and gives hope to the distressed patient
who has been notified of exposure or disease.
The nurse confronts and calms the angry,
hostile, and all-too-often dangerous patient
who has given up and no longer cares about
himself or others. The public health nurse
persists through heat or snow, wind or rain,
dogs, gangs, or alligators and finds the patients
and persistently guides, cajoles, or bribes them
through treatment. If, along the way, that
means baking a few extra cookies, making an
extra trip after work to deliver a home-cooked
meal to a homeless or lonely patient, buying
an extra can of soup or a chicken for an im-
poverished patient while grocery shopping, or
taking the time to put a grubby little 4-year-
old on the lap and reading a story in hope of
making the treatment seem a little more
palatable . . . that’s nothing special. That’s just
the way DOT happens: good people doing
good things.  No bells, whistles, or wreaths of
laurel — just another great stride taken in
silence and out of public view.
Public health nurses, of course, don’t work in
isolation or independently. Without a doubt,
each stride is made easier by the clerk who
greets the patient kindly and patiently, then
helps expedite the visit. Each stride is made
easier by the outreach worker who helps
ensure each dose of medication is ingested and
each appointment is kept. Physicians who take
time from their busy practice to conduct
regular clinics at the health department also
make each stride easier, more sure, and more
purposeful. And the advances in science, the
effective anti-TB drugs available, and the
emerging technology for more rapid and
accurate diagnosis have been and are unques-
tionably essential to the progress we have
made.
Yes, DOT has been a vital tool for ensuring
progress and managing cost. We used it as the
fulcrum to move Mississippi from a deepening
rut and to change the direction of TB control.
But, DOT was only part of the plan. Progress
cannot be achieved by DOT alone.  DOT
requires achievement goals; community sup-
port; good legislation; adequate infrastructure
and funding; a dedicated, determined public
health field staff; and the strong support of
administration.
Baltimore at the New Millennium
by Kristina Moore, RN, and
Richard E. Chaisson, MD,
Professor of Medicine, Epidemiology,
and International Health
Johns Hopkins University
Mr. C, a Baltimore City resident, knows he
was diagnosed with active pulmonary and
lymphatic TB in May 1999.  He receives his
TB treatment through the Baltimore City
Health Department (BCHD)/Eastern Chest
TB Control at the Millennium
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Clinic (ECC) by directly observed therapy
(DOT) in his home on Mondays and Thurs-
days. Provided he does not miss either of his
twice-weekly intermittent supervised doses
(TWIS) of TB medications, he receives two $5
food coupons on Thursdays to fortify his
nutritional intake.  If Mr. C needs to come
into the ECC  for a clinician evaluation, his
transportation is provided by BCHD. A nurse
outreach team manages Mr. C’s case. His case
manager is a registered nurse and his DOT
manager is a licensed practical nurse. Mr. C’s
case is reviewed by the nurse team weekly and
by a BCHD clinician monthly. As a result of
contact with Mr. C, his family and friends
have all been offered TB screening evaluations
and follow-up, free of charge. Mr. C is also
participating in a national TB research proto-
col, one that is evaluating the efficacy and
safety of a rifabutin-based treatment regimen
for HIV-related TB. His BCHD/ECC clini-
cian is also his HIV care provider at the Johns
Hopkins Hospital HIV Clinic.
What Mr. C may not know is that the com-
prehensive care he is receiving through the
BCHD took years to develop, research, and
refine. He also may not know that as a result
of the once innovative, now national standard
of care he is receiving, the Baltimore TB case
rate is at the lowest level ever recorded, and
that the resurgence of TB that occurred else-
where in the US between 1985 - 1992 did not
affect Baltimore (see graph).
In Baltimore, DOT was the brainchild of the
late Dr. David Glasser, Baltimore City’s
Director of Disease Control/Assistant Com-
missioner of Health. Implemented in 1978 for
high-risk clinic TB patients, DOT was ex-
panded in 1981 to a community-based,
citywide program.  As a result, between 1978
and 1992, TB case rates in Baltimore declined
by 81%, and the city’s national rank for TB
dropped from second in 1978 to 28th in 1992,
despite the emergence of an HIV/AIDS epi-
demic. Cases and case rates have continued to
decline to a record low of 84 cases (13 per
100,000) in 1998.
Baltimore’s declining TB case rates are also
attributable, in part, to another of
Dr. Glasser’s novel approaches to TB control.
In the mid 1970s he convinced Baltimore’s
City Council to pass an ordinance mandating
pharmacies to report any issuance of anti-
mycobacterial drugs to the BCHD. Pharmacy
reporting led to improved TB case reporting,
improved treatment regimens, and an increase
in DOT through BCHD managed cases. These
treatment and management improvements also
explain, in part, Baltimore’s low incidence of
drug resistance (5.9% in 1998), and high inci-
dence of treatment completion (96.5% in
1997).
Yet another of Dr. Glasser’s foresights was to
develop an outreach and liaison program with
the City’s methadone maintenance clinics.
Recognizing injecting drug use as an important
risk factor for TB, Dr. Glasser implemented a
TB screening and preventive treatment pro-
gram at the city’s methadone clinics. By the
mid-1990s, BCHD had bridged TB efforts
with nearly all of the city’s drug treatment
programs.
Dr. Glasser’s ideas laid the foundation for the
hard-working members of Baltimore’s TB
program, who have continued to build upon
his TB control legacy through the years.
Baltimore has implemented additional innova-
tive TB control strategies in the last two
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decades. The development of liaisons with
Maryland Department of Health and Mental
Hygiene, Maryland Division of Corrections,
and private providers has improved case
reporting, case management, case follow-up,
and case prevention efforts.  Forging a treat-
ment, prevention, and research collaboration
with nearby Johns Hopkins University’s
(JHU) Center for TB Research has also con-
tributed to improved BCHD TB control
measures. BCHD/ECC’s Medical Director,
clinician staffing, and radiology support are all
provided through a contractual agreement
with JHU. In addition, this cooperative rela-
tionship has resulted in several exciting TB
research projects, including neighborhood-
based TB screening, TB prevention studies in
injection drug users, and DNA fingerprinting
studies. BCHD and JHU have also collabo-
rated to form a contract site for the TBTC
(Tuberculosis Trials Consortium).
The challenges for Baltimore City TB Control
in the new millennium will involve continu-
ing the successful case reduction efforts of the
past century through new initiatives. A main
priority will be focusing efforts on the treat-
ment of latent TB infection (LTBI). Efforts to
evaluate the possibilities of even shorter course
therapy and additional treatment options for
both active cases and LTBI will also be para-
mount. Another key interest will be partici-
pating in the efforts to develop a more effica-
cious TB vaccine. All of these new initiatives
will depend upon the development of national
and international collaborative networks in
TB research. For TB elimination to finally
take its place in history, a global approach is
an absolute necessity.
As the new millennium begins, Baltimore City
TB Control is ready to join the world in
meeting its challenges. Patients like Mr. C will
continue to benefit from the dedication of a
City Health Department committed to the
ultimate goal: treating the last case of TB.
From Crickets to Condoms and Beyond
by Carol Pozsik, RN, MPH
South Carolina TB Controller
It’s history now but people still chuckle about
the story of the man who was given crickets
for fishing as an incentive when he couldn’t be
located to take his TB medications. Clearly,
fishing was more important that his TB treat-
ment. His public health nurse recognized that
it was going to take an unusual motivator to
get him to meet her for directly observed
therapy, and thus was born the story of the
crickets given to the fisherman. It wasn’t the
first time that nurses or other health care
workers had given incentives to encourage
patients to comply and it certainly wasn’t
going to be the last. For TB nurses in South
Carolina, incentives and enablers became
something that they could not do without.
The concept has spread nationwide, and is
now an accepted intervention in the treatment
of TB infection and disease.
For many years the American Lung Associa-
tion of South Carolina (ALASC) had given
money for patient needs to the State Tubercu-
losis Sanatorium. As the sanatorium popula-
tion dwindled in 1981, the Executive Director
of the Lung Association began to wonder how
the Patient Needs Funds could be used to help
TB patients who were not in the hospital. It
was at that time that the fisherman’s TB nurse
approached the ALASC and appealed for
funds to provide incentives to more patients
who needed them. That was the beginning of
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At first some of the nursing staff resisted the
idea of using incentives. Change was difficult
to accept; about that same time, the program
was also starting what was then called SIT
(supervised intermittent therapy), and is now
called DOT (directly observed therapy). Some
nurses could be heard griping about “spoon-
feeding” the patients. (Translated, this meant
that they felt that the patients should take
total responsibility for their treatment, and
that the nurses shouldn’t have to give them
anything to get them to be responsible.) For
some staff, it was all too much: asking them to
not only watch patients take their medicines,
but then, asking them to give the patients
small gifts as well — it was just more than they
could bear! However, as time wore on, these
same nurses became zealous about doing DOT
and giving incentives. (In fact, one nurse fell
and broke her leg during the course of giving
DOT and, in spite of a compound fracture,
she demanded that the ambulance drivers take
her on to her next two visits so she could
complete her DOT rounds.) Those big hearts
in the TB nurses were hooked and the con-
cepts of DOT and incentives really took hold.
Soon everyone in South Carolina was using
DOT and the stories of the incentives that
were used were told and the success rate of
completion of therapy got better and better.
In those early days the incentives were simple:
juice, hamburgers, chicken snacks, fruit,
candy, even condoms. Today, the staff have
moved to more sophisticated incentives such
as smoke alarms for fire protection in substan-
dard housing and swimming lessons for under-
privileged children. TB nurses and DOT
workers have big hearts and they dig deep to
personalize the incentives and enablers for
their patients.
Dr. Dixie Snider, former Director of CDC’s
Division of TB Elimination, knew about the
success of the incentives and enablers program
in South Carolina and gave us encouragement
to publicize the stories about incentives and
DOT in order to educate other TB programs,
so that they might begin to use incentives.
With the help of the ALA of South Carolina,
the booklet Using Incentives and Enablers in a
Tuberculosis Control Program was published.
The book gives the history of incentives and
helpful advice about their use. Still popular
after many printings, the book continues to
help TB workers in their use of incentives
both in the United States and in other coun-
tries. TB workers and others love to hear the
stories and see the pictures of real patients
with their caregivers. The pictures give a real
face to TB and give encouragement to new
staff in the program that they too can be
successful with incentives. Whenever I am
asked to speak about improving compliance,
naturally I also talk about the importance of
using incentives and enablers to make our
work easier, but more importantly to bond
the caregiver with the patient in a trusting
relationship.
The successful use of DOT and DOPT in
South Carolina could not have ever happened
without the use of incentives. Who would
have thought that something as unscientific as
a red bridle for a mule, a cold drink on a hot
day, a pair of warm socks, or an old
overstuffed chair would contribute signifi-
cantly to the successful treatment and preven-
tion of TB in the United States?
The Denver TB Program:
Opportunity, Creativity, Persistence,
and Luck
by John A. Sbarbaro, MD, MPH, FCCP
Professor of Medicine and Preventive Medicine
University of Colorado Health Sciences Center
Four words — opportunity, creativity, persis-
tence, and luck — summarize the successes of
Denver’s TB program.
For decades, Colorado had been a mecca for
the victims of TB. However, along with the
demise of the sanatorium era, Denver’s TB
control program had progressively deterio-
rated. As in other large cities, the insured
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disappeared into the private sector, while the
poor and those from the street continued to be
housed for months upon months on a forgot-
ten floor of the public hospital.
In 1965, Denver was awarded a CDC TB
Branch grant, which included the assignment
of one of the CDC’s first six TB medical
officers. The project award was designed to
enhance the city’s decimated TB clinic. How-
ever, the standard of treatment, 24 months of
daily INH and PAS, presented a daunting
obstacle to the ambulatory treatment of a large
population of chronic alcoholics and disadvan-
taged, socially isolated inpatients.  How to
treat effectively yet compassionately was the
question.
A little-noticed report in a foreign journal
provided an answer. In Madras, India, the
British Medical Research Council (BMRC)
appeared to have successfully treated patients
with high doses of INH and streptomycin
given intermittently over one year. The
regimen made sense scientifically and pro-
grammatically. If directly administered
throughout treatment, the opportunity for
cure would be maximized and a concerned
public assured that these ambulatory patients
did not place the community at risk because
they were receiving adequate treatment
(“chemical isolation”). Fortunately, at that
moment there was no local health department
authority to say “no” and the regimen was
implemented, although modified to include a
three-drug intensive phase and an 18-month
two-drug continuation phase.
The uniqueness of this treatment approach
spawned widespread changes in Denver’s
ambulatory TB program. The resultant emer-
gence of one-to-one relationships between
nurses and patients led to a major role expan-
sion, with nurses encouraged to function more
independently, including reading x-rays and
determining which standing treatment orders
to implement. By early 1966, both DOT and
the nurse-directed TB clinic had indeed arrived
in the US.  And what nurses do, they docu-
ment — every action and every outcome —
and with that documentation, Denver’s ongo-
ing research program was established. Innova-
tion, when measured, becomes meaningful
clinical research. A long list of skilled TB
nurse specialists such as B.J. Catlin, Jan Tapy,
and Maribeth O’Neill not only provided care
to thousands of patients but served as the
cornerstone for Denver’s contributions to the
scientific and social understanding of TB
control.
However, organizations either continue to
grow or they die, and growth requires change.
As new knowledge emerged and new drugs
became available, so did new opportunities.
Fortunately, the arrival of Mike Iseman early
in the program and subsequently of Dave
Cohn ensured that no opportunity would pass
unnoticed.   Program components were evalu-
ated for cost-effectiveness and community
impact. Denver was amongst the first to
eliminate the mobile chest x-ray in favor of
selected population skin testing; to focus on
the effect of  inducements and enforcement on
patient compliance; and to create a meaningful
role for community outreach workers. New
short-course DOT regimens were developed
and tested; screening programs were evaluated;
the effect of TB drugs  in infected human
macrophages documented; and “molecular
epidemiology” was applied to a long-standing
database and a freezer  stored with isolates of
mycobacteria.
The emergence of HIV stimulated new ques-
tions, new initiatives, and an opportunity to
further build upon 30 years of close working
relationships with, and support from, the
CDC.  Denver’s long history of integrating
federal, state, and private grants into a single
local program encouraged its early inclusion in
multicenter national studies sponsored by
CDC and the National Institutes of Health
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Denver’s TB program was, and is, based upon
the principle that it is responsible for curing
the patient.  In the long run, the persistence of
that belief is the true foundation of Denver’s
success.
National Jewish:
The 100-Year War Against TB
by Jeff Bradley and
Michael Iseman, MD
Director, National Jewish Medical
and Research Center
Denver, Colorado
National Jewish Medical and Research Center,
which celebrated its centennial in 1999, is
known today for its expertise in a wide array
of respiratory, immunologic, allergic, and
infectious diseases. At the time of its founding,
however, it had a single purpose: the care of
impoverished victims of TB.
The need for a TB hospital became acute in
Denver in the 1880s. In those days, people
believed that the dry climate of the high plains
on which Denver is located would cure
tuberculars (i.e., persons with TB disease).
Consequently, many TB sufferers spent their
last dollars coming to Colorado.  By the 1890s,
it was estimated that one out of every three
residents of the state was there for respiratory
reasons.
In Denver, TB patients were literally dying on
the streets.  Boarding houses often banned
“lungers,” as they were called, and many of
them were too sick to support themselves.  A
woman named Frances Wisebart Jacobs recog-
nized the need for a TB hospital and, after
Old National Jewish Hospital
(NIH).  Strong academic ties with the Univer-
sity of Colorado’s Health Sciences Center,
collaborative teaching at the National Jewish
Medical and Research Center, consultation
with the IUATLD and WHO, and member-
ship on ACET provided expanded opportuni-
ties to share the “Denver experience” and to
learn from colleagues throughout the world.
During these years, the recruitment of
Denver’s retired TB “greats” such as Gen. Carl
Temple and Drs. Roger Mitchell and Jack
Durrance to work regular hours each week in
the clinic ensured that the knowledge of the
past would not be forgotten in the excitement
of the future. Unhappily, their days of contri-
bution have passed, but the camaraderie
established between physicians, nurses, and
clinic staff produced an environment in which
professional creativity continues to flourish.
Challenging existing beliefs and methods has
become standard operating behavior. The
entrance of Randall Reeves and later of Bill
Burman ensures that it will continue, high-
lighted by their scientific leadership in the TB
Trials Consortium.
The underlying philosophy driving the Den-
ver TB Clinic is perhaps best summarized in
two quotes from a 1970 publication, “The
Public Health Tuberculosis Clinic, Its Place in
Comprehensive Health Care” (Am Rev Respir
Dis 1970;101:463-465):
In the private sector, “even with the
best intentions of the physicians and
staff, the actual responsibility for care
rests with the patient.  In TB control,
the responsibility for care rests with
the clinic.”
“...the clinic is the best way to husband
the meager resources of personnel and
money and the only way to fix respon-
sibility on the providers of service
rather than on the recipients... ”
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joining forces with a young rabbi, the two
raised enough money to buy some land and
erect a building, which was ready for patients
in 1893.  Unfortunately, however, Denver was
hit with the Silver Crisis that year, and there
was not enough money to open and run the
hospital.
This setback convinced the organizers that
they should expand their fundraising efforts
beyond Colorado. The thinking in Denver
was that, since patients came there from all
over the nation, people all over the United
States should help support the hospital.  They
turned to B’nai B’rith, a national Jewish
service organization, and contributions came
in from across the country.  The building
finally opened in 1899 as the “National Jewish
Hospital for Consumptives.”
National Jewish was the first hospital in the
nation to focus exclusively on indigent TB
patients. As expressed in a singular motto, this
philosophy was “None may enter who can
pay, none can pay who enter.”  From day one,
National Jewish was non-profit and non-
sectarian.
The hospital opened with a capacity of 60
patients; the goal was to treat 150 patients per
year.  This was made possible by putting a 6-
month limit on patient stays.  Furthermore,
National Jewish only accepted patients in the
early stages of TB.  At least that was the plan.
In reality, however, several chronic sufferers
were admitted, and after a few months, the 6-
month limit was lifted.
The treatment at National Jewish was in line
with the protocols at other turn-of-the-century
TB sanatoria: plenty of fresh air, lots of food,
moderate exercise, and close scrutiny of every
aspect of patients’ lives.  The inhabitants of
National Jewish, thus, could expect to sleep
outside — or with their heads outside — every
night, and were all but stuffed with food.  In
1911, for instance, the annual report records
that National Jewish spent $3,631 on eggs —
roughly equivalent to $62,000 today — for just
120 patients.
In 1914, National Jewish erected a building for
the study of TB; this was the first place in
which research on the disease was done out-
side of a medical school setting.  Other ad-
vances included the nation’s first self-con-
tained facility for treating children with active
cases of TB and work on anti-TB drugs such as
isoniazid (INH) in the early 1950s.  Later in
that same decade, doctors at National Jewish
came up with a new protocol for TB that
included abandonment of bed rest and a
substitution of physical activity; use of micro-
biological assay measurements to determine
the proper dosage of INH; and combined drug
therapy using streptomycin, INH, and para-
aminosalicylic acid.
As TB gradually came under control in the
United States, National Jewish expanded its
mission to include asthma and other respira-
tory diseases, but maintained a strong presence
in TB.  Research continued on better drugs,
and the institution expanded its education
efforts.  In 1963, the 1- to 2-week TB control
course was offered for specialists from all over
the world, a course that is still offered today.
Indeed, over the past 20 years, nearly 5,000
physicians and nurses have visited Denver for
the course.
Rifampin, the most widely used drug for TB
today, was tested at National Jewish in 1970.
Two years later, federal funds established a
state-of-the-art laboratory to study difficult TB
cases. This helped establish National Jewish as
a highly specialized center for drug-resistant
TB and atypical mycobacterial infections.
Today, National Jewish continues to be a
steady contributor in the fight against TB.
The hospital offers compassionate care to
victims of MDR TB, often providing treat-
ment for the poor at no charge.  Leading
pharmaceutical companies collaborate with
National Jewish to test new drugs.  Perhaps
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the greatest contribution of National Jewish is
in education.  In addition to the TB course,
the hospital maintains a Mycobacterial Con-
sult Line, a free service whereby physicians
anywhere in the world can call up and receive
advice from our specialists.  Over the past 5
years this service has responded to over 2,000
calls annually.
At the opening of National Jewish back in
1899, the president of the institution, speaking
of TB in the exalted rhetoric of that day,
declared that it was his dream for the hospital
“that its doors may never close again until the
terrible scourge is driven from the earth.”
Now, at the time when the World Health
Organization estimates that one out of every
three people in the world is infected with TB,
those doors are still open.
Earthquakes, Population Growth, and TB
in Los Angeles County
by Paul T. Davidson, MD
Los Angeles TB Controller
In the late 1960s, Los Angeles County built a
state-of-the-art TB hospital. Most of the 1,300
or more persons being diagnosed with new
cases of this disease each year were spending
many months in the hospital before receiving
treatment as outpatients.  The Sylmar earth-
quake of 1971 essentially destroyed the hospi-
tal and propelled the County into considering
other approaches to managing this disease.
Some patients were transferred to Rancho Los
Amigos Hospital, a long-term rehabilitation
facility.  The majority were referred to the
over 40 Public Health Centers then in exist-
ence throughout the county. This began what
has since become a largely outpatient system
for the follow-up and care of TB patients. Six
county hospitals have continued to diagnose
and treat many TB patients. Liaison nurses
assigned by the TB Control Program facilitate
the transfer of these patients to the Public
Health Clinics.  Approximately 25% of TB
patients are diagnosed and followed by the
private health sector.
During the past 30 years there have been
numerous changes in Los Angeles County that
have impacted upon the TB problem.  A
dramatic increase in the population has oc-
curred.  Many of the new residents are immi-
grants from countries where TB is prevalent
and in many cases increasing in incidence.  By
the end of the 20th century nearly 75% of all
the new cases in Los Angeles occurred in the
foreign born.  Poverty and homelessness have
been a persistent social and cultural factor
supporting continued spread of TB.  By the
late 1980s, the emergence of HIV infection and
disease contributed to the number of TB cases,
reaching a peak of 15% of all the cases being
HIV positive in 1991.
In the 1980s efforts were increased to fight the
TB problem among the homeless.  A satellite
clinic in the Skid Row area of downtown Los
Angeles was established.  This clinic depended
on outreach workers to find and transport
patients to the clinic for directly observed
medication and medical management.  Because
many of the homeless still defaulted on treat-
ment and spent repeated episodes in the hospi-
tals, a pilot project funded by the State of
California was instituted.  It provided housing
and food incentives to the homeless in Skid
Row in exchange for taking medication and
completing TB treatment.  The results were
dramatic, with better than 95% of the partici-
pants completing therapy and the number of
hospital days being much reduced. The pro-
gram was eventually funded by the County
and extended to other areas where
homelessness is also a problem.  This program
continues, and the number of TB cases among
the homeless is declining more rapidly than
the overall number of cases.
In the late 1980s an HIV/TB program was
established to provide liaison with HIV pro-
viders. Screening guidelines for TB were
established regarding admission of HIV pa-
tients to hospitals, hospices, and other congre-
gate living facilities. The liaison nurse essen-
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tially case-managed all known HIV/TB cases
and helped to facilitate their care throughout
the healthcare system. To date, there have
been no known outbreaks of TB in any of the
health care facilities within the County.
Today the HIV/TB liaison program continues
to work closely with the many early interven-
tion clinics where TB testing is a standard of
care for all patients.
The 1990s have been a time of rapid influx of
both federal and state funding for the elimina-
tion of TB. This allowed the implementation
of a number of new programs. Directly ob-
served therapy (DOT) is now the standard of
care and in 1998 more than 75% of public
health clinic patients were on DOT.  The TB
Control Program has contracted with a num-
ber of community-based organizations (CBOs)
to screen high-risk persons for TB and provide
preventive therapy. This has resulted in thou-
sands of persons being screened and given
preventive therapy who otherwise would not
have been reached by the health department.
A project to screen homeless persons for TB
by using a mobile radiology unit detected
dozens of cases of TB that were treated earlier
than otherwise, preventing further transmis-
sion of infection to this vulnerable population.
This helped to accelerate the decline of TB
disease in the homeless.  An MDR unit was
established to monitor and consult on every
MDR patient in the county whether under
private or public care.  The percentage of such
cases has been kept below 2% of the total cases
for many years.  Most of the cases that do
occur come into the county from other loca-
tions already with MDR.  Most of them are
successfully treated while remaining in Los
Angeles County.  The Public Health Labora-
tory for the county was given personnel
resources and the latest technical equipment to
better serve the needs of the TB control pro-
grams.
The State of California has been very active in
addressing many of the problems that have
hindered TB control.  For example, a law is
now in place that requires health care facilities
to obtain permission from the local health
officer or TB controller before any person
suspected or diagnosed with TB is discharged.
The health officer can refuse discharge if the
follow-up plan is inadequate or the patient
continues to be a threat to the public health of
the community.  Another law establishes a
process for the legal detention of patients with
TB who represent a threat to the public
health.  The State has also appropriated money
to pay for the detention of TB patients and
also to pay for housing of the homeless.  Los
Angeles County has taken full benefit of these
actions.  The Surveillance Unit at the TB
Control Program and the Liaison nurses at the
county hospitals have been given the responsi-
bility for approving hospital discharges under
the Director’s supervision. The County, with
the help of State funding, has recently opened
a Southern California regional center for the
detention of TB patients at one of our county
facilities. This facility can also provide long-
term skilled nursing care for any TB patient
needing it and the services of a drug and
alcohol treatment center.
An earthquake of another nature occurred in
1995.  The Los Angeles County Department
of Health Services faced the possibility of
bankruptcy.  A huge, complicated reorganiza-
tion of the department resulted.  TB services as
well as all public health services were con-
densed into 11 locations throughout the
county where previously there had been more
than 30.  This created trying times, but fortu-
nately TB cases were not lost.  On the other
hand there was a significant drop-off in the
number of patients being screened and placed
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on preventive therapy.  In addition, the Public
Health Programs and Services Division of the
Department of Health Services has continued
to undergo extensive reorganization, redirec-
tion of priorities, and change of leadership.
The 20th century has clearly ended with a
period of constant change.  One can only
predict that the new century will continue in
the same mode, possibly as the norm.  In the
meantime, the number of TB cases continues
to decline, to an all-time low by the turn of
the century.  Hope, tempered by the reality of
a huge problem with TB in the world as a
whole, suggests that the goal of elimination of
TB can be reached in Los Angeles County
during the early decades of the 2000s.
TB in Alaska
by Robert Fraser, MD
Former Alaska TB Controller
TB is probably a relatively new disease in the
Alaska population that was introduced by
early explorers and other newcomers to the
territory of Alaska. One of Captain Cook’s
mates died of TB at the time of his voyage in
1786 to Alaska.  By the early part of the 20th
century, TB was widespread in the villages of
Alaska, and treatment options were very
limited.  Attempts at isolating individual
family members in the home was the major
treatment available.  In the late 1940s a small
TB hospital was opened in Skagway. In the
early 1950s coordinated efforts by the Bureau
of Indian Affairs and the territory of Alaska
were directed to this major public health
problem.
In a large land area like Alaska with poor
transportation, case finding was a major
challenge. In the early 1950s the territory of
Alaska operated three health boats that visited
coastal communities and communities along
the Yukon River. These ships carried x-ray
facilities, a physician, a dentist, and public
health nurses. By the mid-1950s most commu-
nities had “bush” air service, which enabled
portable x-ray facilities to be taken into com-
munities and chest x-rays taken. Hospital
facilities also improved with the availability of
the facilities at the old naval base in Sitka,
which was turned over to the Bureau of Indian
Affairs, and the construction of a new hospital
facility for the Bureau of Indian Affairs, which
opened in Anchorage in 1953. At the same
time, medication effective against M. tuberculo-
sis became available, with streptomycin avail-
able in 1946, PAS in 1947, and INH in 1953.
These treatment modalities permitted the
effective treatment of TB.
In the mid-1950s the TB reactor rate among
children in rural Alaska was about 50% in
school enterers and approached 90% in the
third grade.  Deaths from TB in some years
approached 500, and thousands of residents of
Alaska awaited hospitalization for treatment
of their disease. The initial studies using INH
to prevent TB were effectively carried out in a
number of villages in the Bethel area of
Alaska, demonstrating better than 80% effec-
tiveness in preventing the development of TB
in infected individuals.  The results also raised
the possibility of treating people with active
disease outside of the hospital.  Subsequently
most patients with TB had been treated in
Alaska with either no hospitalization or short
hospitalization followed by outpatient treat-
ment.
As the incidence of TB fell, supervision of the
infected individuals in smaller communities
was possible using traveling x-ray technicians
and the identification of problem communities
was done on the basis of tuberculin testing.
Tuberculin testing programs were imple-
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mented in selected age groups in the schools.
Review of immigrants coming to Alaska from
Southeast Asia and South America allowed
public health personnel to identify and treat
active disease, thus minimizing the spread of
TB into Alaska.
Effective treatment of TB has increasingly
required directly observed therapy, or DOT,
for successful management of the disease.
Many communities in Alaska have few tuber-
culin reactors among school age children, but
there still remains a significant reservoir of
individuals who have had TB infection in the
past and who may potentially develop disease,
posing a challenge for public health. How to
identify new cases of TB at a time when
concern for the disease has diminished and
how to provide direct administration of
medication to infected individuals in remote
areas are continuing challenges.
As Alaska enters a new century, there is a
potential to eliminate TB from the population
and there is also the potential that the disease
will remain a chronic problem. The new
century will pose new challenges with dimin-
ished public awareness of TB, and with HIV
infections in rural communities complicating
the problem.
CDC and the American Lung Association/
American Thoracic Society: an Enduring
Public/Private Partnership
by Fran DuMelle, MS
Deputy Managing Director, ALA
and Philip Hopewell, MD
Associate Dean, Univ of California, San Francisco
The origins of the American Lung Association
(ALA) and the American Thoracic Society
(ATS) and of their collaborations with the
CDC lie within the anti-TB movement of the
late 1800s and early 1900s. The potential value
of an organized voluntary society constituted
of both physician and lay members was recog-
nized in the late 1800s and marked by the
founding of the Pennsylvania Society for the
Prevention of Tuberculosis in Philadelphia in
1892. Twelve years later, in 1904, under the
guidance of many of the luminaries of Ameri-
can medicine at that time — Osler, Trudeau,
Welch, Janeway, Knopf — the National Asso-
ciation for the Study and Prevention of Tuber-
culosis (NASPT) was founded. Although the
NASPT was largely composed of physicians
and other health professionals (only two
laymen were included on its first 29-member
board of directors), its mission was public
education and public policy, not clinical care
or research.
In 1918 the NASPT changed its name to the
National Tuberculosis Association (NTA), a
name it retained for the next 50 years. Because
the organization was progressively involving
itself in a broader range of activities, in 1968,
after considerable discussion and debate, the
name was changed to the National Tuberculo-
sis and Respiratory Disease Association
(NTRDA). After being burdened with this
unwieldy name for 5 years, the NTRDA
became simply the American Lung Associa-
tion in 1973.
In 1905, a year after NASPT was chartered, a
subgroup — the American Sanatorium Asso-
ciation (ASA) — was formed by physician
members of NASPT who, for the most part,
were directors of TB sanatoria. This group was
focused on the science of TB and on the
clinical care of patients with the disease.
Although comprising initially only sanato-
rium-based physicians, the ASA subsequently
became more inclusive, with membership
open to all physicians and researchers in the
field. In 1939 the name of the ASA was
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changed to the American Trudeau Society,
honoring Edward Livingston Trudeau and
recognizing the broader interests of the mem-
bers. Finally in 1960 the name was again
changed to the American Thoracic Society
(ATS) in keeping with the evolution of the
medical specialty area from pthisiology to
pulmonology, including TB and the whole
range of respiratory disorders.
The involvement of the ancestral ALA and
ATS with organized TB control efforts in the
United States began well before there was even
a United States Public Health Service
(USPHS), let alone a CDC.  In fact, a major
activity of the NASPT was promoting the
establishment of public health departments
with TB control programs in every commu-
nity in the country. Lawmakers were urged to
support such programs and to use taxes to
make care for TB free to all patients. Thus,
from its inception, the progenitor of the ALA
had as its core mission advocacy for effective
TB control and accessibility of clinical services
for patients with the disease.
Among the factors recognized as limiting the
ability to mount a countrywide TB control
program were the lack of data describing the
magnitude of the disease and the absence of
any assessment of the availability of facilities
for the care of patients with TB. The first of
these voids was filled by an analysis conducted
on behalf of the Charity Organization Society
(COS) of the City of New York by Miss
Lillian Brandt in 1903. This report, “The
Social Aspects of Tuberculosis, Based on a
Study of Statistics,” compiled the data avail-
able for the US and presented in a systematic
fashion both the scale and complexities of TB
in the United States in the early 1900s.
Miss Brandt also provided the initial collection
of data describing existing facilities and pro-
grams for patients with TB, “A Directory of
Institutions and Societies Dealing with Tuber-
culosis in the United States and Canada.” This
survey, which served to highlight the dearth of
facilities for TB, was jointly funded by COS
and NASPT, and was the first project of the
new society. Subsequent editions of the “Di-
rectory” were funded and published entirely
by NASPT and provided the focus for the
society’s major advocacy program: to increase
public funding for TB and to have TB control
programs in all departments of public health.
In 1916 the NASPT adopted a resolution
stating that participation of the federal govern-
ment in TB control is “desirable and neces-
sary” and that the “proper federal agency for
the purpose is the US Public Health Service.”
A bill providing that a division of TB should
be set up in the US Public Health Service was
introduced in the House of Representatives in
1916. This plan was not realized, however,
until nearly 30 years later, in 1944.
In 1961 the federal government instituted the
funding of state programs that were designed
to support community-based outpatient care
efforts, to shift TB control away from
inhospital treatment. Funding increased
progressively through the 1960s but declined
precipitously in 1970 as federal support was
shifted to block grants. By 1973 there were no
categorical funds for TB control at the CDC.
After several years’ experience with block
grants, it was clear that the states were spend-
ing few or none of these funds for TB control.
It was logical, therefore, that when the ALA
opened its first full-time government relations
office in Washington in 1980, among its first
priorities was funding for TB control. In fact,
the first victory logged by the fledgling office,
under the leadership of long-time ALA and
ATS employee Robert Weymuller and its
legislative counsel Harley Dirks, was the
Congressional authorization of the “Project
Grants for Tuberculosis for Preventive Health
Projects” (replacing block grants). This bill
restored categorical funds for TB control to
the CDC in 1980 after an 8-year hiatus. Fol-
lowing this success, the ALA/ATS proceeded
with an intensive advocacy campaign to secure
funding — $1 million in FY1982, a significant
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amount in 1982 dollars. Throughout the 1980s
the ALA/ATS continued to advocate for
increased funding for the CDC, but it was not
until 1993, after the resurgence of TB in the
US had peaked, that funding increased dra-
matically.
The success in gaining increased funding for
TB was facilitated by having in place the
Advisory Council for the Elimination of
Tuberculosis (ACET), an advisory group to
the CDC that was specifically authorized by
Congress as a result of ALA/ATS lobbying
efforts. Among the first tasks of the ACET
was the development of the Strategic Plan for
the Elimination of Tuberculosis. This plan,
plus the newly-created National Coalition for
the Elimination of Tuberculosis (NCET),
provided new energy and focus for the advo-
cacy efforts, and funding levels grew to their
current level of approximately $120 million by
1995.
The creation of NCET harkens back to the
early days of the ALA and its activities in
community organization. NCET was formed
at a time when TB cases were increasing and
there was rising concern about drug resistance,
yet public apathy and Congressional inaction
continued. The goals of ALA in fostering the
creation of NCET were nearly identical to the
goals of the NASPT almost 90 years earlier:
increasing public awareness of TB and advocat-
ing for adequate public funding of control
programs. As noted above, NCET played an
important role in the intensified response to
the resurgence of TB in the 1990s. In 1998
NCET reevaluated its role and structure and is
focusing on advocacy at the state level for
funding and for ensuring an appropriate legal
framework for TB control, while not aban-
doning it national activities.
Both the ALA and the ATS have concerns
with international, as well as domestic, TB
control — concerns that are consistent with
the traditions of the organizations, with
current epidemiologic realities, and with the
increasing interna-
tional focus of the









1908. True to its origins, the ALA currently
is an important constituent of the Interna-
tional Union Against Tuberculosis and Lung
Disease (IUATLD). Additionally, the ALA
and the ATS are founding partners of the Stop
TB Initiative, together with the CDC, the
World Health Organization, the World Bank,
the IUATLD, and the Royal Netherlands
Antituberculosis Association. The Initiative is
a global partnership to accelerate TB control
worldwide and in part is a product of the
successful efforts of the ALA/ATS in advocat-
ing for funding of international TB control
through the US Agency for International
Development.
At the first annual meeting of NASPT in 1905,
two committee reports were read, “Early
Diagnosis” and “Clinical Nomenclature.”
These reports, which served to define the state
of the art on one hand and standard terminol-
ogy on the other, set the pattern for future
activities of both the NASPT and ASA. The
Society’s journal, the American Review of
Tuberculosis (subsequently the American
Review of Tuberculosis and Pulmonary Disease,
then the American Review of Respiratory
Disease, and now the American Journal of
Respiratory and Critical Care Medicine) was
first published in 1917. The first issue carried
an article, “The Classification of Pulmonary
Tuberculosis,” which was the first of an
ongoing series of statements entitled “Diagnos-
An illustration from Huber the Tuber, a book about tuberculosis
written and illustrated by H. A. Wilmer, MD, and published by
the National Tuberculosis Association in 1942.
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tic Standards and Classification of Tuberculo-
sis” (first so-named in 1920). The “Diagnostic
Standards” document continues to provide
important guidance to TB control efforts in
the US. The most recent revision has just been
completed.
In addition to the “Diagnostic Standards,” the
early ATS developed expert opinions, pre-
sented in the form of committee reports, on
various clinical, research, and public health
aspects of TB. Obviously, because there was
no TB control agency within the federal
government until 1944, when the Division of
TB Control was established, these reports
were not collaborative ventures but were,
nevertheless, intended to guide the public
health aspects of TB. Although persons em-
ployed in various federal agencies were mem-
bers of some of the committees, there was no
official USPHS representation (at least none
identified in published committee reports)
until 1943 when, in the “Report of the Com-
mittee on Tuberculosis Sanatorium Stan-
dards,” it was noted that a Dr. Sharp was
representing the USPHS. Additional involve-
ment of the ATS with the Division of Tuber-
culosis Control was noted in the “Report of
the Committee on Postgraduate Medical
Education” in 1946. Dr. Herman Hilleboe, the
first director of the Division, requested sugges-
tions for the training of medical officers in TB
control and asked for the committee to review
courses that he had outlined.
In the same year the Committee on Rehabilita-
tion (of patients with TB) reported that the
USPHS, the NTA (and ATS), and the Federal
Office of Vocational Rehabilitation would
jointly provide a team to study rehabilitation
programs in the US. Also in 1946, the NTA
and ATS, together with the USPHS and the
American Hospital Association, developed an
informational package describing how hospi-
tals should conduct mass radiography screen-
ing (“Report of Committee on Tuberculosis
Among Hospital Personnel”). These sorts of
collaborations continued on a more or less
informal basis through the 1950s and early
1960s. In the 1960s there were several instances
in which the ATS specifically endorsed
USPHS reports (the US Public Health Service
Task Force Report on Tuberculosis Control;
the USPHS Recommendations on the Use of
BCG Vaccine in the United States.)
It was not until 1971 that the first formally
acknowledged joint ATS/CDC statement was
published (Preventive Treatment of Tubercu-
losis: A Joint Statement of the American
Thoracic Society, National Tuberculosis and
Respiratory Disease Association and the
Centers for Disease Control).  Since that time
joint statements have also been published on
BCG vaccines (1975), eradication strategies
(1978), short-course chemotherapy (1980), TB
control (1983), treatment and prevention
(1986, 1994) and diagnostic standards and
classification of TB (1990). Currently, there
are three joint statements: “Diagnostic Stan-
dards and Classification,” and “Targeted
Testing and Treatment of Latent Tuberculous
Infection,” both of which have been revised
recently, and the “Treatment of Tuberculosis”
that is now undergoing revision.
Although the historical and ongoing collabora-
tions between the ATS and the CDC are
exemplified most clearly by the formal joint
statements, the interactions go well beyond
these activities. Staff of the Division of Tuber-
culosis Elimination are active and valued
members of the ATS, participating especially
in the programs of the Assembly on Microbi-
ology, Tuberculosis, and Pulmonary Infec-
tions, and assuming leadership roles in many
of the Assembly’s undertakings. Likewise ATS
members, both as Society representatives and
as individuals, are regular participants in a
variety of CDC activities, including serving in
advisory roles, contributing to training
courses, and conducting program evaluations
(often organized by state ALAs).
It is striking to note the degree to which the
current collaborations of the ALA and the
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ATS with the CDC Division of Tuberculosis
Elimination are consistent with the goals and
activities of their forebears and adhere to
traditions established early in the lifetimes of
the organizations — to support and advocate
for scientifically sound, publicly funded,
government-based TB control.
The Unusual Suspects
by Lee B. Reichman, MD, MPH
Professor of Medicine,
Preventive Medicine and Community Health
Executive Director,
New Jersey Medical School National TB Center
A Founding Component of the International Center
for Public Health
TB people have always been an “in” group.
They always tend to talk to each other, and
meet at their own meetings such as the Inter-
national Union Against Tuberculosis and
Lung Disease, the American Thoracic Society,
and the National Tuberculosis Controllers
Association. Before 1992, if you went to
meetings of other groups (the Infectious
Diseases Society of America, the American
Public Health Association, the American
College of Physicians, the European Respira-
tory Society to name a few), there was pre-
cious little TB, if any, on the program.
But TB docs aren’t the only ones who treat
TB, and since TB remains a serious global
problem, they shouldn’t be the only ones
concerned about TB.
TB in the United States is now in a downward
spiral. Even though TB in the world remains
rampant, in the United States TB rates are
down 7 years in a row including 1999. But,
paradoxically, during this period of decline,
interest in TB seems to have markedly in-
creased, and such interest apparently has
increased outside the parochial TB commu-
nity. This to my mind is the factor that is
reinvigorating TB and TB control worldwide.
It leads me, on the basis of present evidence, to
humbly suggest that the salvation of TB
control in the world as well as in the United
States will only occur when the players are no
longer exclusively from that “in” group. The
new outside players could be characterized as
unusual suspects.
In the past I’ve been very publicly critical of
the WHO’s ex-Global Tuberculosis
Programme staff for all too often going it
alone, but I’d like to now commend them and
their successes, tentatively at least, for adopt-
ing and leading more of a team approach to
deal with worldwide TB. And their leadership
in the “Stop TB” Initiative, which necessarily
requires partnerships, will hopefully be one
more important (if seriously overdue) ex-
ample. There is now increasing evidence that
they have reached out to many other “unusual
suspects.” In March 1998 WHO called to-
gether an Ad Hoc Committee on the Global
TB Epidemic (the London conference). This
certainly isn’t big news. However, the Ad Hoc
Committee of 19 consisted not only of physi-
cians; more importantly, it included several
unusual suspects: the Commissioner of the
Securities Commission of Jordan, an econo-
mist from Zambia, a civil service administra-
tor from India, a nonphysician university
professor from Indonesia, and others. When
this group called on heads of state, parliamen-
tary leaders, finance, planning, and health
minsters, as well as the Director General of
WHO, each to exercise his or her own pivotal
role, it certainly carried more weight than the
opinions of a cadre of self-serving TB doctors
and nurses, TB controllers, or TB researchers.
And when the committee called upon govern-
mental leaders to address TB as an issue out-
side the health sector which, if not dealt with
properly, must increase costs for the labor
force and reflect negatively on tourism and
foreign investment, it also carried important
influence. When they suggested that TB
should be handled as a defense program rather
than a social program, such a theme stood a
better chance of success than if broached by
the usual interested parties.
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For several years many in the TB community
have pleaded with USAID to get involved in
international aspects of TB control, if only
because of the realization that this is the best
way to control TB in the United States, where
increasing numbers of cases (now 42% in 1998)
are in the foreign-born. But it wasn’t until
Ralph Nader’s Princeton Project 55 (unusual
suspects, to say the least) got involved, that
USAID made a commitment to worldwide
control of TB and properly made the United
States a significant donor nation in the global
fight against TB.
In a similar vein, the Public Health Research
Institute of New York and the Open Society
Institute (the George Soros Foundation) —
again, at least for TB, unusual suspects — were
able to get Russia to mount significant TB
involvement in Russian prisons, which will
necessarily require prison as well as civilian
DOT, something that WHO and CDC had
been unable to do for years.
The recognition that DOTS works in drug-
sensitive cases but may amplify already exist-
ing drug resistance and that MDR TB can be
effectively treated by tailored second-line
regimens was made not by TB physicians, but
by Partners in Health, a group from Harvard
University specializing in anthropology and
human rights, and which has led to acceptance
by WHO of the so-called DOTS Plus move-
ment (tailored treatment of MDR TB).
We stand at a crossroads. Some of the players
have now acknowledged that teamwork and
partnerships are needed to realistically deal
with TB. A fresh look at a thorny problem by
unusual suspects can have lively and useful
results.
In 1992 at the National Commission on AIDS,
Joseph A. Califano, Jr., who had been Presi-
dent Jimmy Carter’s Secretary of Health,
Education and Welfare, warned that the
conjoined epidemics of AIDS, TB, and drug
addiction form the most frightening threat to
public health America had ever faced. He
likened the link of the three epidemics to
Cerberus, the mythological three-headed dog
guarding the gates of Hell!
Mr. Califano, another unusual suspect as far as
TB is concerned, would likely be pleased to
know about the progress made in TB  domesti-
cally since introducing his metaphor, but
global TB still remains a major problem.
I’d like to suggest that the proper approach to
dealing with the global TB epidemic is also
three-headed; however, not a Cerberus, but a
three-headed or three-pronged thrust into the
21st century, reflecting a new collaboration
between usual and unusual suspects.
I think we all must agree that government,
whether it be WHO, CDC, or individual
ministries of health, cannot do the job alone,
and it is hoped that they will continue to reach
out meaningfully both for advice as well as
assistance. Nongovernmental organizations
such as IUATLD, ALA/ATS, or KNVC
(Royal Netherlands TB Association) cannot do
this job alone either, and need to include
academe and foundations, which are unusual
suspects. But the third prong, previously
totally neglected except as a source of dona-
tions and therefore a very unusual suspect as
far as TB goes, is commercial industry!
Industry is the one potential player that has
usually demonstrated the ability to create and
maintain an infrastructure, motivation, exper-
tise, and perhaps most importantly, an ability
to get things done. They get things done, to
my mind at least, because they are in it for
profit, and profit still seems to be a stronger
motivation than “doing good.”
In 1996 at the Lancet conference and then in
1997 at the IUATLD annual conference in
Paris, I castigated industry. I asked why,
currently, the most widely used diagnostic test
for TB infection was introduced in 1880. I also
asked why there was essentially only one drug
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company trying at that time to license a new
drug with admitted TB indications.
At that time I stated that drug companies
don’t sit with us at the TB table because as
public corporations they must ask, “What’s in
it for us?” To a great extent, if we want them
with us, there must be something in it for
them beyond “doing good,” a virtue that
shareholders and financial analysts probably
understand less well than even politicians.
I’m not the only one suggesting this. In Busi-
ness Week, April 6, 1998, the cover story
stated: “Still, TB, like malaria, attracts fewer
resources than other infectious diseases. And
it’s not hard to figure out why. . . There’s
been the least effort to develop new anti-
infectives (against these diseases) because of the
inability of the population in the most affected
areas to pay. That’s just one reason the war
with microbes may never be fully won. Com-
panies and nations need to launch — and
maintain — effective campaigns not only
against strep and flu but also against the
scourges that ravage far too many of the
world’s people. Only then would we have a
chance of relegating these killers to the pages
of our history books.”
So in response, we need to define strategies to
allow drug and technology companies to be
full prospective players, along with govern-
ment and nongovernment organizations,
academe and foundations. Let’s find out what
they need and want, and then let’s provide
them with incentives and enablers; let them
promote their wares as well as promote our
needs. And let’s let them earn a fair and
proper profit for what they do.
Many years ago, the IUATLD Council (I
think it was 1979 in Brussels) held an exten-
sively prolonged discussion over whether the
Bulletin of IUATLD, the predecessor to the
International Journal of Tuberculosis and Lung
Disease, would be irreparably corrupted if it
accepted paid advertising. But TB control is
too fragile and important to attack with only
the usual suspects. Adding unusual suspects as
full participants, such as nongovernmental
organizations, academe, foundations and
industry, is the only way we can ever imple-
ment and carry out the global plan, rectifying
the continuing worldwide embarrassment and
danger of TB.
In 1955, soon after the introduction of wide-
spread use of TB drug therapy, Professor
James Waring at Colorado pointed out in
JAMA that TB was unique in that, essentially,
it stayed around and spread until it was prop-
erly treated. In other words, it doesn’t go
away.
The global situation with TB reminds me of
the man who advertised FRAM Oil Filters on
television several years ago. In that commer-
cial, a scruffy garage-mechanic type ap-
proached the camera holding an oil filter in
one hand and a burned out car engine in the
other. He stated: “Last week the owner of this
car could have had a new FRAM Oil Filter for
$4.95.  He decided not to buy it. Today he has
to buy a new car engine for $1,275.00.
“You can pay me now. . . or you can pay me
later.”
The Model TB Prevention and Control
Centers: History and Purpose
by Elizabeth J. Stoller, MPH
Former Director, Francis J. Curry National TB Center
and Russ Havlak
Former Assoc. Dir. for Special Projects, DTBE
On January 22-23, 1992, a conference on
multidrug-resistant TB (MDR TB) was held at
CDC in Atlanta.  Part of the strategy outlined
in the resulting National Action Plan to Com-
bat Multidrug-Resistant Tuberculosis was to
establish centers of excellence for treating
difficult-to-manage TB cases, especially MDR
TB cases. The Plan also called for developing a
cadre of health-care professionals with exper-
tise in the management of TB and MDR TB
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through training. In 1993, the CDC Division
of TB Elimination released a request for
proposals for Model TB Prevention and
Control Centers as a competitive supplement
to the Surveillance, Prevention, and Control/
Elimination cooperative agreements. The
federal funds appropriated to support emer-
gency TB grants were targeted to the 13 states
and cities that had reported the largest num-
bers of TB cases in 1992.
Model TB Centers were to be located in high-
incidence urban areas. The recipient health
department was required to utilize a current,
or establish a new, relationship with a school
of medicine or public health for Center opera-
tion. The Centers were to provide
1. Comprehensive, coordinated state-of-
the-art diagnostic, treatment,
prevention, and patient education
services for TB cases, suspects, contacts,
and recipients of preventive therapy
(treatment for latent TB infection);
2. Innovative approaches for ensuring
adherence with drug therapy and for
carrying out other prevention and
control activities; and
3. Training for all levels of health care
workers providing TB screening,
prevention, and control services within
the targeted area.
Three sites were selected for Model Center
awards: Newark, NJ, New York City, NY,
and San Francisco, CA.
The New Jersey National Tuberculosis Center
is located at the University of Medicine and
Dentistry of New Jersey, serving Newark and
Essex County. The New York City operation
is located at the Harlem Hospital Center, and
serves Central and East Harlem.  The San
Francisco Center is operated by the TB
control program of the San Francisco
Department of Public Health, and includes the
surrounding Bay Area counties as the target
area.
The programmatic emphasis of each Center
was designed to address the needs of each
respective target area.  New Jersey developed
an integrated approach to managing high-risk
urban populations through interdisciplinary
teams and a nurse case management model,
telephone information services for health care
professionals and the general public, and a
comprehensive training program.  The
Harlem Center featured enhanced clinical
services, a clinic-based DOT model, and
training of house-staff and community
physicians.  The San Francisco program was
designed to replicate local successful program
components in surrounding jurisdictions in
the target area, as well as offer enhanced
regional surveillance, laboratory and
institutional “hazard evaluation” services,
clinical and epidemiologic consultation
services, and a comprehensive training
program.
In 1997, Kenneth Castro, MD, Director,
Division of TB Elimination, CDC, called a
meeting of the Model Center principals to
discuss a change in programmatic emphasis for
the Centers.  While the expectation was that
activities would continue, efforts should be
made to “capture” the outcome of each major
effort in some sort of enduring product.  This
would allow other TB Control programs in
the nation to make use of the strategies and
tools developed, tested and/or perfected by
each of the Centers.  The Centers were asked
to redesign their programs in accordance with
the new directive and submit proposals with
exhibits organized under three headings: State-
of-the-Art Care, Training, and Innovative
Activities.  Effective January 1998, the Centers
shifted into “product” mode.  In less than 2
years, the Centers have developed and
disseminated the following innovative
program products:
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Harlem:
• Six case studies to be used for training
physicians in clinical management of
TB infection and disease
• Improving Treatment Completion for
Latent Tuberculosis Infection among
Health Care Workers, a guide for
employee health services and chest
clinics
• Tuberculosis Training for International
Medical Graduates, a guide for
residency program directors, health
administrators and TB control
programs
• Social Support Services for
Tuberculosis Clients, a guide to help
providers establish and enhance social
support services
New Jersey:
• A TB School Nurse Handbook
• Guidelines for a School-Based Directly-
Observed Therapy Program
• Tuberculosis Preventive Therapy
Database for patient tracking and
outcome evaluation
• TB drug treatment pocket card for
clinicians
• Standardized patient scenarios
San Francisco:
• A series of guidelines on institutional
infection control measures
• A videotape on engineering methods
for institutional  M. tuberculosis
prevention
• A CD-ROM on patient management
• A searchable database of TB training
and education resources from
throughout the US and international
programs
• A software program (TB Info) for real-
time program data analysis
The three Centers have undertaken several
collaborative efforts, including the
development of a national strategic plan on
tuberculosis training and education; a national
satellite broadcast series for health care
providers; and print-based educational
materials for civil surgeons and panel
physicians.  Collectively, the Centers have
provided training to tens of thousands of
health care providers and the public health
workforce, and consultation to providers from
a broad range of practice settings.
The Centers continue to operate in response
to the needs of the programs in their
respective target areas and, with guidance from
the CDC, the National TB Controllers
Association (NTCA), and the National TB
Nurse Consultant Coalition (NTNCC),
increasingly in response to the needs of the
nation. These Centers are designed to meet
your program needs: be sure to contact them
for assistance or for resources.




Charles P. Felton National Tuberculosis
Center at Harlem Hospital (New York)
Web address: www.harlemtbcenter.org
Telephone: 212/939-8254
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My Perspective on TB Control over the
Past Two to Three Decades
by Jeffrey Glassroth, MD
Prof of Medicine, Univ of Wisconsin Medical School
President, American Thoracic Society
In 1975 case rates for tuberculosis (TB) in the
United States were in double digits per
100,000.  Increasingly, those patients were
individuals with serious social problems.  A
major concern at CDC that year was the
screening for TB of newly arriving Vietnamese
refugees; the treatment of active cases was
provided, and notification to local health
departments of latently infected individuals
was undertaken. There was also concern about
the quality of immigrant screening done
overseas, but the major focus of “imported”
TB was along the border with Mexico.
Monitoring of TB drug resistance, particularly
primary resistance (i.e., among persons not
previously treated), was pursued and,
reassuringly, indications were found that these
rates were generally stable and low,
particularly with respect to rifampin.  A major
treatment study was beginning and it would
help to define the role of rifampin in so-called
“short-course chemotherapy,” meaning 9
months of daily treatment as opposed to the
standard of 18-24 months that existed at the
time.  “TB Today!,” an intensive educational
program that provided essential knowledge to
TB control staff from around the country,
presented material on TB microbiology and
diagnosis that emphasized the (then) state-of-
the-art methods; a description of classical
microbiologic techniques that had changed
little in the near-century since Koch described
the tubercle bacillus.  Also taught in the course
was a segment on optimizing the use and
interpretation of the tuberculin skin test for
identifying TB infection.  A study was about
to begin to assess the importance of skin test
boosting when sequential tuberculin tests were
applied.  Much of what was underlying those
efforts with tuberculin skin testing actually
reflected concerns and frustrations with the
use of isoniazid (INH) for treating latent TB
infections, so-called TB prophylaxis.  On the
one hand prophylaxis was effective but, on the
other hand, it came with a risk of side effects,
most notably hepatitis. The challenge was to
identify, via skin testing, the persons most
likely to derive benefit from INH and least
likely to be harmed by it; a classic benefit/risk
“equation.”  BCG vaccination, though widely
used outside the US, was rarely used here,
because of perceived limited effectiveness and
problems with skin test interpretation.
The intervening quarter century has seen
remarkable changes with respect to TB but, in
some ways, little has changed.  A number of
years ago, then–CDC Director Dr. James
Mason urged that CDC’s TB unit not think in
terms of TB “control” but of “elimination.”
The name of the unit changed to reflect this
new, more ambitious mission.  Indeed, in the
US, after some years of rising rates, TB rates
are again falling and are a fraction of what
they were 25 years ago.  However, in many
ways the challenges to TB elimination in the
US are greater today than a quarter century
ago.  Worldwide, TB prevalence is increasing,
and today over 40% of cases reported in the
US are “imported” in the person of
immigrants from high-prevalence countries.
The worldwide TB burden is fueled by HIV
infection, an entity unknown in 1975, which
facilitates every aspect of the natural history of
TB from transmission to disease.  In
recognition of this, and to more efficiently
combat these interrelated public health
problems, the TB division at CDC is now
administratively “housed” with the HIV
division.  Moreover, CDC has dramatically
increased its worldwide collaborations to assist
in efforts at containing TB abroad.
Rifampin is now well entrenched as a
cornerstone of treatment, and several related
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rifamycins have come into use.  Short-course
therapy has been further abbreviated to a
standard of 6 months’ duration by adding
pyrazinamide during the first 2 months of
treatment.  Moreover, the proven efficacy of
intermittent treatment has facilitated the
widespread use of directly observed or
supervised therapy (“DOT”) as a means of
improving adherence to treatment and is a
major factor in treatment success.
Unfortunately, drug resistance has become an
additional issue contributing to treatment
problems.  Moreover, resistance is increasingly
a problem with the rifamycins (almost
unheard of 25 years ago), and outbreaks and
sporadic cases of multidrug-resistant TB (MDR
TB) represent a major concern for clinicians
and public health officials alike.
Perhaps nowhere has change been more
dramatic than in the area of diagnostics.
Although skin testing is fundamentally
unchanged, the microbiologic approach to TB
diagnosis has been revolutionized by the
application of molecular biologic techniques.
Thus, laboratories are now capable of
obtaining genetic material from small numbers






segments of DNA or
RNA that are unique to
TB.  Refinements of
these techniques also
permit the identification
of resistant strains in
some cases and the
tracking of outbreaks or
mini-epidemics, and help
us better understand the
epidemiology of the disease as it currently
exists.  Such techniques hold the very real
promise of rapid, highly sensitive, and
specific diagnostic tests for TB disease.
Powerful tools indeed!
Preventive treatment of latent TB infection
still emphasizes the use of INH.  However,
because of occasional concerns about resistance
to INH, and also in an effort to reduce the
time required to complete a course of
preventive therapy, other regimens —
particularly those using rifampin — have been
increasingly used and shown to be effective
(though more costly) alternatives to INH.
Although additional studies have documented
the limitations of BCG vaccination, there is
increasing interest, in the US and abroad, that
through the technical developments of recent
years, more effective vaccines are feasible.
Given the worldwide problems I have noted,
application of a truly effective vaccine would
be a logical strategy for dealing with this
disease.
So what has happened in TB in the last 25
years?  Lots of change and technologic
development but fundamental challenges
remain.  Worldwide the number of cases is
rising and treatment is becoming more
difficult in some regions.  In the US, numbers
have declined but current cases often require
more resources and sophistication to treat than
they did even just a few years ago.
History of the IUATLD
by Donald A Enarson, MD
and Annik Rouillon, MD
International Union Against TB and Lung Disease
68 boulevard Saint-Michel, 75006 Paris FRANCE
The International Union Against Tuberculosis
and Lung Disease (known to its members as
“the Union”) is the only international
voluntary organization dealing specifically
with TB. It is very special in terms of its
structure, membership, and diversity of
activities.
Roots of the Union, 1867-1914
TB was presented as a communicable disease
in the first international conference of
medicine specialists convened in Paris in 1867.
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Conferences specifically addressing TB
followed in Paris in 1888, 1891, 1892, and
1898. The 1899 conference took place in Berlin
and, for the first time, official representatives
from both governments and nongovernmental
agencies were present. The independent
developments of sanatoria (1854), the
discovery of the bacillus (1882), the opening of
TB dispensaries (1887), the development of the
voluntary movement (1890), and the
organization of periodic conferences called for
a centralized agency for coordination and
communication. The Central Bureau for
Prevention of Tuberculosis was formalized in
Berlin in 1902, and the double-barred cross
was adopted then as its symbol. Periodic
international conferences systematically
addressing clinical, research, and sociological
aspects of TB were held until the outbreak of
the First World War in 1914.
Establishment of the Union, 1920-1939
In 1920, a conference on TB was convened in
Paris in which 31 countries participated,
including Australia, Bolivia, Brazil, Chile,
China, Colombia, Cuba, Guatemala, Japan,
Panama, Paraguay, Iran, and Thailand, in
addition to those of Europe and North
America. In an impressive procession,
delegates one by one pledged “to agree on the
means to fight TB, to make a consensus on the
strategy, to jointly apply the most effective
weapons to combat this common enemy,”
thus establishing the International Union
Against Tuberculosis (IUAT) in its present
form. It was conceived as a federation of
national associations (130 by 1999). Ten
international conferences followed until 1939.
In order to supplement the routine reports of
the conferences, a regular publication was
commenced in 1923. In this prewar period, the
Bulletin included administrative reports and
statistics (subsequently compiled by WHO) as
well as information on the strategy and
policies for the fight against TB and results of
numerous surveys on specific aspects of the
disease and the campaign. The Bulletin
continued publication until mid-1940, the final
editions containing the main reports to have
been given at the 11th conference planned for
Berlin in September 1939, the very month
when the Second World War commenced.
Relaunching of the Union, 1946-1961
At the first reunion of the Executive
Committee after the war in 1946, the IUAT
recommended to the planners of the future
World Health Organization “establishment of
a strong Division of Tuberculosis.” Official
relations with the WHO were then established
which continue to the present time.
The first postwar conference in 1950 in
Copenhagen, with participation of 43 nations,
was followed by a series of conferences, with
the 29th world conference in Bangkok in 1998,
when 105 countries participated. Conferences
outside North America and Europe were held
in Brazil in 1952, India in 1957, and Turkey in
1959. During this period a series of
international symposia were also organized,
generally in Paris, addressing a variety of
topical issues such as TB in Africa, strain
variation in BCG, radiography for TB, new
drugs, and the role of voluntary agencies,
among others.
In order to strengthen the administration of
the growing agency, a post of full-time
Executive Director was established in 1952. A
system of quotas was devised for membership
contributions. Over many years, the
American Association has continually
maintained a high quota share. Fees were also
levied from individual members. In 1951,
scientific committees were commenced and
met annually for intensive discussion of the
emerging strategy for the fight against TB. In
1953, regions were established in order to
remain close to where the needs are. In 1958,
the first international collaborative clinical
trial for treatment of any disease was
undertaken, with a total of 17,391 patients
from 17 countries evaluated for drug
resistance. This was followed by a
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collaborative controlled clinical trial starting
in 1960, to evaluate the efficacy of
chemotherapy in previously untreated
patients. In this period, the IUAT contributed
to annual international courses on TB control
sponsored by WHO in Istanbul, Prague,
Rome, and Caracas.
A global view 1961-1978
In 1961, at the suggestion of the Executive
Director, Dr. Johannes Holm, the Mutual
Assistance Program was launched to
encourage transfer of technology, resources,
and information from industrialized to newly
independent countries, through the agency of
national associations in the developing
countries. This was followed by travelling
seminars in Africa and in Eastern and Middle
East regions, and by field projects in Mali, Sri
Lanka, Peru, and India, among many others.
In this period, the scientific committees
continued to focus on the strategy for TB
control. Some examples of the activities
follow. In 1961, two international
collaborative studies evaluated the test
characteristics of 1,099 films read by 90 readers
from 7 countries and WHO. A subsequent
study evaluated sputum smear microscopy.
Starting in 1965, an international collaborative
study on tuberculin skin testing evaluated
75,000 children in 21 countries. Further
controlled clinical trials addressed the issue of
previously treated patients and daily self-
administered versus intermittent supervised
regimens. In 1968, a survey evaluated adverse
reactions to BCG vaccination, with over
10,000 events analyzed.  Also in 1968, A
Technical Guide for Sputum Smear Microscopy
was published; the 5th edition of this guide was
published in 1999.
In 1965, the Tuberculosis Surveillance
Research Unit was established under Dr. Karel
Styblo. It developed an index to evaluate
infection and its trends, clarified the natural
history of the disease (including transmission
probabilities and risk factors), and estimated
the impact of control measures. In 1969, in
collaboration with the then–Communicable
Disease Center of the United States and seven
member countries in Eastern Europe, an
international trial of preventive chemotherapy
for fibrotic lesions of the lung in 25,000
individuals was commenced and was evaluated
over 5 years of follow-up. In 1973, it was
proposed that the mandate of the IUAT be
extended to include other lung diseases.
However, the name of the organization was
not changed to reflect this extension until 13
years later.
In 1975, Dr. Halfdan Mahler, Director
General of WHO, publicly acknowledged the
crucial role played by the IUAT in the fight
against TB.  In early 1976, 18 NGOs
(nongovernmental organizations) responded to
IUAT’s invitation to consider jointly the role
which NGOs may and should play in primary
health care (PHC) programs. The resulting
position paper was presented at the joint
UNICEF / WHO International Conference
on PHC in Alma Ata in 1978.
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Modeling the global fight against TB, 1978-
1991
In 1978, in response to a request from the
Minister of Health of Tanzania, the IUAT
proposed the establishment of a National TB
Program under the direction of the
government and with support and
coordination of the IUAT. This proposal was
the basis of a new program of Technical
Assistance of the IUAT and became the basis
in 1979 for the first edition of the TB Guide.
Such assistance eventually extended to nine
low-income countries and became the basis of
the current DOTS Strategy of the WHO.
In 1981, the IUAT became the first
organization to adopt a policy that its
meetings be designated “non-smoking”
conferences.  In 1982, the Koch centenary was
celebrated at the 25th conference in Buenos
Aires, where the Koch Medal of the IUAT
was awarded to Drs. Johannes Holm and
Wallace Fox. That same year saw the
establishment of World TB Day on March 24
each year, following a proposal by the Mali
Association.  In 1984 the IUAT was officially
registered with USAID, a very rare privilege
for a non-US agency.  The IUAT officially
changed its name in 1986 to the IUATLD to
reflect the inclusion of other lung diseases in
its mandate. In 1987, a delegation from the
IUATLD visited WHO to encourage it to
consider the problem posed for TB by the
emergence and spread of HIV infection that
had been noted in the collaborative projects.
In 1989, the Burden of Health Study carried
out by Harvard University was pivotal in
demonstrating the cost-effectiveness of the
IUATLD model, which was instrumental in
convincing planners and policymakers to
adopt the strategy as a part of the general
health services.
A global fight, 1991-present
The principles of the model National TB
Program, outlined on the occasion of the
retirement of Dr. Styblo in 1991, were
subsequently enumerated as the “DOTS”
Strategy, promoted as the official policy of the
WHO. In that year, the international TB
training course of the IUATLD was first held
in Arusha, Tanzania, to illustrate the
principles of the model program. From 1993
to 1996, the training and technical support
activities of the IUATLD were extended from
a largely African base to represent every
region of the world. In 1996, the IUATLD
entered into a formal agreement to provide
training fellowships with support from the
International Fogarty Foundation.
By 1998, field activities involved 10 countries
in the Eastern Region, 5 in the Middle East, 10
in Africa, 15 in Europe, 8 in Latin America,
and 2 in North America. The network of
courses in management included Tanzania,
Benin, Nicaragua, and Viet Nam, and the
courses on research methods included Turkey,
Kenya, South Africa, Mexico, Chile,
Argentina, Brazil, Peru, Malaysia, and China.
During this period, more than 1 million
patients with TB were cared for in the context
of the collaborative programs of the IUATLD.
In 1998, the IUATLD joined with the WHO
and other international partners to form the
“Stop TB” Initiative in the hopes of extending
the model to all countries of the world.
These activities were made possible thanks to
funds entrusted to the Union from richer
associations and by governments of a number
of affluent countries.
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Characteristics of the IUATLD
The distinguishing qualities of the IUATLD,
besides its universality, its spirit of solidarity,
and its tolerance, are its continual striving for
quality and its independence. Thanks to these,
it provides the international community with
an invaluable asset, namely, its pioneering role
in devising and encouraging or testing
innovations. It provides a neutral platform for
international collaboration, exchange of
information, friendship, mutual esteem and
education, and a reduction of prejudice. It
maintains not only a program of scientific
conferences and publications but also a
program of action for health in the
community, comprising technical assistance,
education, and research. Dr. Gro Harlem
Brundtland outlined the future in the
following statement to the 51st session of the
World Health Assembly in Geneva in 1998:
“We must reach out to the NGO community.
Their reach often goes beyond that of any
official body. Where would the battle against
leprosy, TB, or blindness have been without
the NGOs?”
Thoughts about the Future of TB Control
in the United States
by Charles M. Nolan, MD
Director, TB Control Program
Seattle-King County Dept of Public Health
It is gratifying, isn’t it, to be back on the
pathway toward TB elimination.  I guess it’s
true that we who work in TB control had
more prominence and visibility in the recent
era during which TB was resurgent; a
declining public health problem is never very
newsworthy.  Still, speaking personally, the
satisfaction of watching the regular declines in
US TB morbidity each year since 1992 exceeds
the cheap thrill of being interviewed by local
TV news personalities about the looming
threat to our community of resurgent TB.
But what does the future hold for TB
controllers?  Will we continue to see our
efforts rewarded by predictable declines in TB
case numbers and rates into the indefinite
future, until we finally arrive at our goal, the
elimination of TB from the US?   Even though
we are good people, working toward a noble
cause that we deserve to achieve, I submit that
this optimistic view of an inevitable future
decline of TB in the US is not necessarily our
destiny.  I fear that as we continue to work
against TB in its current epidemiological
expression in the US, we may be destined to
reach a point at which the force of TB control
is balanced by the force of the disease in our
population. In that scenario, with neither
opposing force having the upper hand, TB
morbidity in the US will not continue to
decline but will become level.
I am emboldened to hypothesize, in the
absence of new factors in the equation, a
forthcoming equilibrium between TB and TB
control in the US, and a stabilization in the
TB incidence rate in the US, because that is
precisely what has happened in recent years in
my community. The accompanying figure
portrays the numbers of TB cases reported in
Seattle-King County, Washington, and in the
US from 1990 through 1998.  Even though the
numbers of cases represented in the two
jurisdictions differ dramatically, the trend is
unmistakable; during a period in which the TB
morbidity in the US declined by 35%, that in
Seattle-King County remained basically stable.
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(If annual incidence rates rather than case
numbers had been presented, the trends would
have been the same).
Here is my explanation for the trends shown
in the figure. At the national level, we are now
reaping the harvest of reinvesting in good TB
control. We have secured the necessary
funding and have applied those funds
strategically throughout the country to
strengthen surveillance and case finding, to
expand directly observed therapy for TB cases
in order to increase completion rates and
reduce acquired drug resistance, and to stop
nosocomial transmission and other pockets of
current transmission of TB.
Speaking in terms of a theory of TB control,
our investment has allowed us to regain the
ground that was lost during the resurgence by
applying to their best advantage our current
tools (this fact was noted in a JAMA editorial
written in 1997 by Drs. Bess Miller and Ken
Castro of the Division of TB Elimination).  In
that sense, the drop in cases and case rates
nationally represent a reduction in “excess
morbidity” that arose during the time when
the national infrastructure was weakened in
relation to the strength of the dual epidemics
of TB and HIV, increased immigration from
high-prevalence areas, and person-to-person
transmission of TB,  including nosocomial
transmission.
Some places such as Seattle, however, did not
experience the full power of the TB
resurgence. For example, we were only
modestly impacted by the HIV/TB
phenomenon, with rapid person-to-person
spread of disease, and MDR TB.  Our
infrastructure had not been dismantled, and
we experienced less excess morbidity in those
bad days.  In the decade of the 1990s, however,
even though we believe we have a good
program structure, a talented staff, and
funding sufficient to allow us to do good TB
control work, we have failed to effect a
meaningful reduction in TB morbidity in our
community.  In other words, we appear to
have reached an equilibrium with our target
disease, given its current epidemiological
pattern in our community.  This experience is
the basis for my suggestion that it is possible
that the nation as a whole will also reach such
an equilibrium point, once its excess TB
morbidity has been “mopped up.”  When that
point may be reached, and at what level of
morbidity, I of course cannot say.
I don’t want to leave the impression that we
have passively accepted the current status quo
in Seattle.  We are aggressively attempting to
disrupt the equilibrium between TB and TB
control by learning more about the
epidemiology of TB in our community and by
increasing the effectiveness of our community-
based TB control plan.  For example, in our
community, persons born outside the US
account for 70%-75% of cases, and RFLP
survey data suggest that nearly all of our cases
in foreign-born persons arise through
reactivation of latent infection, including
persons who have received preventive therapy.
This information suggests that we need to
expand treatment of latent TB infection in
high-risk foreign-born persons; to accomplish
that, we have established a Preventive Therapy
Partnership Program with a number of health
care facilities that provide primary health care
to high-risk foreign-born persons.  Also, given
that we regularly see TB occur in foreign-born
persons who have received preventive therapy
in the past, we are reevaluating the traditional
approach to preventive therapy, and have
secured funding to develop new approaches to
increase the uptake and completion of
preventive therapy by newly-arrived
immigrants and refugees.
Should the nation encounter such a “mud
hole” in the road to TB elimination, similar
strategies will be required to move beyond it.
ACET, in its recent publication, TB
Elimination Revisited: Obstacles, Opportunities,
and a Renewed Commitment, has made several
practical suggestions, including the need for
Notable Events in TB Control
39
every locale and/or state to understand the
unique nature of its own TB problem, in order
to apply current tools for TB control to their
best advantage. The establishment of new
partnerships to reach locally-identified high-
risk groups is another important new concept.
Another way that an equilibrium between TB
and TB control may become tipped in favor of
TB control is by the introduction of new tools
for the diagnosis, treatment, or prevention of
TB.  This point was also made by Dr. Miller
and Dr. Castro in their JAMA editorial.
Consider, for example, the advantage of being
able to identify, among a population of 100
persons screened and found to have positive
tuberculin skin tests, the handful that are
destined to develop TB in the future, and to
offer treatment only to those who are truly at
risk, rather than to the entire cohort.
Likewise, based on forthcoming ATS/CDC
recommendations, we now have a range of
options for treatment for latent TB infection,
which should result in more effective use of
that preventive intervention. Finally, given the
events of the past year, with burgeoning
interest in a TB vaccine on the part of the US
government, private philanthropic
organizations, and the pharmaceutical
industry, the notion of a TB vaccine at last (in
the immortal words of Ken Castro) “passes the
laugh test.”
Even as Seattle’s current impasse with TB has
served to motivate us to redouble our efforts,
to think creatively, and to engage new
partners in our struggle, I am confident that,
should our trend become a national one, the
nation will be equal to that challenge.  “The
man (or woman) who is tenacious of purpose
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Where We’ve Been and
Where We’re Going:
Perspectives from CDC
Early History of the CDC TB Division,
1944 - 1985
by John Seggerson
Associate Dir. for External Relations, DTBE
In 1944, Congress passed the Public Health
Service Act, which authorized grants to the
states for TB control and established the
“Division of Tuberculosis Control,” then
located in Washington, DC. At the time of the
creation of the TB Division, TB drugs were
not available, and the primary method of TB
control was the isolation of persons with
active disease in TB sanatoria where they were
“treated” with healthful living, bed rest,
calorie-laden meals, fresh air, sunshine, and
sometimes with surgery and/or collapsed lung
therapy.
From the beginning of the 20th century, the
National Tuberculosis Association (later the
American Lung Association), and its state and
local affiliates, played a major role in establish-
ing and supporting the TB sanatorium move-
ment in the US. During the post-WW II
period and into the 1950s, TB associations and
health departments employed small-film x-ray
units to conduct TB screening in general
populations, with one x-ray unit often screen-
ing as many as 500 persons per day. The
screening did not effectively cover large city
populations and by 1947, the PHS Division of
TB Control was operating mobile x-ray unit
teams in some 20 cities of more than 100,000
population which participated in this PHS big
city program. By 1953, after some 20 million
people had been x-rayed for TB, the program
was discontinued owing to declining yield and
high cost. Many health department and TB
association community x-ray screening pro-
grams were also discontinued, although some
continued until the late 1960s.
In 1959, a group of nationally recognized TB
experts was convened in Harriman, New
York, to review the status of US TB control,
and they issued the “Arden House Report,”
which recommended the eradication of TB
with effective treatment programs to cure
disease and prevent spread. The Arden House
group also recommended isoniazid treatment
of latent TB infection based on extensive PHS
chemoprophylaxis trials.
In late 1960, the PHS TB program, by then
renamed the “Tuberculosis Branch,” was
transferred from Washington, DC, to Atlanta,
to what was then called the Communicable
Disease Center. The TB research activity
remained in Washington for the time being,
then was also transferred to Atlanta in the
early 1970s.
In the 1960s it became increasingly obvious
that long-term hospitalization of patients with
active TB was no longer necessary because of
the availability of effective chemotherapy, and
the TB Branch began to advocate that patients
receive most or all of their care on an out-
patient basis. The sanatoria began to close,
with most of them being closed by the end of
the 1970s. It has been estimated that the
closing of the sanatoria represented a savings
of more than $400 million to state and local
governments.
In 1963, in response to a special Surgeon
General’s Task Force report on TB, categori-
PHS mobile x-ray unit
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cal TB grant programs were established and
funds were utilized to address the two newly
emerging major challenges in TB control:
establishing outpatient TB control services and
designing ways to effectively identify and treat
TB and asymptomatic latent TB infection.
Long before the hospitals all closed, sanato-
rium clinicians began lowering the hospitaliza-
tion period from the entire treatment period
of 18-24 months gradually down to only the
first 6 months or less. This meant that patients
with uncomplicated TB were treated on an
outpatient basis for up to 18 months. There
literally were no outpatient clinic programs in
most of the country; and in many places,
when patients were discharged to outpatient
care, they had to return frequently to the
sanatorium for outpatient exams and medica-
tion refills. Public health nurses had for years
been doing routine contact investigations in
the field, but most health departments did not
have the outreach staff needed for all these TB
patients suddenly being treated on an out-
patient basis.  Acquired drug resistance due to
outpatient treatment lapse became an impor-
tant problem.  So as TB sanatoria began to
increasingly discharge patients early, health
departments had to provide both the TB
clinics and the follow-up staff needed to ensure
completion of treatment and preventive
therapy. The TB branch consulted with health
departments in this undertaking which in-
cluded establishing or improving TB registers
needed to effectively monitor and track TB
treatment and follow-up for TB patients.
INH had been introduced in 1952, but its
prevention possibilities were not realized until
Edith Lincoln in New York noted that chil-
dren with primary TB treated with INH had a
much lower incidence of serious TB complica-
tions. She suggested controlled trials to look at
the possibility of using INH as preventive
therapy for TB. Soon, the controlled trials
conducted by TB Research Section staff
(Shirley Ferebee, Carol Palmer, George
Comstock, Lydia Edwards, and others) and
other institutions began demonstrating that
INH could be effectively and inexpensively
used to prevent TB infection from progressing
to disease.  In the mid-1960s, the TB Branch
began to promote and fund the implementa-
tion of the “Child-Centered Program,” which
prioritized the screening of school children to
identify TB infection and ensure that identi-
fied children completed a preventive course of
INH.  Part of the “Child-Centered Program”
was a concerted effort to conduct “cluster
testing” or follow-up of contacts to children
with TB infection to identify the infecting
“source case” and also to identify other in-
fected children who may have been exposed to
and infected by the same source case.
In addition to providing health department
categorical funding to help address these
challenges, the TB Control Branch and the
ALA’s American Thoracic Society regularly
updated and widely disseminated guidelines
for the diagnosis, treatment, prevention, and
control of TB.
Almost since its inception, the TB Branch had
collected, analyzed, and reported national
morbidity, hospitalization, and screening data,
and has also provided consultative staff to
support and review TB prevention and control
efforts at the state and local levels. During the
early 1960s, the TB Branch also began work-
ing with health departments to establish the
TB program management reports to evaluate
the effectiveness of TB prevention and control
efforts. Program management reports continue
to be an important component for evaluation
of national, state, and local TB prevention and
control efforts. Don Brown managed this
activity from the early 1960s until the mid-
1990s.  A new concept in the type of assistance
provided by the TB Branch was initiated in
the mid-1960s with the assignment of CDC
TB Public Health Advisors to assist health
departments in the operation and evaluation of
TB prevention and control programs. The TB
Branch also began recruiting and assigning TB
Medical Officers to health departments for 2-
year periods. These Medical Officers, along
with CDC Public Health Advisors, began
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working as a team with state and local TB
Controllers and their staff.  These assignees
were in effect “on loan” to the health depart-
ments and operated as state or local employ-
ees, although they were subject to frequent
transfer by CDC among the health depart-
ments.  By the mid-1960s, almost every state
plus Guam and Puerto Rico had a TB project
grant (Wyoming did not).
The number of TB Medical Officers began to
decline after 1967 as recruitment became more
difficult and the categorical grants were phased
out. However, Public Health Advisors contin-
ued to be requested and effectively work in
health department TB programs where they
were supported by Partnership for Health and
later prevention block grants. The Advisors
and TB Medical Officers had a major impact
on TB control in the areas where they were
assigned and afterwards.  After serving in the
field, many of the TB Medical Officers contin-
ued on in public health and national TB
leadership.  Larry Farer and Dixie Snider
started as TB Medical Officers in Utah and
Oklahoma, respectively, and both later went
on to become directors of the TB Division.
There is a long list of other former TB Medical
Officers who continued in leadership roles in
TB including current ATS president Jeff
Glassroth, John Sbarbaro, Phil Hopewell,
Tony Catanzaro, and others.  The last of the
original TB Medical Officer field group was
Eric Brenner. (The concept of field Medical
Officers was revived on a smaller scale in the
early 1990s and continues today.)  The TB
Branch in the late 1960s and early 1970s also
supported a number of “Clinical Associates”
who were not PHS medical officers but
worked like “TB fellows” in pulmonary
training and were assigned to key institutions.
For example, Mike Iseman was assigned to
Harlem Hospital under Julia Jones. These
clinical associates were basically pulmonary
fellows working in pulmonary clinics who
concentrated on TB and worked in the TB
clinics. Lee Reichman was also a TB Branch
Clinical Associate, as was Ray McDonald,
who works in New Jersey with Dr.
Reichman.
No early history of the TB Division would be
complete without a mention of the “TB
Today!” course, which was conducted by the
TB Division from the late 1960s until the early
1990s. The course evolved from courses taught
at National Jewish Hospital in Denver and
Battey Hospital in Rome, Georgia. Seth
Leibler directed the development of this
course, working closely with the Director, Al
Holguin, and Don Kopanoff, who later served
as the TB Division’s Associate Director for
External Affairs. Later the course was imple-
mented by Ginny Bales, now CDC Deputy
Director for Program Management, and Kathy
Rufo, now Deputy Director of the Diabetes
Translation Division; they were all essential to
the design and early conduct of this course.
Later, Barbara Holloway (currently Deputy
Director of the CDC Epidemiology Program
Office) directed the course. It was designed for
key TB program managers including physi-
cians, TB Controllers, TB nurses who had
management responsibilities, and other TB
program managers. The course was presented
in a workshop format with heavy emphasis on
program evaluation and management by
objectives. The attendees worked through the
course using their own program’s TB morbid-
ity and program evaluation data. They devel-
oped objectives for their program based on
their unique problems, and developed strate-
gies for achieving the objectives.  They went
back to their programs and began to imple-
ment the plans and achieve the objectives.
Many of the TB Controllers from that era will
testify the course changed their whole ap-
proach to TB from a perspective of clinical
management of TB patients to one of manag-
ing programs and effectively supervising
people. Since the late 1960s, nearly every state
and major city TB Controller and head TB
nurse has attended the course, which has been
revised over time.
The 1970s were belt-tightening times for TB
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control staff at CDC and across the nation.
The last of the special TB project grants were
phased out by 1973. The TB Research Section
was transferred from Washington to Atlanta
with Jerry Weismeuller as Chief, but many of
the TB Research Section staff retired or moved
on to other positions rather than move to
Atlanta.  In 1974 the TB Branch again became
the TB Division. In 1976, Larry Farer became
Director of the TB Division and Dixie Snider
became Chief of the Research Branch.  John
Seggerson came to CDC as the Chief of Field
Services in late 1977, replacing Larry Sparks
who had served there before going to the
CDC Washington office and later serving as
Executive Director for NIOSH and then as
Deputy Director of NCIPC. Jerry Brimberry
worked as a TB consultant with Larry Sparks
and later moved on to Executive Officer of the
Diabetes Field Services Branch. The last of the
original TB Medical Officer field assignees,
Eric Brenner, left the field for Atlanta and the
TB Division in 1978.  In the late 1970s and
early 1980s, the role of the TB Division pro-
gram consultants was enhanced and they
became the lead contacts with health depart-
ment TB control programs for the Division,
establishing ongoing contact and close work-
ing relationships between the Division and the
field.  A long parade of very effective and
motivated TB program consultants moved
through the Division and on to higher level
positions: Charlie Watkins transferred to the
regional offices and then to CDC Chief of
Regional Affairs; Wilmon Rushing became
one of the first CDC AIDS officials and
moved up to the NCID Associate Director for
Management; Willis Forrester became Chief of
Field Services for the AIDS program; Chris
Hayden became Chief of the TB Communica-
tions and Education Branch;  Mack Anders
headed the TB Division field staff; George
Rogers is the PHS Deputy Regional Health
Administrator Director (Chicago), and Carl
Schieffelbein is the current DTBE Associate
Director for Special Projects. (The current
DTBE Field Services Section Chiefs, Joe
Scavotto and Greg Andrews, were also DTBE
program consultants.)
1980 was an especially difficult time for TB
programs when the block grants were com-
pletely phased out for a short time, there were
no categorical TB grants, and TB program
managers had to scramble to cover lost re-
sources.  This was a tough time also for TB
Division Public Health Advisor field assignees,
some of whom had to accept assignments in
other programs, while many stayed on in TB
field assignments where local health depart-
ments were able to cover their salary costs
with state or local funds under the Intergov-
ernmental Personnel Assignment Act.  Things
began to look up again in 1981 and 1982 when
categorical TB project grants were again
funded, although initially on a very small
scale. Since the TB Medical Officer field
assignee activity had been phased out by 1978,
the Division began recruiting physicians and
other scientists from the EIS officer group for
TB Division medical posts beginning with
Rick O’Brien, George Cauthen, Ken Powell,
Bess Miller, Hans Reider, and Alan Bloch,
who were the first of this respected group.
The TB individual case report was introduced
in the mid-1980s, enhancing the national TB
surveillance system.  Nonetheless, through the
late 1970s and early 1980s, many TB programs
increasingly felt the impact of cutting re-
sources that began in the early 1970s.  The first
documented outbreak of drug-resistant TB
occurred in 1976 and 1977 in rural Alcorn
County, Mississippi.  TB-related resources and
infrastructure continued to deteriorate in most
areas, and in the early 1980s, HIV/AIDS
began to affect TB, at first in Florida and then
in the New York City metropolitan area and
elsewhere.  Because of the decline of the
infrastructure, many health departments were
simply unable to cope with the emerging TB-
related problems associated with AIDS, along
with increasing numbers of foreign-born TB
patients and other problems having an impact
on TB.  By the mid-1980s the long-time de-
cline in the Nation’s TB morbidity trend
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ended and outbreaks of MDR TB in hospitals,
prisons, and other institutions were underway.
The following articles by the lead staff of
DTBE’s branches and programs will provide a
more current perspective on division activities.
CDC Funding for TB Prevention and
Control
by Patricia Simone, MD
Chief, Field Services Branch, DTBE
and Paul Poppe
Deputy Director, DTBE
Federal fiscal support for TB control began
with the passage of the Public Health Service
Act, which was created to assist states in
establishing and maintaining adequate mea-
sures for the prevention and control of TB.
To enhance case-finding activities, the 1955
Appropriation Act (Public Law 83-472) di-
rected federal grants with local matching funds
to be used only for prevention and case-
finding activities.  In 1961, Congress provided
for project grants that were to be used for
improving services to known TB patients
outside of hospitals, examination of contacts,
and diagnosis of suspects.  In December 1963,
the Surgeon General’s task force issued a
report recommending a 10-year plan to en-
hance the federal role in national TB control
through increased grants for services for
unhospitalized cases and inactive cases, contact
investigations, school skin test screening, and
hospital radiograph screening programs.  By
1967, there were 82 TB control programs in
the United States, with federal appropriations
of $3 million in formula grants and $14.95
million in TB project grants.
However, in 1966 the Public Health Services
Act was amended, changing project grants to
block grants. These new grants did not require
that any funds be used for TB control, and
many health departments eventually redistrib-
uted the funds to other programs.  While
categorical TB appropriations were restored in
1982, there were very modest amounts of
federal funding (approximately $1 million to
$9 million per year) available for TB control
until fiscal year 1992.
Despite an overall decline in funds being spent
for TB control, the number of reported TB
cases continued to decline nationally through
1984.  However, from 1985, the number of
cases began increasing and continued to rise
through 1992.  Recognition of the outbreaks
of multidrug-resistant TB, the high mortality
associated with TB in HIV-infected persons,
and transmission to health-care workers
resulted in strong recommendations for en-
hanced funding for TB prevention and control
programs and more stringent infection control
practices.  In fiscal year 1992 the appropriation
was increased to $15 million from the previous
year’s funding of $9 million. It increased again
in 1993 to $73 million, when Congress appro-
priated $34 million for the continuation and
expansion of the TB cooperative agreements
and $39.2 million in emergency funds for use
in the areas of the country most heavily
affected by the increased cases. Congress
appropriated yet another increase for categori-
cal TB grants in 1994, and the appropriation
for TB project grants was increased to over
$117 million. In addition, approximately $25
million in redirected HIV funds have been
available for TB control activities each year
since 1992, for a total of over $142 million in
funding for CDC for TB-related activities. As
a result of this infusion of funding, TB pro-
gram infrastructures have been rebuilt and the
results are evident with six consecutive annual
decreases in the number of reported TB cases
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Since 1994, however, CDC has received
approximately level funding for TB-related
activities. The Tuberculosis Elimination and
Laboratory Cooperative Agreement was
revised for FY2000 to ensure prioritization of
the core TB activities (completion of therapy,
contact investigation, surveillance, and labora-
tory) for all TB programs, with separate
funding provided on a competitive basis for
targeted testing and treatment of latent TB
infection for high-risk groups in programs
demonstrating good performance on the core
activities.
Federal funds are intended to supplement the
state and local activities for TB control and
prevention, and in many states, federal funds
represent only a small fraction of the total
funds available to the TB program. However,
in many other states, federal funds represent
the majority of TB funding available. Further-
more, some areas are actually reporting a
reduction in their state or local TB funding.
Yet the level of federal funding is expected to
again remain the same in fiscal year 2000 and
2001, which will result in a decreased amount
of available funds when inflation factors are
applied. Although cases have declined since
1993, the case rate of 6.8 per 100,000 in 1998 is
still far short of the target of 3.5 per 100,000
by the year 2000 set by CDC, and aggressive
TB prevention and control efforts must be
sustained to continue on a successful course to
elimination.  This will require the continua-
tion of our current efforts and the develop-
ment of new or increased funding initiatives at
every level, including federal, state, and local.
The Advisory Council for the Elimination of
Tuberculosis (ACET) published “Tuberculosis
elimination revisited: obstacles, opportunities,
and a renewed commitment” in the MMWR,
August 13, 1999/Vol. 48/No. RR-9, and also
stated the need for additional resources to fully
implement effective elimination strategies. In
addition to fiscal resources, ACET recom-
mended building a stronger advocacy at every
level of government as well as engaging new
partners at the local level, and strengthening
coalitions by revitalizing the National Coali-
tion for the Elimination of Tuberculosis
(NCET) to garner more private support, and
strategically utilizing the media to inform the
general public and legislators regarding TB.
Managed Care and TB Control –
A New Era
by Bess Miller, MD, MSc
Associate Director for Science, DTBE
After the TB sanatoria were closed during the
1960s and 1970s, typically both clinical care
and public health functions for TB control
were carried out in the health department
setting. However, during the past three de-
cades, there has been an increasing trend
toward the provision of clinical care for
patients with TB by the private sector. By
1998, about 50% of the care for patients with
TB was provided either partially or totally by
the private medical sector. More recently, the
managed care transformation has increased
this movement of patients with TB away from
clinical care in health department settings.
Patients with TB may be enrolled in managed
care organizations as a result of coverage under
employee benefit plans, privately purchased
insurance policies, or as a result of enrollment
in Medicaid or Medicare programs. The
Omnibus Budget Reconciliation Act of 1993
(OBRA) permitted states to extend Medicaid
coverage to persons with TB, and some states
have used this legislation to enroll such pa-
tients in their Medicaid programs. In addition,
as part of overall Medicaid managed care
restructuring, a few states have expanded
coverage to include previously uninsured
persons. The vulnerable populations among
the newly insured are likely to include persons
at high risk for TB. The shifting of care of
patients with TB into managed care plans,
with the emphasis on management of costs,
has raised new concerns in the public health
community with regard to the ability to
maintain adequate community TB control as
well as to provide optimal management of
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patient care in light of these changes.
A survey of state and big city TB controllers
conducted in collaboration with the National
TB Controllers Association in late 1997
revealed the following: 1) health departments
are still acting as the traditional provider of
TB clinical services in most areas of the coun-
try; 2) in some areas, however, managed care
has changed the way TB clinical services are
being delivered (examples of these new ar-
rangements included managed care organiza-
tions as providers of clinical services to their
enrollees with TB, health departments acting
as members of managed care organizations
provider networks, and health departments
acting as non-network, fee-for-service provid-
ers to managed care organizations); 3) health
departments are providing the majority of
public health services for TB patients who are
enrolled in managed care organizations (con-
tact tracing, providing directly observed
therapy, and returning lost patients to care);
4) many managed care organizations are using
their own or other private laboratories to
process TB specimens, rather than state labora-
tories; and 5) in many areas, health depart-
ments are not being consistently reimbursed
for providing TB services to patients with
private insurance coverage or Medicaid
coverage.
During the past several years, there have been
a number of symposia addressing the impact of
managed care on TB control, which were
conducted at national meetings of the Ameri-
can Public Health Association, the National
TB Controllers Association, and the Centers
for Disease Control and Prevention.  In these
symposia, a number of themes have emerged,
including the urgency of ensuring quality care
for TB patients by health care providers with
expertise in treating TB; continuous treatment
and completion of therapy with the use of
DOT; use of laboratories with expertise in
mycobacteriology; timely reporting of cases to
the health department and initation of contact
investigations; development and use of perfor-
mance measures to monitor patient care and
“public health performance”; and systems to
ensure ongoing dialogue between health
department staff and managed care organiza-
tion providers.
At the same time, there is recognition that the
delivery of health services through managed
care organizations presents opportunities to
public health leaders, including improved
access to high-risk populations for preventive
services and to health care providers for
training and education on best practices.  In
addition, the administrative data systems of
managed care organizations may provide
opportunities for improved surveillance and
evaluation of quality of care.  The Division of
Tuberculosis Elimination has collaborated
with Harvard Pilgrim Health Care, a large
mixed model health maintenance organization
in New England, to review the use of adminis-
trative data systems to augment tuberculosis
surveillance and the use of pharmacy records
to assess the management of tuberculosis.
(Please see “Supplementing tuberculosis sur-
veillance with automated data from health
maintenance organizations.” Yokoe DS,
Subramanyan GS, Nardell E, Sharnprapai S,
McCray E, and Platt R. Emerging Infectious
Diseases 1999; 5:779-787, and “Using auto-
mated pharmacy records to assess the manage-
ment of tuberculosis.” Subramanyan GS,
The pioneering industrial social worker Lee
Frankel envisioned insurance as a powerful
means toward improving the lot of the
underprivileged. When he was hired by the
Metropolitan Life Insurance Company, he
established MetLife’s Welfare Division.
Frankel’s early work centered on the
prevention of TB, the “white plague” that
accounted for 20 percent of all death claims.
He realized that public education was the
key. In 1909, 10,000 MetLife agents deliv-
ered Frankel’s pamphlet A War Upon
Consumption to millions of urban poor, who
are most at risk for TB (source: Metropoli-
tan Life Insurance Co. Web site).
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Yokoe DS, Sharnprapai S, Nardell E, McCray
E, and Platt R. Emerging Infectious Diseases
1999; 5:788-791).  Administrative data sets
provided useful information in both studies.
To assist health departments, State Medicaid
Agencies, and managed care organizations in
the development of written agreements to
ensure the provision of quality patient care
and public health TB prevention and control
practice, DTBE has collaborated with the
Office of Health Care Partnerships of the
Epidemiology Program Office, CDC, and
with the George Washington University
Medical Center’s Center for Health Policy
Research to develop model contract specifica-
tions. (Refer to the article “Tuberculosis
control in a changing health care system:
Model contract specifications for managed
care organizations.” Miller B, Rosenbaum S,
Stange PV, Solomon SL, and Castro KG.
Clin Infect Dis 1998;27:677-686.)  These
specifications can be accessed on the internet
at the following website: http://
www.gwu.edu/~chsrp.
Early Research Activities of the TB
Control Division
By George W. Comstock, MD, DrPH, FACE
Alumni Centennial Professor of Epidemiology
Johns Hopkins University
School of Hygiene and Public Health
Herman E. Hilleboe was the first Chief of the
Tuberculosis Control Division of the United
States Public Health Service, with Carroll E.
Palmer as director of the Field Studies Sec-
tion, the unit responsible for most of the
Division’s research.  This review is based
largely on perusal of the 70 Tuberculosis
Control Issues, published during the first week
of every month as special issues of Public
Health Reports.  This arrangement continued
from March 1, 1946, to December 7, 1951,
when Public Health Reports changed to a
monthly schedule.
The Student Nurse Study was initiated by
Palmer, and was supported by the National
Tuberculosis Association until the foundation
of the Tuberculosis Control Division. During
the period from 1943 to 1949, some 22,000
student nurses in 76 schools were given tuber-
culin tests every six months by a specially
trained team. On one of these occasions,
approximately 10,000 nurses were also given
chest radiographs. Comparison of skin test and
radiographic findings showed that many
pulmonary calcifications were due to histoplas-
mosis, that histoplasmosis was concentrated in
certain areas of this country, and that many
positive tuberculin reactions were due to
nontuberculous mycobacteria.
Confirmation of these results came from a
research unit established in 1945 in Kansas
City, Missouri, to study the epidemiology of
histoplasmosis.  Two little-known findings
deserve emphasis. In two midwestern counties,
there was remarkable local variability in the
frequency of histoplasmin reactions among
cattle. Farms with histoplasmin-positive cattle
were interspersed irregularly among those with
no reactors. (This marked small-area variability
was later found in Maryland among high
school students, suggesting that risk factors for
endemic and outbreak histoplasmosis are
different.)
Studies of tuberculin, histoplasmin, and various
nontuberculous mycobacterial antigens reached
their peak with the testing of more than a
million US Navy recruits from 1958 to 1969. A
detailed report of the results of the first half-
million tests delineated the extent of these
infections in cities, counties, and states. Other
important findings were as follows: a) in any
area with nontuberculous mycobacterial
infections, the larger the tuberculin reaction,
the greater the probability that its cause was
tubercle bacilli; b) the risk of developing TB
after infection was high among underweight
persons and low among the obese; c) there was
a suggestion that nontuberculous mycobacte-
rial infections conferred some resistance against
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TB; and d) there was also a suggestion that
social stress increased the risk of
developing TB.
A major purpose of the Muscogee County
(GA) Tuberculosis Study, started in 1946, was
to evaluate the role of mass chest x-ray surveys
in TB control. The prospectus and a descrip-
tion of the coverage of the survey and preva-
lence of TB were included in the first two
papers published on this study.  Calculation of
participation rates was made possible by the
population denominator provided by a private
census. Basic factors associated with participa-
tion and the prevalence among participants
were described, as well as reasons for not
taking part in the survey. Subsequent papers,
building on this foundation, were able to
provide information on the incidence of TB
among tuberculin reactors and the risks of
reactivation among persons with inactive TB,
information that has been used to the present
time.
The first report of the BCG trials in Muscogee
County and Russell County (AL) appeared in
1951. The school children vaccinated in 1947
were retested 6 months later, and many con-
trols and vaccinees were tested with tuberculin
again in 1950. Both groups had had less than 5-
mm induration to the 100-TU dose of PPD
tuberculin in 1947.  Although 46% of the
vaccinees had 5 or more mm of induration to
5 TU of PPD-tuberculin 6 months later, only
24% of them had reactions this large in 1950;
at that time, only 3% of controls had similar
reactions.  Subsequent follow-up of persons in
these trials produced findings that were com-
pletely unexpected at the time of their initia-
tion. In contrast to the belief that most TB
occurred very shortly after infection and that
those who survived this short-term risk were
relatively safe thereafter, approximately 80%
of TB developed among the initially positive
reactors who continued to be at risk.  This
finding dashed an early hope, namely that the
source of a new case of TB ought to be readily
found among recent contacts.  An unpublished
finding involved the first 56 cases among
survey participants who did not have a known
case in the household. Some 13,000 possible
contacts were identified (relatives, friends,
workers in the same factory, school mates,
etc.). Approximately 11,000 were examined,
with the identification of only one possible
but unlikely source case.  The facts that so
little TB developed among nonreactors (those
eligible for vaccination) and that BCG ap-
peared to cause harm among school children
and to afford very little protection to older
persons were major considerations in the
hesitancy to advise BCG vaccination in the
United States. Over a 23-year period, there
were slightly but significantly more cancer
cases among vaccinees than controls, most
markedly for tumors of the lymphoid tissues.
Many other studies were carried out by the
Field Studies Section during this period.
There were numerous reports relevant to mass
chest x-ray surveys, then in their heyday,
dealing with topics such as x-ray generators,
fluorescent screens, films, protection of per-
sonnel, and the feasibility of taking photofluo-
rograms without having participants disrobe.
The development of standardized fungal
antigens, notably histoplasmin, was also an
important endeavor. Finally, and far from
least important, was the publication of Carroll
Palmer’s ideas for research that could be done
in conjunction with the mass tuberculin
testing and BCG vaccination then underway
in the International Tuberculosis Campaign.
(Editor’s note: Dr. George Comstock con-
ducted the trials in Georgia from 1946 to 1955.
He continued to make major contributions to
the knowledge of TB and measures to prevent
the development of TB. After retirement from
the PHS he became the Alumni Centennial
Professor of Epidemiology at Johns Hopkins
University. Dr. David Sencer, a medical
officer, was then assigned to Georgia to con-
tinue Dr. Comstock’s work. He subsequently
rose through the CDC ranks to become the
Director of CDC, serving from 1966 to 1977.)
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The First TB Drug Clinical Trials
by Rick O’Brien, MD
Chief, Research and Evaluation Branch, DTBE
and George Comstock, MD, DrPH, FACE
Alumni Centennial Professor of Epidemiology
Johns Hopkins University
School of Hygiene and Public Health
The United States Public Health Service
(USPHS), together with the British Medical
Research Council (MRC) and the US Armed
Forces–Veterans Administration Cooperative
Trials, played a key role in the development of
the chemotherapy of TB.
The first USPHS trial, a placebo-controlled
study of streptomycin, was initiated by  the
Field Studies Section and the Tuberculosis
Study Section of the National Institutes of
Health (NIH) in 1947, the same year as the
much smaller but better known MRC study of
streptomycin. In the PHS study, a total of 541
patients with moderate to far-advanced pulmo-
nary TB were enrolled at 14 hospitals and
sanatoria throughout the US and Alaska.  The
published account gives no hint of how this
controlled evaluation of streptomycin was




a study of streptomy-
cin in the treatment
of TB had been
allocated, probably




there were to be no
controls, he was
upset and expressed
his concerns to Dr. Van Slyke, director of the
NIH. Van Slyke agreed with Palmer, and
directed that a controlled trial be planned and
conducted under the general supervision of the
newly convened Tuberculosis Study Section.
Dr. Esmond Long, from Phipps Clinic in
Philadelphia, was the chairman of the Study
Section’s Steering Committee.  Ms. Ferebee,
Chief of the Therapy Evaluation Branch, Field
Studies Section, became the study administra-
tor.  With some grumbling from those who
had lost their streptomycin allocation, a
controlled trial was conducted, although
without the placebo controls Palmer and
Ferebee had wished. All investigators took
part in various reviews of clinical and radio-
graphic findings and in committees set up to
consider appeals from the protocol, proce-
dures continued in future PHS therapy trials
as a way to bring investigators together and
give them a real part in major decisions.
The study demonstrated the remarkable
ability of streptomycin to reduce mortality
and improve clinical status. However,
monotherapy with streptomycin led to the
development of drug resistance in a significant
number of patients. In 1951, the one-year
status was reported for the patients given
streptomycin: 40% had negative cultures, 5%
had died, 17% still had tubercle bacilli sensi-
tive to streptomycin, and 39% had resistant
organisms.  In another 1951 report, PAS was
found to be highly effective in preventing
resistance to dihydrostreptomycin (similar in
action to streptomycin but with a higher risk
of ototoxicity.)
The second USPHS study, begun in 1949 at 11
institutions, randomized a total of 315 patients
to either streptomycin or streptomycin-PAS.
After 6 months of treatment, over 40% of
patients receiving monotherapy developed
streptomycin resistance, compared to only
12% of patients on combination therapy.
A major advance in TB treatment occurred in
1952 with the initial report of an MRC study
of isoniazid. During the next 2 years, a total of
5,324 patients were enrolled in three USPHS
trials (which became known as Studies 1, 2,
and 3), examining a variety of combinations of
the three drugs. The conclusion of these
studies was that the triple combination did not
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appear to be more efficacious than the combi-
nations of any two of the drugs.  However,
the combination of isoniazid and PAS was
much better tolerated.  Evidence from an
MRC study indicated that initial streptomycin
did contribute to treatment efficacy in patients
with advanced disease. Another MRC study
determined that the optimal duration of
therapy with these drugs was 2 years.
With the scientific basis for TB chemotherapy
firmly established, the PHS turned its atten-
tion to the next drugs that became available
for clinical study, pyrazinamide and cyclos-
erine. However, initial evaluation of pyrazina-
mide at much higher dosages than are cur-
rently used suggested that the drug was too
toxic for use in initial treatment, although it
appeared to have a role in the treatment of
drug-resistant disease.  Subsequently, through
a series of elegant studies in Africa and Asia,
the MRC defined the critial role of that agent
in modern short-course therapy.
While continuing to conduct treatment effi-
cacy studies, the USPHS also embarked on
pioneering studies of isoniazid for the preven-
tion of TB in persons with latent TB infection
(LTBI). Between 1955 and 1959, nearly 65,000
persons including children with primary TB,
contacts of infectious TB patients, patients in
mental institutions, and Alaskan villagers,
were entered into placebo-controlled trials that
demonstrated the efficacy of isoniazid for
treatment for LTBI.
In 1960, CDC was given responsibility for TB
control and research. However, the research
division resisted pressure to move to Atlanta
and continued its work from Washington. In
USPHS studies 12 to 16, the role of ethambu-
tol as a first-line drug replacing PAS was
defined.  In 1969, the USPHS began the first of
a series of studies of rifampin, ushering in the
modern era of short-course therapy.  Study 18
found that the combination of isoniazid and
rifampin was superior to the best regimen that
had been evaluated up to that time. USPHS
Study 19 evaluated various dosages of rifampin
and found that the optimal daily dosage was 10
mg/kg or 600 mg for most adults.
As rifampin-based short-course therapy be-
came firmly established, support for therapy
trials in the US began to wane.  Study 20, the
first USPHS study initiated after the research
division moved to CDC, attempted to dupli-
cate a smaller MRC study of a 6-month regi-
men of isoniazid and rifampin and found that
the relapse rate of 10% was unacceptably high.
Study 21, which began enrollment in 1981,
was plagued by continuing shortages in finan-
cial support such that the study was nearly
terminated several times before it successfully
completed enrollment. That study confirmed
the results found by the MRC and led to the
adoption of 6-month therapy in the US.  It
was not until the resurgence of TB in the US,
with the concomitant increased support for
TB research, that the capacity of the USPHS
to conduct high-quality TB treatment trials
was restored.
Current TB Drug Trials:
The Tuberculosis Trials Consortium
(TBTC)
by Andrew Vernon, MD, MHS
Research and Evaluation Branch, DTBE
The USPHS and the Veterans Administration
(VA) have a distinguished history of conduct-
ing clinical trials to evaluate new drug regi-
mens for both the treatment and prevention of
TB.  In 1960, CDC assumed a major role in
these studies when the USPHS Tuberculosis
Division was transferred to CDC. Subse-
quently, CDC coordinated a series of
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multicenter clinical trials that helped to estab-
lish rifampin-based, short-course therapy as
the standard for TB treatment.  It also con-
ducted studies to provide the scientific basis
for preventive chemotherapy, which remains a
major component of our TB elimination
strategy.
Support for the infrastructure required for
these studies gradually diminished, so that the
last completed trial, USPHS Study 21, was
nearly terminated several times during its
course for lack of adequate funding. With the
infusion of federal support for TB control and
elimination in the early 1990s, CDC estab-
lished a consortium of clinical investigators for
the specific purpose of conducting USPHS
Study 22, a trial of once-weekly isoniazid and
rifapentine in the continuation phase of
therapy for pulmonary TB. This consortium,
whose sites include public health departments,
academic medical centers, and VA medical
centers (VAMC), required both time and
substantial financial resources to establish and
support, but is now functioning efficiently.
   Did you know that...
   Aspirin was developed as a cure for
  tuberculosis? Researchers in Switzerland
   looking for a cure for TB were excited to
  discover that one particular compound
   was able to relieve the fever and pain of
   TB patients. They subsequently found that
   it only provided temporary relief, not a
   cure, and they put the drug aside.  The
  compound was later rediscovered and named
   aspirin (from A. Karlen, Man and Microbes,
     Putnam & Sons, NY, 1995).
Currently new drugs and regimens for both
TB treatment and prevention, new diagnostic
tests, and new vaccine candidates are becoming
available for clinical investigation. Concur-
rently, the challenges posed by the goal of TB
elimination are increasing, as global rates of
drug resistance increase and as the costs associ-
ated with assuring high rates of adherence rise.
The consortium now provides a unique and
important resource for further clinical studies,
and has demonstrated its ability to play an
important role in TB treatment and
prevention.
The original group of clinical sites included 12
academic centers and health departments (7
contracts issued in 1993, and 5 more in 1994),
and 15 VAMCs (funded through a Memoran-
dum of Agreement with the Washington, DC,
VAMC). Enrollment into USPHS Study 22
began in April 1995, and continued to comple-
tion in November 1998.  In 1997 CDC began
working with the USPHS Study 22 investiga-
tors to develop a structure that would engage
more fully the capacities of the study investiga-
tors in the work of the group. The TBTC was
thus organized, with formal by-laws adopted
in 1998. Several working committees were
established; these are composed of selected
Consortium investigators and coordinators, in
collaboration with CDC staff. One committee
(Core Science) oversees the scientific program
of research, a second (Implementation and
Quality) supervises the conduct and quality of
ongoing studies, and a third (Executive Af-
fairs) serves as the executive arm of the steer-
ing committee.  This structure is modeled on
the Community Programs for Clinical Re-
search on AIDS (CPCRA), which is supported
by the National Institute of Allergy and
Infectious Diseases (NIAID).
In 1999 the TBTC underwent a formal exter-
nal re-competition. New 10-year contracts
were awarded to 13 offerors (7 prior TBTC
members and 6 new sites). The VA side of the
consortium underwent a similar process, and
funded 10 VA Medical Centers to continue as
members of the TBTC.
The current studies of the TBTC are as fol-
lows:
Study 22: Randomized open-label trial to
evaluate the efficacy of once-weekly isoniazid
and rifapentine in the continuation phase of
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therapy for pulmonary TB. Enrollment closed
in November 1998 with 1,004 HIV-negative
participants. Follow-up will continue through
mid-2001.
Study 22 PK Substudy: Substudy to evaluate
isoniazid, rifampin, and rifapentine pharmaco-
kinetics in 150 patients enrolled in Study 22.
Currently in analysis.
Serum Bank Study: Collection of docu-
mented serum specimens from patients with
suspected or proven TB, from baseline
through the course of therapy.  Nearing
completion.
Study 23: Single-arm clinical trial to evaluate
the safety and efficacy of rifabutin-containing
short-course therapy for HIV-infected TB
patients receiving HIV protease inhibitors.
Aims to enroll 200 patients over 2 years, with
2-year follow-up. Enrollment began in March
1999.
Study 23a: Substudy to evaluate isoniazid and
rifabutin pharmacokinetics in Study 23 TB
patients with HIV receiving antiretroviral
therapy. Enrollment began July 1999.
Study 23b: Substudy to evaluate rifabutin and
nelfinavir pharmacokinetics in TB patients
with HIV receiving nelfinavir as part of
antiretroviral therapy. CDC IRB approval
granted in November 1999.
Study 23c: Substudy to evaluate rifabutin and
efavirenz pharmacokinetics in TB patients
with HIV receiving efavirenz as part of
antiretroviral therapy. Enrollment began
December 1999.
Study 24: Single-arm study of largely
intermittent, short-course therapy for patients
with INH-resistant TB or INH intolerance.
Aims to enroll 200 patients over 2 years with 2
years of follow-up. Enrollment began
September 1999.
NAA Substudy: Study of the performance of
several nucleic acid amplification
methodologies in the diagnosis and
management of active TB. CDC IRB approval
granted in October 1999.
Study 25:  Phase I-II dose escalation study of
rifapentine using same design as Study 22, with
patients completing 2-month standard
induction randomized to 600, 900, and 1200
mg of once-weekly rifapentine/isoniazid.
Expected to demonstrate safety and
tolerability of higher doses of rifapentine,
which may improve efficacy, prevent acquired
rifampin resistance in HIV-infected patients,
and permit use of once-weekly treatment in
initial phase. Enrollment began July 1999.
Study 26: Trial of short-course treatment of
latent TB infection among contacts of active
cases, using a 3-month once-weekly regimen of
isoniazid and rifapentine, compared to the
recently recommended 2-month daily regimen
of rifampin and pyrazinamide.  Protocol in
design.
For further information about the
Consortium, please visit the TBTC web site at
http://www.cdc.gov/nchstp/tb/tbtc
TB Communications and Education
by Wanda Walton, M. Ed.
Chief, Communications and Education Branch
Training and education in TB have changed
dramatically over the years. In the not-too-
distant past, these efforts were primarily
limited to face-to-face classroom instruction
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and the distribution of print-based materials.
Educational films, then later videotapes, were
developed and distributed, but often these
materials had a very limited distribution
because of the costs of the films and tapes and
the limited availability of audiovisual
equipment for viewing.
Today, through the availability of technology
and reduced production costs, we have a vast
array of materials and courses that are
distributed through a wide variety of media.
Some of the media include print-based
curricula with slides (e.g., the Core
Curriculum on Tuberculosis); CD ROM (e.g.,
Tuberculosis: An Interactive CD ROM for
Clinicians); satellite-based courses (e.g., the
Satellite Primer on Tuberculosis); videotapes
(e.g., the Skin Testing Video); audiotapes (e.g.,
the TB voice information system); and
Internet-based courses (e.g., the Web-Based
Self-Study Modules). With the use of satellite-
based courses, instructors can simultaneously
reach thousands of health care providers in
every US state and territory with accurate, up-
to-date information. Reduced costs for the
reproduction of videotapes and CD ROMs
allow for wide-spread distribution of
materials. In addition, the Internet allows for
distribution of materials and courses to
audiences we may have never reached before,
both professionally and geographically, at no
additional cost after initial production.
Print-based materials are also accessible in a
variety of ways. Hard copies can be ordered
by mail, by telephone, by fax, or through the
Internet online ordering system. Materials can
also be downloaded and printed from the
Internet. The electronic files of the materials
available through the Internet can also be
utilized as the basis for adaptation and
development of site-specific or population-
specific materials.
Another big change in TB training and
education is in the methodologies used to
influence health care providers’
implementation of TB recommendations. In
the past, the primary method utilized was
information dissemination to increase the
health care providers’ knowledge of the
recommendations. However, we know that
information alone is not sufficient to change
the practice of many health care providers.  In
addition to knowledge or information, health
care providers must be persuaded to try the
new recommendations. This persuasion can
occur if the health care provider thinks that
the recommendations provide an advantage
(is it better than what it’s replacing?); is
compatible with the current system (no major
conflicts created in the current system to
implement); is not too complex (how hard is it
to do or use?); can be tried beforehand (can I
try it before I decide to really use it with
patients?); can be observed (can I actually see
the result of using this innovation?); and is
flexible to being adapted to the current system.
After being persuaded that there is an
advantage to the new recommendation, health
care providers must progress through a
decision process (adopt or reject), then to
implementation, then to continued, ongoing
use of the recommendations. Behavioral
theories and models can be utilized to guide
the development of educational and training
interventions to aid in this progress.
Interventions such as academic detailing and
the use of opinion leaders can be utilized to
facilitate the progress.
For current and future efforts, utilization of
TB Control at the Millennium
56
behavioral science and implementation of
operational research are essential for
developing effective interventions in TB
communications, training, and education.
With decreasing TB cases in the United States,
it becomes even more important to be vigilant,
efficient, and effective in our efforts to keep
health care providers aware of recommend-
ations, and utilizing them appropriately.
Note: Please feel free to use the DTBE
Educational and Training Materials order
form included in this issue. Materials can also
be ordered from the DTBE web site at http://
www.cdc.gov/nchstp/tb
TB Control in the Information Age
by Jose Becerra, MD, MPH
Chief, Computer and Statistics Branch
“TRS is a computer-based
system devised to furnish
current information on clinical
management of patients and up-
to-date statistical summary
reports for public health
administrative purposes.” -
Tuberculosis Branch, State and
Community Services Division,
National Communicable
Disease Center, Sept. 1969.
Thus was recorded one of the first iterations of
an electronic information management system
for the purpose of tracking the epidemiology
and clinical management of TB in the United
States. The Tuberculosis Record Service
(TRS), a mainframe system using punch cards
and computer tapes for data processing, was a
predecessor of the DOS-based SURVS-TB
(Software for Expanded Tuberculosis
Surveillance).  SURVS-TB, a microcomputer
system depending on mailed diskettes for data
transfer, and the Tuberculosis Database
System (TBDS), a patient management
recordkeeping system, were used until 1998
when the Tuberculosis Information
Management System (TIMS) was
implemented. Regardless of names and
versions, TB information management systems
pursue the same general objective: the use of
meaningful data, that is, intelligence-added
data, to perform organizational work and
monitor outcomes.
TIMS is an integrated client-server application
in Windows, meaning that many users
(“clients”) may simultaneously access a fully
relational database residing in a secure server
within a computer network, using the
Microsoft Windows graphics user interface.
TIMS has replaced the mailing of diskettes
with dedicated modem communications for
data transfer purposes. Furthermore, TIMS
allows the generation of surveillance data from
the patient management module integrated
within TIMS. Soon, TIMS will also be able to
import surveillance data from other systems to
completely eliminate the need for double data
entry.
However, when TIMS was originally
designed, the Internet revolution that
nowadays dominates the informatics world
was just beginning. The World-Wide Web
model, wherein interactive and secure data
transactions are conducted using a common
viewer or “browser,” regardless of the original
platform in which an application is developed,
poses new opportunities and challenges to the
future of TIMS. Among these challenges are
1) the speed with which information
technology is being adopted (and abandoned);
and 2) the call for fully “integrated”
information systems.
The transition of TIMS into a Web-enabled
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application will eventually occur. We can
envision a local department of health, with a
low-end (“thin”) computer and a browser,
logging in to a state or regional server to
securely send in interactively validated TB
data or to browse the results of some
descriptive trend analyses. We can also
envision a health maintenance organization
uploading data on a batch of TB suspects and
contacts to be worked up by local health
department staff. These data would be
subsequently sent to CDC without personal
identifiers, using a commonly agreed-upon
format. However, the speed with which
information technology is changing many
times hinders the wise selection of platforms,
software development tools, and practices that
permit the design of durable and reliable Web-
based surveillance systems.
The word integration is trendy nowadays.
However, integration is a value-laden term
that may mean consolidation to some, as in
block grants, while it may mean coordination
of efforts to others. TIMS might be considered
an integrated system: it integrates patient
management with surveillance data. And
TIMS will become fully integrated with other
information management systems once its data
import utilities are completed and a new
version is released complying with public
health, clinical, and laboratory informatics
standards now in development as part of the
CDC-wide surveillance integration efforts.
The future of TIMS hinges on the assumption
that TB will remain a categorically funded
program, possibly integrated with other
disease-prevention efforts in a patient-centered
health care delivery model, but ultimately
accountable for its funding. Therefore, TIMS
will reflect this funding accountability by
protecting TB data integrity and its proper use
for program evaluation purposes.
Our organizational mission is to promote
health and quality of life by preventing,
controlling, and eventually eliminating TB
from the United States. Our National
Strategic Plan calls for a reduction of the TB
case rate to less than one per million
population by the year 2010. Therefore, we
need to leverage information technology to
manage, analyze, and synthesize practical
knowledge at the local, state, national, and
international level to facilitate the
organizational work that will move us closer
to that organizational objective.
Data are processed; information is managed;
knowledge empowers. Information becomes
knowledge, and thus power, when
systematically structured and functionally
organized for a specific purpose. But there is
one crucial premise in this line of reasoning:
the existence of an organizational will. An
organizational will requires commitment to
accomplish a mission, and that commitment
begins with a will to know. Once that
organizational will is present, and it certainly
is present in the TB prevention community,
TIMS is and will be ready to facilitate the
organizational work that will move us closer
to achieve our organizational objectives for the
year 2000 and beyond.
Field Services Activities
by Patricia M. Simone, MD
Chief, Field Services Branch
In the early 1960s, with the initiation of
categorical project grants, the Tuberculosis
Branch moved to Atlanta to join CDC, called
then the Communicable Disease Center. In
1974, the Tuberculosis Branch became the
Old TB recordkeeping system.













Services Branch was reorganized into two
sections: the Program Operations Section and
the Program Support Section. The Program
Operations Section was responsible for
providing technical assistance and
administering cooperative agreement funding
to the state and local TB programs. A team of
program consultants served as project officers
for the project sites, and field staff were
assigned to various state and local TB
programs to assist with program
implementation. The Program Support
Section was responsible for training and
educational activities as well as program
evaluation through information collected in
the Program Management Reports.
In 1991, the name of the division changed to
the Division of Tuberculosis Elimination. In
1996, the Division of Tuberculosis
Elimination was reorganized. The Program
Services Branch became the Field Services
Branch (FSB).  The Program Support Section
of the Program Services Branch became the
Communications and Education Branch,
although the program evaluation activities
remained in FSB. The Program Operations
Section became two sections, Field Operations
Sections I and II, with approximately one half
of the project sites covered by each. A medical
officer was assigned to each of the new
sections to work closely with the program
consultants to enhance technical assistance and
program evaluation capacity. A third medical
officer conducts studies and other activities
centered around program evaluation and
program operations.
The number of field staff positions grew from
a low of 25 in 1980 to over 60 by 1996.  In
addition to assigning more Public Health
Advisors to the project sites for enhanced
capacity building, FSB has hired several field
medical officers serving as medical
epidemiologists and medical directors in
various TB project sites. These positions also
serve as key training positions to develop TB
clinical and programmatic expertise as older
TB experts retire. In order to better meet the
needs of the larger field staff, the Field Staff
Working Group was established to enhance
communication between headquarters and the
field, and a field staff training and career
development coordinator was added to the
headquarters staff of FSB.
The last group of persons hired in the Public
Health Advisor (PHA) series were recruited in
1993. Through attrition and promotion, the
pool of PHAs has continued to diminish
without being replenished with new recruits,
yet the demand for Public Health Advisors to
be assigned to the TB project areas continues.
FSB is in the process of completing work on a
recruitment and training program for junior-
level field staff to be assigned to state and local
TB programs.
FSB is looking to the future by continuing to
emphasize core TB prevention and control
activities, enhancing program evaluation
activities to help ensure that programs are as
efficient and productive as possible, and
working toward TB elimination.
TB’s  Public Health  Heroes
by Dan Ruggiero, Olga Joglar,  and Rita Varga
Division of TB Elimination
Tuberculosis is frequently called a “social
disease with medical implications.” The popu-
lations most affected by TB today are urban
and poor; they are the medically underserved
low-income populations such as high-risk
minorities, foreign-born persons, alcoholics,
✴✢  
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intravenous drug users, residents in long-term
care facilities such as correctional facilities, and
the homeless. Active tuberculosis with subse-
quent spread of infection to contacts poses a
significant threat to the community. Practicing
physicians, for the most part, focus on the
individual patient, and to some extent on the
family; public health officials focus on patients
as a group, on families, and on the commu-
nity. So, in controlling TB, who are the real
heroes?  Who, on a daily basis, deals with the
patients, their families, and the health care
providers? Who does the leg work required to
ensure patients are monitored through
completion of treatment, and that contacts are
identified and evaluated? Public health field
workers are the real heroes in the fight against
tuberculosis.
Historically, in the United States, community
outreach workers have played an important
role in waging a successful battle in the war
against tuberculosis. Hermann Biggs, in 1896,
called for health inspectors to visit homes of
TB patients and educate their families on how
to deal with those suffering with the disease
and how to prevent future cases. In the 1920s
and 1930s visiting nurses were climbing and
jumping over New York City tenement roof
tops to visit TB patients who were being given
the “fresh air treatment.”
In the 1950s, federal public health advisors
were assigned to local health departments to
provide technical assistance and treatment
guidelines and to assist local health depart-
ments with TB surveillance and control activi-
ties. In the 1960s New York City hired “lay
tuberculosis investigators” to track down
noncompliant patients. The workers would
visit patients’ homes, and as needed, track
them to unsavory locations, such as  local bars,
clubs, and hangouts.  Since then, most state
and local health departments have hired and
trained lay persons and nurses to carry out
similar functions and activities.  Who are these
people that have played an important role in
the fight against tuberculosis and why is it that
we hear so little about them? They are the
backbone of the TB control program, the foot
soldiers who are willing to place their lives on
the frontline each day in order to do battle
against the common enemy - tuberculosis.
TB control programs have used public health
field workers with different backgrounds and
expertise to monitor patients and assist them
in adhering to and completing the recom-
mended course of treatment. Responsibilities
assigned to these workers vary by area and
degree of complexity. Some workers conduct
surveillance activities by visiting hospitals,
laboratories, and infection control officials;
others provide services out in the field such as
conducting home visits or providing DOT,
which can put them in risky situations. And
even under difficult circumstances, field
workers continue doing their work. Field
reports document clients and patients directing
violent threats and hostile incidents to public
health workers. Field workers survive by
learning conflict resolution and field safety
and by using precautionary measures when
conducting their activities. The threat of
violence that field public health workers
experience while in the line of duty cannot be
controlled by detection devices used in office
Nurse crossing roofs to visit patients
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facilities to provide protection to workers.
Although these workers know of the risks
involved, they continue to carry out their
efforts to control TB in their areas.
Many names have been used to describe the
job of these dedicated individuals. Outreach
workers, public health advisors, case manag-
ers, DOT workers, and epidemiology techni-
cians are some of the titles given to the public
health field workers. The heroes of TB come
from all backgrounds, education, and ethnic
groups. Hiring requirements vary from state
to state, and while many have advanced col-
lege degrees, others may be from the same
population group as the patients they serve
and have little or no schooling.
Public health workers have the responsibility
of establishing effective communication with
patients. The outreach workers are usually the
first contact the patients have with the health
department and TB programs. The ability of
outreach workers to use their interpersonal
and communication skills in dealing with
patients will set the stage for a positive or
negative attitude toward the healing process,
and consequently whether the patients will
comply with the recommended regimen. Field
workers must be culturally sensitive and must
understand patients’ beliefs, cultures, and
environment; in many instances they develop
relationships with patients that extend beyond
the duration of treatment. Just like the TB
heroes at the turn of the century, they bring
with them a spirit, zeal, vision, and determina-
tion to assist those individuals afflicted with
TB disease and infection and to bring about an
end to this disease.
The dramatic decrease in the number of TB
cases in the US since 1993 could not have been
accomplished without the persistent hard
work of theses individuals. The success we
enjoy today came about, and continues,
through the efforts of thousands of outreach
workers. Whether it is a public health advisor
purchasing pizza out of his or her own pocket
to ensure DOT compliance, or a nurse driving
long distances to make sure that patients living
in rural areas receive their medication or are
transported to a clinic or hospital for tests,
public health field workers do whatever is
necessary to achieve their objective: tuberculo-
sis control.
What do we call these individuals who have
been central figures in the tuberculosis control
movement for the past 40 years? Public health
heroes!
Infection Control Issues
by Renee Ridzon, MD
Surveillance and Epidemiology Branch
In recent years, transmission of TB within the
workplace has received much attention in the
scientific and popular press. However, the
notion of TB as an occupational hazard is not
new, and since the beginning of this century
TB has been recognized as an occupational
hazard for doctors and nurses. In fact, there
have been several studies published in the first
part of the 1900s documenting low rates of
M. tuberculosis infection among medical and
nursing students prior to the start of training.
After completion of clerkships caring for TB
patients, high rates of tuberculin skin test
conversions and even cases of TB were seen.
Concern about this occupational risk waned,
however, with the dramatic fall in the number
of TB cases in the US.
With the re-emergence of TB in the mid-1980s,
the emergence of multidrug-resistant TB
(MDR TB), and recognition of the increased
morbidity caused by MDR TB and HIV-
related TB, concern regarding TB was
reawakened in this country. Media reports
about the danger of TB were fueled by a
number of published reports regarding
explosive outbreaks of MDR TB in hospitals,
mostly in New York City, among persons
with HIV infection. Concern was further
heightened by episodes of transmission of
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disease to health care workers caring for the
patients involved in these outbreaks.
With recognition of the increased risk for TB
among persons with HIV infection, in 1990
CDC issued Guidelines for Preventing the
Transmission of Tuberculosis in Health-Care
Settings with Special Focus on HIV-Related
Issues. Despite these guidelines,
implementation of appropriate infection
control measures was incomplete in many
hospitals, and some of the published reports of
nosocomial transmission documented lapses in
or absence of infection control measures in the
health care facilities. Because of its legal
mandate to ensure that no worker is harmed
as a result of his or her work experience, as
well as the outbreaks of MDR TB, in 1992 the
National Institute for Occupational Safety and
Health (NIOSH) recommended the use of
powered-air purifying respirators (PAPRs) by
health care workers potentially exposed to
M. tuberculosis.
As a result of the ongoing outbreaks of TB and
the NIOSH recommendation for the use of
PAPRs, the adequacy of the 1990 guidelines
was discussed at a large national meeting
convened in 1993. In attendance at this
meeting were representatives from multiple
groups concerned with nosocomial
transmission of M. tuberculosis, including
infection control practitioners, labor
representatives, and occupational medicine
practitioners. The meeting concluded that in
most of the outbreak settings, the 1990
guidelines had not been adequately
implemented, and there was a need for revised
and expanded guidelines. In 1993 a draft of the
revised guidelines was published in the Federal
Register for public comment.  After a period of
comment and public meetings, the report
Guidelines for Preventing the Transmission of
Mycobacterium tuberculosis in Health-Care
Facilities, 1994 was published in the Morbidity
and Mortality Weekly Report. This document
contained detailed, comprehensive
recommendations for prevention of
nosocomial transmission of M. tuberculosis.
Included in the recommendations was a
hierarchy of controls composed of, most
importantly, administrative controls
(including assignment of responsibility, risk
assessment, development of a TB infection
control plan with periodic reassessment, and
tuberculin skin testing of health care workers),
followed by engineering controls, and then by
personal respiratory protection. Personal
respiratory protection devices that were
recommended for use in the health care setting
needed to meet the following criteria:
1) ability to filter particles of 1 micron with a
filter efficiency of 95%, 2) ability to be fit
tested to obtain a face seal leak of 10% or less,
3) ability to fit different face sizes, and
4) ability to be checked for face-piece fit by
health care workers each time the respirator
was used. At the time the 1994 guidelines were
written, the only respiratory protection device
that was NIOSH-approved and met the above
criteria was the high efficiency particulate air
(HEPA) filter respirators. In July 1995
NIOSH updated its respirator testing and
certification requirements to permit the
approval of other respirators. Under the
updated testing, respirators that contain a
NIOSH-certified N-series filter with 95%
efficiency (N-95) rating meet the
recommendations of the CDC guidelines.
Like NIOSH, the Occupational Safety and
Health Administration (OSHA) has a legal
mandate for the protection of workers;
however, unlike NIOSH, which can only
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capacity to enforce its
standards. In 1997,
OSHA published a





was a period for
public comment
followed by a series of hearings for testimony.
Detailed comments were submitted from a
CDC committee including staff members of
NIOSH, the Hospital Infections Program, and
the Division of Tuberculosis Elimination, as
well as many other professional organizations.
In July 1999, OSHA reopened the docket for
further public comment.  The OSHA TB
standard is currently undergoing revision, and
its final content and release date are not yet
known.
In order to better understand the risk of
transmission of M. tuberculosis to health care
workers, CDC undertook several studies
designed to examine rates of skin test
conversions in health care workers. The most
comprehensive of these was a study initiated
in 1995 called StaffTRAK-TB. This study
included over 13,000 health care workers.
Data from this study demonstrate a rate of
skin test conversions among health care
workers of 4.4 conversions per 1,000 person-
years of follow-up. For US-born persons, the
rate was even lower at 3.2 conversions per
1,000 person-years. From data currently
available from studies such as StaffTRAK-TB,
the risk of nosocomial transmission of TB
appears to be quite low. As a result CDC is
considering revision of the 1994 guidelines,
especially in the areas of frequency of
tuberculin skin testing of health care workers.
The risk of transmission of M. tuberculosis in
health care settings is a real one. However, the
magnitude of this risk depends on many
factors such as implementation of
administrative and engineering controls,
prevalence of patients with infectious TB
within the facility, and risk for infection
outside of the healthcare facility. All of these
factors need to be weighed in decisions
regarding recommendations or mandates for
TB control measures within health care
facilities. As the rates of TB in the US
continue to decline, these recommendations
will need to be tailored to offer protection to
patients and workers within the health care
setting, without an unnecessary burden of
testing and expense.
A Decade of Notable TB Outbreaks:
A Selected Review
by Scott B. McCombs, MPH
Deputy Chief, Surveillance and Epidemiology Branch
The Surveillance and Epidemiology Branch is
charged with monitoring TB morbidity and
mortality in cooperation with state and local
health departments. One of the most
fascinating and important parts of our role is
to assist our partners in responding to
outbreaks of TB when they occur. This article
summarizes a cross-section of some of the
more notable outbreaks from the 1990s.
Extensive transmission of Mycobacterium
tuberculosis from a child (Curtis, Ridzon,
Vogel, et al. N Engl J Med 1999;341:1491-
1495).
Although young children rarely transmit TB,
infectious TB was diagnosed in a 9-year-old
boy in North Dakota in July 1998. The child
was screened because extrapulmonary TB was
diagnosed in his female guardian. The child,
who had come from the Republic of the
Marshall Islands in 1996, had bilateral cavitary
TB. Because he was the only known possible
source of his guardian’s TB, an investigation of
the child’s contacts was undertaken.  Family,
school, day-care, and other social contacts
were notified of their exposure and given
tuberculin skin tests (TST). Of the 276
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contacts tested, 56 had a positive TST (10 mm
induration), including 3 of 4 household
members, 16 of his 24 classroom contacts, 10
of 32 school-bus riders, and 9 of 61 day-care
contacts.  A total of 118 persons received
preventive therapy. The 9-year-old patient’s
twin brother had TB, but was deemed not
infectious on the basis of a negative sputum
smear. This investigation showed that children
with TB, especially cavitary or laryngeal TB,
should be considered infectious, and that
screening of their contacts may be required.
Spread of Strain W, a highly drug-resistant
strain of Mycobacterium tuberculosis, across
the United States (Agerton, Valway,
Blinkhorn, et al. Clin Infect Dis 1999;
29:85-92).
Strain W, a highly drug-resistant strain of
Mycobacterium tuberculosis, was responsible for
large nosocomial outbreaks in New York in
the early 1990s.  This article is a review of data
from epidemiologic investigations, national
TB surveillance, regional DNA fingerprinting
laboratories, and the CDC Mycobacteriology
Laboratory to identify potential cases of TB
due to Strain W. From January 1992
through February 1997, 23 cases were
identified in nine states and Puerto Rico; 4
of the 23 cases transmitted disease to 10
other people. Eighty-six contacts of the 23
cases were presumed to be infected with
Strain W. The authors conclude that Strain
W  TB cases will occur throughout the
United States as persons infected in New
York move elsewhere. CDC asked health
departments to notify CDC of cases of TB
that were resistant to isoniazid, rifampin,
streptomycin, and kanamycin. The references
for this article include citations for earlier
investigation results that have been published,
including this next one.
Transmission of a highly drug-resistant
strain (Strain W1) of Mycobacterium
tuberculosis: Community outbreak and
nosocomial transmission via a contaminated
bronchoscope (Agerton, Valway, Gore, et
al. JAMA 1997;278:1073-1077).
In 1995, eight patients with MDR TB were
identified in South Carolina; all were resistant
to seven drugs and had matching DNA
fingerprints (Strain W1). Community links
were identified for five patients (patients 1-5),
but no links were identified for the other three
patients (patients 6-8) except being hospitalized
at the same hospital as one community
patient. Patients 5 and 8 both died of MDR
TB less than one month after diagnosis.
Patients 6 and 7 each had one positive culture
for MDR TB; specimens were collected during
bronchoscopy. Patient 6 had a skin test
conversion after bronchoscopy.  Neither
patient 6 nor patient 7 had a clinical course
consistent with MDR TB, neither was treated
for MDR TB, and both are alive and well.
There was no evidence of laboratory
contamination of specimens, transmission on
wards, or contact among patients. All four
received bronchoscopy in the same month.
Observations revealed that bronchoscope
cleaning and disinfection was inadequate and
led to subsequent false-positive cultures in
patients 6 and 7, transmission of infection to
patient 6 and active
MDR TB to patient 8.
An outbreak involving
extensive transmission




al. N Engl J Med
1998;338:633-639).
From 1994 to 1996 there was a large outbreak
of TB in a small, rural community with a
population at low risk for TB. Twenty-one
patients with TB were identified; the DNA
fingerprints of the 13 isolates available for
testing were identical. To determine the extent
of transmission, we investigated both the close
and casual contacts of the patients. Using a
mouse model, we also studied the virulence of
the strain of Mycobacterium tuberculosis that
caused the outbreak. The index patient, the
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source patient, and one other patient infected
the other 18 persons.  In five, active disease
developed after only brief, casual exposure.
There was extensive transmission from the
three patients to both close and casual
contacts. Of 429 contacts, 311 (72%) had
positive skin tests, including 86 documented
skin test conversions. The growth
characteristics of the strain involved in the
outbreak greatly exceeded those of other
clinical isolates of M. tuberculosis. The
extensive transmission of TB in this outbreak
may have been due to the increased virulence
of the strain rather than to environmental
factors or patient characteristics.
A nosocomial outbreak of multidrug-
resistant tuberculosis (Kenyon, Ridzon,
Luskin-Hawk, et al. Ann Intern Med
1997;127:32-36).
This article details an outbreak of seven cases
of MDR TB (in six patients and one health
care worker, all of whom had AIDS) that
occurred in a hospital in Chicago. The
hospital had a respirator fit-testing program
but no acid-fast bacilli isolation rooms. All
seven M. tuberculosis isolates had matching
DNA fingerprints. Of patients exposed to M.
tuberculosis, those who developed TB had
lower CD4+ T-lymphocyte counts and were
more likely to be ambulatory than those who
did not. Of 74 exposed health care workers,
the 11 who converted their skin tests were no
more likely than those who did not convert to
report that they always wore a respirator with
a HEPA filter. Transmission of M. tuberculosis
occurred in a hospital that did not have
recommended isolation rooms. A respirator
fit-testing program did not protect health care
workers in this setting.
Outbreak of drug-resistant tuberculosis
with second-generation transmission in a
high school in California (Ridzon, Kent,
Valway, et al. J Pediatr 1997;131:863-868).
In the spring of 1993 four students in a high
school were diagnosed with TB resistant to
isoniazid, streptomycin, and ethionamide. A
retrospective cohort study with case
investigation and skin test screening was
conducted in the school of approximately
1,400 students. DNA fingerprinting of
available isolates was performed. Eighteen
students with active TB were identified.
Through epidemiologic and laboratory
investigation, 13 cases were linked. Nine of the
13 had positive cultures for M. tuberculosis
with isoniazid, streptomycin, and ethionamide
resistance, and all eight available isolates had
identical DNA fingerprints. No staff member
at the school had TB. One student remained
infectious for 29 months and was the source
case of the outbreak. Another student was
infectious for 5 months before diagnosis and
was a treatment failure. This student
subsequently developed additional resistance
to rifampin and ethambutol. The initial skin
test screening found 292 of 1263 (23%)
students tested had a positive TST. Risk of
infection was highest among twelfth graders
and classroom contacts of the two students
with prolonged infectiousness. An additional
94 of 928 (10%) students tested later had a
positive TST; 22 were classroom contacts of
the student with treatment failure and 21 of
these were documented TST conversions.
This article documents extensive transmission
of drug-resistant TB along with missed
opportunities for prevention and control of
the outbreak. Prompt identification of TB
cases and timely interventions should help
reduce these problems.
Transmission of multi-drug resistant
Mycobacterium tuberculosis during a long
airplane flight (Kenyon, Valway, Ihle, et al.
N Engl J Med 1996;334:933-938).
In April 1994 a passenger with infectious
MDR TB traveled on commercial-airline
flights from Honolulu to Chicago and from
Chicago to Baltimore and returned one month
later. We sought to determine if this passenger
infected any of her contacts on this extensive
trip. Of 925 people on the airplanes, 802
responded to a request to complete a
questionnaire and be screened by tuberculin
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skin test. All 11 contacts with positive TST
who were on the April flights and 2 of 3
contacts with positive TST on the Baltimore-
to-Chicago flight in May had other risk factors
for tuberculosis. More contacts on the 8.75
hour flight from Chicago to Honolulu had a
positive TST than on the other three flights.
Of 15 contacts with a positive TST on the
Chicago-to-Honolulu flight, six (four with
skin-test conversions) had no other risk
factors; all six sat in the same section as the
index patient. Passengers seated within two
rows of the index patient were more likely to
have a positive TST than those in the rest of
the section.  Transmission of M. tuberculosis in
this setting involved a highly infectious
passenger, a long flight, and close proximity of
contacts to the index patient.
The Division of TB Elimination and our
partners in state and local health departments
have benefitted tremendously from what has
been learned from these and other outbreaks.
Our continued cooperation, diligence, and
timely systematic response to future outbreaks
are critical to our eventual success in
eliminating TB from the United States.
International Activities
by Nancy Binkin, MD, MPH,
Chief, International Activity and
Michael Iademarco, MD, MPH
International Activity
As the rate of tuberculosis (TB) cases falls in
the United States (US), an increasing
percentage of TB cases occur among US
residents born in countries with a higher
burden of TB. The US rate of TB cases is
relatively low compared with the rate in 22
high-burden countries where 80% of global TB
cases occur and where 62% of the world’s
population resides. Given the latency period
between TB infection and disease, continued
immigration into the US, and increasing
international travel, efforts to eliminate TB in
the US must extend beyond our geographical
borders. Recognition of the public health
impact of the global TB epidemic led CDC to
officially organize an International Activity
within the Division of TB Elimination
(DTBE) in 1994 as international efforts are
part of the overall strategic plan of DTBE.
The mission of the International Activity is,
first, to provide leadership and coordination
for CDC activities related to improving TB
prevention and control efforts among foreign-
born persons in the US. Its mission is, second,
to contribute to global TB prevention and
control efforts by conducting operations
research and providing technical support to
high-priority countries, i.e., those that have a
major TB burden or that are of strategic
interest for TB control efforts in the US.
Coordination and collaboration with other
international public health partners are critical
to accomplish our mission.
Immigrants from Mexico, the Philippines, and
Viet Nam are the leading contributors to the
US foreign-born TB case burden and therefore
constitute a high priority for TB control
efforts in the US. The aim of International
Activity efforts in these countries is to reduce
the burden of TB by improving the TB
control capacity of the respective national
programs, by providing technical assistance











social changes. More recently, however,
progress has been made.
Mexico
Because of their proximity and our shared
border, persons born in Mexico represent the
single largest group of foreign-born persons in
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the US with TB. Previously CDC worked
with the Mexican government to conduct
surveillance of drug-resistant isolates of TB in
Mexico as part of a WHO collaborative study.
More recently, DTBE has been working with
the United States Agency for International
Development (USAID) and the National TB
program of Mexico to identify areas of
potential collaboration as part of a proposed 5-
year project to improve TB control. Proposed
activities include expanding the number of
directly observed treatment, short-course
(DOTS) pilot projects, improving operations
research capacities, and developing activities to
foster public-private health sector
collaboration.
Additionally, DTBE has been a participating
member of Ten Against TB, a binational
initiative developed initially by the Texas
Department of Health beginning in 1995. The
ten US and Mexican border states have
collaborated to reach a consensus on
addressing joint issues of TB control through
community-based public and private sector
partnerships. Along with other partners in the
Division and in the health departments of the
border states, CDC has also been developing a
series of recommendations to improve the
diagnosis and
management of












CDC, DTBE is providing technical assistance
to a USAID-funded project. The objective of
this 5-year project is to reduce the threat of
HIV/AIDS and other selected infectious
diseases in the Philippines. Of those diseases in
the Philippines, TB has the most significant
public health impact and therefore figures
prominently in the project. The broad, cross-
cutting nature of the project design addresses
the decentralized health care organization in
the Philippines. DTBE is working with the
DOH to organize and conduct operations
research training, expansion of directly
observed treatment, short-course (DOTS)
pilot projects, and public-private collaborative
projects.
Viet Nam
Collaboration with the National TB Control
Program of the Socialist Republic of Viet Nam
(NTP) has been more longstanding. Since
1996, DTBE has worked with the NTP to
improve TB control. Several laboratory
quality control projects have been conducted
and others are ongoing with the national
reference laboratory responsible for southern
Viet Nam. In 1997, DTBE conducted a 2-week
operations research course for supervisory
staff of the NTP and provincial TB managers
held in Hanoi. As a result of the course, six
protocols were developed on operational
topics such as risk factors for treatment failure
and for default, reasons for patient delay in
seeking initial TB treatment, and knowledge,
attitudes, and beliefs about HIV and HIV
testing and counseling among TB patients.
Each group has been provided with a CDC
mentor and funding to conduct the research.
The work for one protocol is complete and
has been presented by the Viet Namese
principal investigator at the International
Union Against Tuberculosis and Lung Disease
World Congress in Madrid this past
September. Other projects are near
completion. Based on the success of the
operations research course and with support
from USAID, DTBE has initiated a 3-year
public health practice training program with
the NTP.
Botswana
Other DTBE international efforts have aimed
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to contribute to the global
control of TB and HIV/
AIDS co-epidemics. In
February 1995, at the
request of the Ministry of
Health in Botswana, the
BOTUSA Project was
established as a TB
epidemiologic research
collaboration located in Botswana.
Approximately 25% of the adult population
and 75% of TB patients are HIV-infected. The
BOTUSA Project activities have focused on
improving TB surveillance and electronic
reporting, improving Botswana National TB
Programme (BNTP) activities through
operational research, improving diagnostics
through laboratory and clinical research
studies, and studying the epidemiology of the
disease. At least 17 different formal studies
have been completed to date and highlight the
tremendous impact of the HIV epidemic on
the TB epidemic in the country.
The site is collaborating with WHO and other
countries on several projects, including
involvement of the community in the care of
patients with TB and advanced AIDS,
provision of TB preventive therapy to persons
living with HIV, and improvement of TB
surveillance through the use of a software tool
initially developed by BOTUSA and recently
adopted by the World Health Organization
(WHO) for global application. Through
collaboration with the US Food and Drug
Administration, the site and DTBE have
raised global awareness of the potential for
substandard TB drugs in the market through
the pilot-testing of appropriate technology for
the rapid screening of drugs. Specific research
projects completed in 1998 included a
spectrum of lung disease study in adults
hospitalized with AIDS, an autopsy study to
determine causes of death in adults and
children dying of AIDS, a validation study of
the TB surveillance system, a study of risk
factors for TB transmission in the household,
and a study of transmission at the population
level through the use of RFLP techniques.
Another study underway is assessing the
malabsorption of TB drugs in patients with
TB and HIV, as well as conducting long-term
follow-up of these treated patients to
determine risk factors for relapse, reinfection,
and death.
Strengthening the capacity of laboratory
facilities to cope with the ever-increasing
demands brought on by the TB and HIV
epidemics has been a component of the
BOTUSA project. Substantial support in
terms of equipment, training, and supplies has
been provided to the national TB Reference
Laboratory. BOTUSA also serves as an
important training site for EIS officers, US
medical students, and public health students
from UC-Berkeley.
Russia and countries of the former Soviet
Union
As a result of a joint Department of Health
and Human Services and White House
conference, the Russian Federation and the
countries of the former Soviet Union have
been targeted for CDC TB control technical
assistance efforts. The number of TB patients
and the levels of drug resistance are increasing
at alarming rates. Contributory factors include
an inability to financially support the previous
infrastructure for TB diagnosis and treatment,
the lack of availability of quality drugs, high
levels of TB transmission in prison settings,
and reluctance to adopt the DOTS strategy as
employed in the US and elsewhere and
recommended by the WHO. The DTBE,
USAID, and WHO are collaborating to
institute basic DOTS programs in two oblasts
(territorial administrative divisions) that have
indicated a willingness to begin the DOTS
strategy, and to strengthen DOTS in Ivanovo
oblast, where a WHO-supported program was
implemented in 1995 but where cure rates
remain unacceptably low. A recent study in
this second oblast has documented further
increases in the levels of multidrug-resistant
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DOTS-plus, the WHO strategy for the
management of MDR TB treatment in low-
resource settings, in this oblast. In addition,
DTBE has been involved in the establishment
of a center of excellence for MDR TB in
Latvia, which was formerly part of the Soviet
Union and which has a successful DOTS
program, but nonetheless has one of the
highest levels of MDR TB in the world.
Finally, an MDR TB training course run by
DTBE in collaboration with National Jewish
Medical Center was conducted overseas this
past year in Estonia for participants from
Russia and the Baltics.
The Role of CDC’s Division of Quarantine
in the Fight Against TB in the US
by Paul Tribble
Public Health Advisor, DQ
The Division of Quarantine (DQ), the oldest
organization in the United States Public
Health Service, has had a rich and colorful
history and plays an important role in the
nation’s fight against tuberculosis (TB),
especially with respect to immigrants and
refugees. DQ, which was established by the
National Quarantine Act of 1878, was
transferred to the Centers for Disease Control
(CDC) in 1967. DQ has had several previous
titles, including the Division of Foreign
Quarantine and Quarantine Division, and is
continuing to evolve with another proposed
name: the Division of Global Migration and
Quarantine.
United States (US) immigration law mandates
an overseas health assessment for immigrants
and refugees, with the intent of denying
admission to persons with certain diseases of
public health significance, physical or mental
disorders associated with harmful behavior,
drug abuse or addiction, or likelihood of
becoming a ward of the state. The conditions,
the requirements as to who must be screened,
and the examination and tests to be performed
are prescribed by the Secretary of the
Department of Health and Human Services,
with oversight by DQ.
The current list of communicable diseases of
public health significance that are considered
“inadmissible” are infectious TB, syphilis,
lepromatous Hansen’s disease, HIV infection,
and certain sexually transmitted diseases
(STDs).  The overseas health assessment,
which is valid for 12 months, is carried out by
local physicians known as “panel physicians,”
who are appointed by the US embassy or
consulate. In some cases, clinics or hospitals
are designated as panel physicians in countries
where large numbers of immigrants originate
(e.g., Mexico, the Philippines, and Viet Nam).
Panel physicians are provided with a booklet
of technical instructions concerning the
assessment process which, in addition to the
TB evaluation, consists of a medical history,
physical examination, and screening for
physical and mental disorders, substance
abuse, STDs, Hansen’s disease, and HIV
infection.
Panel physicians make their own
arrangements for the required radiologic and
laboratory tests. Currently, no countries have
on-site supervision beyond the local consular
officer, except Viet Nam, which has a CDC
microbiologist consultant. Panel physicians
do, however, receive periodic visits by CDC
physicians and microbiologists based in
Atlanta. Panel physicians are paid for their
services by immigrant applicants on the basis
of a fee scale set locally. In the case of refugees,
the US Department of State reimburses the
Immigrants of the past awaiting medical clearance
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panel physicians for providing the health
assessment. Presently, there are approximately
650 panel physicians worldwide.
The TB component of the health assessment
consists of a chest x-ray for all persons 15 years
of age or older. (Children less than 15 years of
age who are suspected of having TB or who
have a history of contact with a known TB
case are given a tuberculin skin test. Those
with a positive skin test must undergo a chest
x-ray.) If the x-ray is consistent with active TB
disease, three consecutive early-morning
sputum specimens are collected for acid-fast
staining and microscopic examination. Persons
whose sputum smears are positive for acid-fast
bacilli (AFB) are classified as having Class A,
infectious TB, which is an inadmissible
condition for purpose of entry into the United
States. Such persons may enter the United
States by meeting either of the following two
conditions. First, sputum smear–positive
immigrants and refugees who successfully
complete a recommended course of TB
treatment overseas can be medically cleared
for US travel; they will have been reclassified
as having Class B2 or old, healed TB (see
description of TB classifications below).
Secondly, they may enter the United States
with a medical waiver, once they are no longer
infectious, by providing three consecutive
negative sputum smears. To obtain a medical
waiver, the US relative of the Class A
immigrant must complete an application. This
is signed by a US health-care provider and is
countersigned by the local health department
(or signed only by the local health department
acting as the health-care provider) at the
immigrant’s intended US destination, thus
guaranteeing that the provider will assume
responsibility for the completion of TB
treatment. Class A refugees with TB are not
required to have a relative residing in the
United States, as the waiver is completed by
the resettlement agency at the intended site of
destination. Immigrants are responsible for
paying for their own TB treatment overseas;
in the case of refugees, the costs are assumed
by the US Department of State.
Applicants whose chest x-ray is consistent
with active TB disease but whose three sputum
smears are negative for AFB are designated as
having Class B1 (clinically active, not
infectious) TB. If the initial chest x-ray is read
by the panel physician as consistent with old,
healed TB, no specimens of sputum need be
obtained, and the applicant is designated as
having Class B2 (not clinically active, not
infectious) TB.  Both Class B1 and B2
designations are considered significant health
conditions, but neither is inadmissible for
immigration purposes.
Class A and Class B designations for
immigrants are placed on the official
immigration documents collected by
inspectors of the Immigration and
Naturalization Service at one of 295
international airports, land crossings, or ports
in the United States; refugees must enter the
country through one of eight international
airports that are staffed by DQ inspectors.
This information is sent to or collected at one
of the quarantine stations, where a notification
form is mailed to the state or local health
department at the intended destination of the
arriving immigrant or refugee. Health
departments are expected to complete and
return the forms to DQ, thus reporting on the
outcome of the evaluation.  The immigrant or
Current immigration clearance process
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refugee is informed of the need to be further
evaluated for their TB and to report to the
local health department as soon as possible
after arrival. Persons with Class A TB are
required to report to the local health
department, present all medical records and
chest x-rays from overseas, and submit to the
necessary testing, isolation, and treatment
until discharged.  They risk deportation
should they fail to do so. For persons having
Class B1 or B2 TB, the health department visit
is considered voluntary.
Many health departments in the United States
perform active follow-up of arrivals designated
as having Class B1 or B2 TB, on the basis of
the DQ notification. Studies conducted in the
mid-1990s by the Division of TB Elimination,
DQ, and health departments in various parts
of the country have shown from 3% to 14% of
Class B1 immigrants and refugees were
diagnosed with TB disease within one year of
their arrival; between 0.4% to 4.0% of those
with Class B2 TB were diagnosed with TB
disease within one year of arrival. Of the
remaining persons, many are high-priority
candidates for preventive therapy regardless of
their age because they are tuberculin skin test
positive with an abnormal chest x-ray
suggestive of TB disease.
The current overseas TB evaluation
procedures described above are based upon the
following three principles: 1) the requirements
apply specifically to immigrants and refugees,
as they are most likely to become permanent
US residents; 2) the procedures reduce the
importation of active infectious TB that poses
an immediate public health risk by denying
admission to persons who have positive
sputum smears; and 3) they allow those
persons with evidence of TB disease but whose
smears are negative to enter the United States,
where a more complete medical evaluation can
be performed and appropriate treatment can
be provided under supervision. Forcing
immigrants and refugees with noninfectious
TB to undergo treatment overseas could prove
to be counter-productive, as it may be difficult
to ensure that the drug regimens are adequate,
and that applicants are regularly ingesting the
required medications. In such a scenario,
incomplete treatment as well as development
of drug resistance may be the result.
The overseas screening process for identifying
and treating TB in immigrants and refugees is
responsible for the identification of substantial
numbers of persons arriving in the United
States who have active TB.  However, not all
cases in newly arrived immigrants or refugees
were identified overseas as having suspect TB,
which is in part due to several limitations of
the screening process. Although panel
physicians do function under a contractual
agreement with their respective US consulates,
they receive no formal training or certification
per se. In 1997, a training needs assessment was
performed on a sample of panel physicians in a
study undertaken by the Division of TB
Elimination and DQ. The assessment
indicated that, although 98% of panel
physicians in the sample understood which
immigrants and refugees should receive a chest
x-ray, over 60% indicated a need for training.
Presently, efforts are underway to develop self-
study training materials for panel physicians to
enhance their ability to diagnose and treat TB,
and to improve their ability to monitor the
performance of contracted laboratory and
radiologic services. A training plan will be
developed, and self-study materials will be
pilot-tested later this year in countries with
large numbers of persons who immigrate to
the United States and have a high TB
prevalence.
The STOP TB Initiative,
A Global Partnership
by Bess Miller, MD, MSc
Associate Director for Science, DTBE
Over the past few decades, when we have
looked at the agendas of international health
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agencies, major donors to the health sector,
government health ministries, academia, and
civil society, we have wondered, Where is TB?
Why is TB on the back burner?  The STOP
TB Initiative is a global campaign to move TB
to the FRONT BURNER.
Why now?
With the arrival last year of the new Director
General of the World Health Organization
(WHO), Dr. Gro Brundtland, there has been
an interest in intensifying the relationship
between WHO and its global partners. For a
number of diseases, but especially for malaria
and TB, WHO has initiated campaigns to join
forces with other agencies and donors in the
public and private sectors to achieve global
health objectives.
Additional factors have added fuel to the
sparks of this new campaign. Over the past
several years the World Bank has given an
unprecedented number of loans to developing
countries to strengthen TB control efforts and
has established TB as one of its top priority
diseases. There has been renewed interest in
TB research in the areas of  vaccine
development, new drug development, and new
diagnostics. Large donors such as the Soros
and Gates Foundations have shown an interest
and commitment to TB control and TB
research.  The stars are aligned.
In November 1998, at the annual meeting of
the International Union Against Tuberculosis
and Lung Disease held in Bangkok, Thailand,
Dr. Brundtland launched the STOP TB
Initiative, a WHO-led global partnership
whose mission is to put TB higher on the
international public health agenda and to
substantially increase the investment in TB
worldwide. It aims to increase involvement of
international players at all levels, including
international health agencies, donor agencies,
governments, nongovernmental organizations,
professional societies, and community
organizations involved in TB at the country
level. The focus of the initiative is on the 22
so-called “high-burden” countries which
WHO has identified as responsible for
approximately 80% of all reported cases of TB
in the world. These include India, China,
Indonesia, Bangladesh, Pakistan, Nigeria,
Philippines, South Africa, Ethiopia (Fed.
Democratic Republic of), Viet Nam, Russian
Federation, Congo (Democratic Republic),
Brazil, Tanzania (United Republic of), Kenya,
Thailand, Myanmar, Afghanistan, Uganda,
Peru, Zimbabwe, and Cambodia. In addition,
countries with extremely high rates of TB,
especially those impacted by the HIV
epidemic, will be targeted.
The STOP TB Initiative will focus attention
on addressing the specific constraints to action
on TB identified at the London Ad Hoc
Committee Meeting on the Global TB
Epidemic held in March 1998. The needs
identified at this meeting include political will
and commitment, human resource
development, a secure supply of quality anti-
TB drugs, research, financing, organization
and management, information systems, and
health sector reform.
The founding partners of the STOP TB
Initiative are the WHO, the Royal
Netherlands TB Association (KNCV), the
International Union Against TB and Lung
Disease, the World Bank, the American Lung
Association, the American Thoracic Society,
and the Centers for Disease Control and
Prevention. New partners include UNICEF,
UNAIDS, the National Institutes of Health,
the Japan Anti-TB Association, the
Norwegian Heart and Lung Association, the
Canadian International Development Agency,
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the Soros Foundation, and the Rockefeller
Foundation. Many, many others are joining.
The tremendous energy and inspiration these
new partners bring to the Initiative cannot be
overstated.
Current efforts of the STOP TB Initiative are
directed at the following four areas: 1) the
creation of a global drug supply facility to
provide universal availability of quality TB
drugs; 2) the development of a global
partnership agreement to catalyze and secure
public agreements among donor agencies and
high-burden countries on specific steps to be
taken to control TB; 3) the co-sponsorship of
an initiative to develop new drugs for TB; and
4) the co-sponsorship with the Government of
the Netherlands of a Ministerial Conference in
March 2000.  This conference brought
together the ministers of health as well as of
finance, development, and planning from the
highest burden countries to set the stage for
expanded country action against TB across
sectors of government and society.
While many efforts are underway at the
“global” level, TB control efforts take place at
the local level, and it is at this level that we
will concentrate future efforts. This past
summer, the Initiative sponsored a series of
regional workshops with the highest burden
countries to identify constraints to TB control
at the country level. Suggestions for the STOP
TB Initiative made at these workshops
included the following activities: 1) expand
beyond traditional partners for TB control;
2) strengthen advocacy; 3) develop a social
mobilization campaign; and 4) increase
operations research in affected countries.
CDC is actively participating in the STOP TB
Initiative and is represented on the Steering
Committee (Bess Miller, Associate Director
for Science and Carl Schieffelbein, Deputy
Director for Special Projects, DTBE), as well
as the Secretariat in Geneva (Mark Fussell,
Public Health Advisor, DTBE).
Yes, TB is on the front burner at last, and we
plan to keep it there!
Seize the Moment - Personal Reflections
by Carl Schieffelbein
Deputy Director for Special Projects, DTBE
We all have opportunities during our careers
to stand at critical decision points. Sometimes
it is clear that these are major events; at other
times they appear routine, but subsequently it
is seen that they had (or could have had) major
impact. During the past 33 years I’ve had the
opportunity to stand at many decision points
and now can look back to see where more
could have been done, if the opportunities had
really been fully utilized. I will outline a few
decision points in which I participated and try
to share what went well and what I believe
could have been done better. I will also outline
some of the decisions we will all face in 2000.
Decision point: late 1960s. Closing of the TB
sanatoria. Due to advances in treatment, long-
term sanatorium care was no longer needed.
CDC supported efforts to close TB
sanatoriums and move toward an outpatient
system. We succeeded in reducing the need for
long-term sanatorium care and more rapidly
got patients back to their families and
communities. The costs of maintaining
sanatoria were reduced. However, we did not
do well in diverting the funds available as a
result of the closings to the support of strong
TB outpatient care systems. As cases went
down, political will to support TB programs
also diminished in the early 1970s. We found
that many existing TB control systems were
unable to effectively survive when federal
categorical appropriations for TB were
eliminated in 1972.
Decision point: 1989.  The Strategic Plan for the
Elimination of Tuberculosis in the United States.
The plan articulated the goal of defined
elimination of TB by 2010. It caught the
attention of some advocates and spelled out in
broad strokes (still relevant today) the three
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critical steps needed. However, we later
realized that we talked about the plan only
within the “TB family” and with our peers.
We were not successful enough in getting
influential leaders and  policy and opinion
makers to commit their organizations to full
shared ownership and thus, the necessary
advocacy to fully implement the Strategic Plan
at federal, state, and local levels.
Decision point: November 1991. The rise in
TB cases, and the emergence of multidrug-
resistant TB (MDR TB).  A small group of us
met with Dr. Roper (then CDC Director) to
discuss a plan of action. It was decided a
federal TB Task Force would be created to
bring together all HHS/PHS agencies (and a
few others) to develop a coordinated response
to the MDR TB outbreaks. The Task Force
was created and moved quickly, and in
January 1992 brought together more than 400
experts to develop the National Action Plan to
Combat Multidrug-Resistant Tuberculosis
(published in April 1992). The Action Plan
called for a total federal TB budget of
$610,280,000, of which CDC’s need was
$484,000,000. Along with many of our
partners, we were successful in getting federal
appropriations increased. We were successful
in getting enough resources to meet our
immediate needs, but not enough to allow the
success of our 1989-stated mission of
elimination. We had reached out to some new
partners in the Task Force and through the
National Coalition to Eliminate TB, but again,
after the crisis was over, we had not built
enough effective community partnerships or
new and long-lasting coalitions to help achieve
the level of resources needed. Also, while we
were in the process of obtaining increased
federal funding, we saw many state or local
areas reduce the amount of local resources
going into TB control efforts. In 1990 the
Public Health Foundation reported that 13%
of TB funds at the state and local levels were
federal dollars. In 1998, however, the National
TB Controllers Association reported that 42%
of budgets were now composed of federal
dollars. We succeeded in making state and
local programs too dependent upon federal
dollars; this is a concern known all too well by
those of us who remember the overnight
elimination of categorical federal TB funds in
1972.
Decision point: March 1998. I had the
opportunity to participate in an ad hoc
committee of the Global Tuberculosis
Programme of WHO, convened in London, to
evaluate TB control in the 22 countries that
represent 80% of the global TB burden. The
committee concurred that most of these 22
countries would not meet their Year 2000
goals. The committee also outlined what was
believed to be shared constraints to progress.
These included 1) weak political will and
commitment towards TB control efforts;
2) lack of adequate funding; 3) inability to hire
and keep trained staff; 4) organizational and
management issues, such as health sector
reform, public and private sector interactions
(or lack thereof), and integration and
decentralization issues; 5) an inadequate supply
of quality TB drugs; and 6) lack of adequate
understanding of the magnitude of the
problem and of the possibility of successful
interventions. I believe all but item number 5
are also continuing threats to our national,
state, and local TB programs.
You and I stand at some unique moments of
decision in 2000. If each of us does not act
effectively, we will have missed some
opportunities to move the fight against TB
into the final rounds. Some of the decision
moments at hand:
• The National Academy of Science’s
Institute of Medicine (IOM) will issue a
report on TB control in the United
States.  How will you and I use the
results to evaluate and strengthen our
programs?  How will you use the IOM
report and local data to secure adequate
political will at your state or local level
to secure necessary resources?
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• The HIV/AIDS and TB epidemics
continue to work together to create
unnecessary devastation, both
domestically and especially in some
international communities. Yet we
tend to still work mainly within our
“TB family.” How will we work better
with our colleagues in HIV to develop
effective collaborations to help those at
risk of TB and HIV/AIDS?
• There is growing interest and concern
about TB both at the federal level and
in many state and local areas. How will
you and I create new partnerships and
opportunities to build on the existing
interest to ensure a firm base for
operations and programs?
• The Surgeon General has appointed a
Blue Ribbon Committee to look into
the development of a TB vaccine.
How will you and your TB advisory
committees work to support such an
effort?
• There are areas of social mobilization
and community empowerment that
have not been adequately addressed by
the TB community.  How will we
work with not only lung associations,
but other partners as well, to mobilize
against TB?
• WHO is hosting a “STOP TB”
partnership to create a new global
campaign against TB. How will you
and I support these critically needed
global activities and still ensure strong
domestic programs?
I am aware there are many, many other
decision points that we all will face.   Many of
these opportunities last for very brief
moments of time. I urge each of us to seize
those moments, and if necessary move outside
our areas of comfort, in order to be able to
truly eliminate TB in the United States and see
TB control in the world early in this century.
Carl Schieffelbein, in his first TB control
assignment (1967), adjusting x-ray equipment
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Description of DTBE Training and Education
Resources
Resources for Health Care Providers
Automated information systems
CDC Fax Information System. CDC devel-
oped a fax information system for health care
professionals and others who would like to
receive health information by fax. Telephone
callers first access the main CDC menu and
then select TB-related topics. Designed to
answer many routine questions about TB, the
system can provide up-to-date information by
fax or mail.  Callers can choose to receive
general information about TB or specific
information about treatment, diagnosis, BCG,
infection control, or screening.  The Fax
Information System can be accessed by dialing
toll free 888-CDC-FAXX (888-232-3299).  To
receive a listing of documents available by fax,
request document number 250000.  The fax
sheet may also be viewed on DTBE’s Web site
at http://www.cdc.gov/nchstp/tb.
CDC Voice Information System. CDC
developed a voice information system for
health care professionals and others who call
for specific disease information. Callers first
access the main CDC menu and then select
TB-related topics.  Designed to answer many
routine questions about TB, the system can
provide up-to-date information by voice, fax,
or mail. Callers who choose to listen to the
voice recordings can receive general informa-
tion about TB or specific information about
treatment, diagnosis, BCG, infection control,
or screening. Callers who would like written
information can choose from a variety of
topics and then receive information sheets by
fax or specific educational materials by mail.
The TB component of the Voice Information
System can be accessed by dialing toll free 888-
CDC-FACT (888-232-3228), then pressing
options 2, 2, 1, 5, 2.
DTBE Home Page. DTBE has a Web site on
the Internet. The site provides access to TB-
related Morbidity and Mortality Weekly Reports
(MMWRs), educational materials, and guide-
lines.  The DTBE home page can be accessed
at http://www.cdc.gov/nchstp/tb/
DTBE On-Line Ordering System. DTBE
educational and training materials can now be
ordered via the Internet.  The on-line ordering
system provides a convenient way to order
DTBE materials. Highlights of the system
include order confirmation via the Internet
and, if an e-mail address is provided, order
confirmation when the order has been filled.
The on-line ordering system can be accessed
on DTBE’s Internet home page at http://
www.cdc.gov/nchstp/tb.
Materials
Controlling TB in Correctional Facilities
Booklet and Slides - 1995. This booklet and
accompanying slide set, developed in 1995,
have been updated in regard to the Advisory
Council for the Elimination of Tuberculosis
(ACET) statement with recommendations for
jails and prisons. It also provides a comprehen-
sive basic reference on TB specifically for
correctional facility staff. The booklets are
available from each state TB office or the
DTBE. Slide sets were distributed to all state
and big city TB programs; however, additional
slide sets are available for purchase ($75 per
set) from the National Technical Information
Service (800-553-6847 or 703-605-6000), item
number AVA19830SS00.  The slide set can
also be viewed and downloaded from DTBE’s
Web site at http://www.cdc.gov/nchstp/tb.
Core Curriculum on Tuberculosis Booklet
and Slides - 1994. The Core Curriculum on
Tuberculosis was originally developed in 1990
with the American Lung Association for use
in preparing and planning educational activi-
ties or as a reference for the practicing clini-
cian caring for patients with TB or TB infec-
tion. The Core Curriculum covers TB epidemi-
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ology, diagnosis, treatment, prevention, and
infection control. This document and accom-
panying slide set were revised to include
current recommendations for the diagnosis,
treatment, and control of TB in 1994. The
newest revision will be available in 2000. The
booklet is available from each state TB office
or DTBE. Slide sets are available for purchase
($62 per set) through the National Technical
Information Service (800-553-6847 or 703-605-
6000), item number AVA19830SS00.  The
Core Curriculum may also be viewed on
DTBE’s Web site at http://www.cdc.gov/
nchstp/tb.
Forging Partnerships to Eliminate TB - 1995.
This print-based, self-study module was devel-
oped in 1995 for TB program managers to
provide information on forming partnerships,
resource acquisition, marketing, and media
relations. The module includes information
from the Mobilizing for TB Elimination
workshops, along with a selected bibliography
listing other available resources.  This module
is available from each state TB office or the
DTBE.
Guidelines for Preventing the  Transmission
of Mycobacterium tuberculosis in Health Care
Facilities, 1994 Slide Series. A slide series
based on the 1994 MMWR supplement Guide-
lines for Preventing the Transmission of Myco-
bacterium tuberculosis in Health Care Facilities
was developed in 1995 for use in training
health care workers, infection control practi-
tioners, and others on how to effectively
implement the guidelines.  A limited number
of sets of the slide series were distributed to
TB control programs.  Additional copies are
available for purchase ($80 per set) through the
National Technical Information Service (800-
553-6847 or 703-605-6000), item number
AVA19824SS00.  The slide set can also be
viewed and downloaded from DTBE’s Web
site at http://www.cdc.gov/nchstp/tb.
How You Can Assess Engineering Controls
for TB in Your Healthcare Facility - 1999. A
video and viewer’s guide developed by the
Francis J. Curry National TB Center about
basic techniques that can be used to evaluate
engineering controls, including instructions
for bringing an isolation room into compli-
ance with CDC recommendations.
Improving Patient Adherence to Tuberculosis
Treatment Booklet - 1994. DTBE developed a
guide for TB health care providers to help
improve patient adherence to medication and
follow-up care. This 1994 booklet replaces the
booklet Improving Patient Compliance in
Tuberculosis Treatment Programs.  It is avail-
able from each state TB office and the DTBE.
Mantoux Tuberculin Skin Testing Wall Chart
(1990) and Videotape (1991). Developed  in
1989, the videotape and wall chart are designed
for use by health department TB staff in
teaching tuberculin skin testing to other health
care workers who are providing services to
persons at risk for TB (e.g., STD clinic staff,
drug abuse treatment staff, correctional facility
staff, nursing home staff, etc.). Providers are
encouraged to contact their state TB program
to obtain these materials and to arrange for
training. The wall chart was revised in Septem-
ber 1990 to reflect the latest recommendations
of the Advisory Council for the Elimination
of Tuberculosis. These materials are available
from each state TB office or the DTBE.
Multidrug-Resistant Tuberculosis - 1994. 8-
page article on causes, treatment, and control
of drug-resistant TB.
Reported TB in the United States - 1998.  The
most recently reported statistics on TB cases
and case rates.
Self-Study Modules on Tuberculosis (Modules
1 - 9). In 1995 DTBE developed a series of five
self-study modules to train and educate new
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outreach workers. Modules 1-5 cover transmis-
sion and pathogenesis of TB, epidemiology of
TB, diagnosis of TB infection and disease,
treatment of TB infection and disease, and
infectiousness and infection control. DTBE
subsequently developed a second series, mod-
ules 6-9, consisting of four modules that cover
contact investigations for TB, confidentiality
in TB control, TB surveillance and case man-
agement in hospitals and institutions, and
patient adherence to TB treatment. Both series
of modules are available from DTBE. The
modules are also available through the Public
Health Training Network for continuing
education credit, free of charge; call toll free
800-418-7246 to register.
Self-Study Modules on Tuberculosis broad-
casts on videotape. Satellite Primer on Tuber-
culosis: Modules 1-5 (1995), and TB Frontline
- Satellite Primer Continued: Modules 6-9
(2000). DTBE’s first five Self-Study Modules
on TB were used as the basis for a series of live
broadcasts via satellite entitled A Satellite
Primer on Tuberculosis, conducted in May and
June 1995. The second set of modules served as
the basis for a satellite training course entitled
TB Frontline-Satellite Primer Continued, Mod-
ules 6-9, conducted in January and February
2000. Each broadcast provided information to
supplement the training modules and allowed
participants to telephone their specific ques-
tions to the presenters. Additional videotapes
of A Satellite Primer on Tuberculosis are avail-
able for purchase through the Alabama De-
partment of Public Health at 334-206-5618, or
by FAX 334-206-5640. Videotape copies of TB
Frontline-Satellite Primer Continued, Modules 6-
9 are available on a limited basis from DTBE
at 404-639-8135.
Self-Study Modules on Tuberculosis on the
Web - 1999.  The Web-based version of the
Self-Study Modules on Tuberculosis provides a
base level of TB knowledge accessible world-
wide through the Internet. The Web-based
course builds upon existing products: the
print-based Self-Study Modules on Tuberculosis
and the Satellite Primer on Tuberculosis. The
Web-Based Self-Study Modules on Tuberculo-
sis course has interactive features such as
animation, study questions, case studies, and
links to other TB-related sites. The course can
be accessed at http://www.cdc.gov/phtn/
tbmodules.
TB Facts for Health Care Workers - 1997.
This 14-page booklet is based upon the TB
Fact Sheet that was originally developed in
1984.  It was updated in 1993 to include infor-
mation on MDR TB and again in 1997 to
include current screening and treatment
recommendations. The booklet contains the
key points to remember about the diagnosis,
treatment, and prevention of TB. The in-
tended audience is health care professionals.
This booklet is available from each state TB
office or DTBE. It can also be viewed on
DTBE’s Web site at http://www.cdc.gov/
nchstp/tb.
TB Notes. This quarterly newsletter is distrib-
uted to state and big city TB control officers,
directors of pulmonary and infectious disease
training programs, state epidemiologists,
public health laboratory directors, and many
other people involved in (or just interested in)
TB in the U.S. and worldwide. State and big
city TB control officers are encouraged to
duplicate copies for TB workers throughout
their jurisdictions. TB Notes contains news
about DTBE activities as well as highlights
from state and local TB programs across the
country. It also contains a calendar of events
describing training courses, meetings, confer-
ences, and other educational activities of
potential interest to those working in TB.
Current and previous editions of TB Notes are
now available on the DTBE Internet home
page at http://www.cdc.gov/nchstp/tb.
Think TB Poster. This poster was reprinted
by the DTBE in 1992 with permission from
the Mississippi State Department of Health,
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the original designer of the poster. Prepared
for health care providers and other service
organizations serving high-risk populations,
the poster lists signs and symptoms of TB, and
it reads, “Recognize possible signs and symp-
toms of TB. Early diagnosis and treatment
reduce spread. Contact your health depart-
ment or physician for more information.”
DTBE collaborated with the Mississippi
Department of Health on the development of
a Spanish version of the Think TB poster in
1993. Both the English and Spanish versions
are available from each state TB office or
DTBE.
Tuberculosis Training and Education Re-
source Guide. This resource guide was pro-
duced by the CDC National Prevention
Information Network (NPIN) in collabora-
tion with DTBE, and provides information
available through NPIN databases and other
resources on topics relating to TB. The re-
source guide includes educational materials,
consensus guidelines, journal articles, Internet
resources, and funding organizations. For
more information on NPIN services call 800-
458-5231 (800-243-7012 TTY) or visit the
NPIN Web site at http://www.cdcnpin.org.
(This information is made available as a public
service. Neither CDC nor NPIN endorses the
organizations and materials represented. It is
the responsibility of the user to evaluate this
information prior to use based on individual
needs and community standards.)
Resources for Patients and the General
Public
Automated information sytems
CDC Fax Information System. CDC devel-
oped a fax information system for persons
who would like to receive health information
by fax. Callers first access the main CDC
menu and then select TB-related topics. De-
signed to answer many routine questions
about TB, the system can provide up-to-date
information by fax or mail.  Callers can
choose to receive general information about
TB or specific information about treatment,
diagnosis, BCG, infection control, or screen-
ing.  The Fax Information System can be
accessed by dialing toll-free 888-CDC-FAXX
(888-232-3299).  To receive a listing of docu-
ments available by fax, request document
number 250000.
CDC Voice Information System. CDC
developed a voice information system for
persons who call for specific disease informa-
tion. Callers first access the main CDC menu
and then select TB-related topics. Designed to
answer many routine questions about TB, the
system can provide up-to-date information by
voice, fax, or mail. Callers who choose to
listen to the voice recordings can receive
general information about TB or specific
information about treatment, diagnosis, BCG,
infection control, or screening.  Callers who
would like written information can choose
from a variety of topics and then receive
information sheets by fax or specific educa-
tional materials by mail.  The TB component
of the Voice Information System can be
accessed by dialing toll-free 888-CDC-FACT
(888-232-3228), then pressing options
2, 2, 1, 5, 2.
Materials
Questions and Answers about TB Booklet -
1994. A patient education booklet for persons
with TB disease or infection, it provides
information on TB transmission, pathogenesis,
diagnosis, treatment (including medications
and side effects), infection control, and follow-
up care.  This booklet is also appropriate for
use in educating those who provide services to
persons with or at risk for TB (for example,
staff of drug treatment centers, correctional
facilities, homeless shelters). This booklet is
available from each state TB program and the
DTBE. This publication can also be viewed on
DTBE’s Web site at http://www.cdc.gov/
nchstp/tb.
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Stop TB! Poster and Tear-Off Sheets - 1994.
This pictorial poster was developed to educate
persons with or at risk for TB.  The poster
displays the transmission of TB, progression
from infection to disease, treatment, and
prevention. A smaller version of the poster
was developed for patients to take with them;
this is available as tear-off-pads of 40 8 ½” x
11" sheets per pad. The poster and tear-off-
pads are available from each state TB program
and DTBE.
TB Fact Sheets - 1997.  This series of five fact
sheets was developed for persons with or at
risk for TB. The fact sheets include “TB Facts
— You Can Prevent TB” (item number 00-
5981);  “TB Facts — TB and HIV (the AIDS
Virus” (item number 00-5982);  “TB Facts —
Exposure to TB” (item number 00-5983);  “TB
Facts — The TB Skin Test” (item number 00-
5984); and  “TB Facts — TB Can be Cured”
(item number 00-5985). Each pad of 40 tear-off
sheets is available from each state TB program
and the DTBE. The fact sheets are also avail-
able in Spanish.
TB: Get the Facts! - 1991.  This pamphlet is
for persons with or at risk for TB. The pam-
phlet provides general information about TB,
including signs and symptoms, risk factors,
infection versus disease, skin testing, and
preventive therapy. It is available in English
and Spanish from each state TB office or
DTBE.
Tuberculosis: The Connection between TB
and HIV (the AIDS virus) - 1990. This
pamphlet is intended for use with persons at
risk for HIV-related TB.  The pamphlet covers
the TB/HIV connection and screening and
prevention for HIV-related TB. The TB/HIV
pamphlet is available in English and Spanish
from each state TB office or the DTBE.
TB Control at the Millennium
80
Notable Events in TB Control
81
TB Control at the Millennium
82
